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ABSTRACT
Background: Hereditary haemochromatosis is a heritable disorder caused by an inborn error in 
the metabolism of iron. It results in over absorption of iron by the body, which can manifest 
clinically as fatigue, arthritis, diabetes and cardiovascular problems. The highest prevalence for 
the genetic mutations that cause hereditary haemochromatosis can be found in the Irish 
population. Individuals with diabetes may also have haemochromatosis (and vice versa), due to 
the bi-directional relationship between iron metabolism and glucose metabolism.
Objectives: To determine the incidence of the three haemochromatosis mutations C282Y, H63D 
& S65C, in a population from the North West of Ireland and to investigate whether there is an 
increased frequency of these three mutations in a diabetic population from the same region.
Method: DNA was extracted from 500 whole blood samples (250 diabetic samples and 250 
‘control’ samples) using a Wizard™ kit. PCR was conducted utilising specific primers for each 
mutation and in accordance with a set protocol. Following amplification, PCR product was 
subjected to restriction endonuclease digestion, where different restriction enzymes (Rsa I, Nde II 
& Hinf I) were employed to determine the HFE genotype status of samples.
Results: The incidence of C282Y homozygosity (1/83) and C282Y heterozygosity (1/6) in the 
‘control’ group was similar to those reported for the general Irish population (1/83 and 1/5, 
respectively). Incidences of H63D homozygotes and H63D heterozygotes or ‘carriers’ in the 
diabetic population were greater than that of the ‘control’ population. A significant finding of this 
study was that of an incidence of 1/32 S65C carriers in the control population. This is, to our 
knowledge, the highest incidence of the genotype reported to date in the general Irish population. 
Statistical analysis showed that there was no significant differences between the HFE genotype 
frequencies in the Diabetic and Control Populations.
Conclusion: Results of the study concord with published literature in terms of C282Y 
homozygosity and C282Y heterozygosity in the general Irish population. An increased frequency 
of the H63D mutation in diabetic individuals was also found but was not statistically significant. 
The biochemical effect of the H63D mutation is still unknown. The significance of such a high 
incidence of S65C carriers in the ‘control’ population warrants further investigation.
_______________________Abstract ________________________________
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1.0 LITERATURE REVIEW
Literature Review
__________________ ___________Literature Review___________________________________
1.1 Introduction
Haemochromatosis is a common heritable disorder which causes the body to absorb excess iron 
from the diet Excessive absorption of iron results from disturbances of iron metabolism, the 
mechanisms of which remain poorly understood. When body iron stores surpass a threshold 
level, iron cannot be sufficiently excreted and the excess is deposited and builds up, with toxic 
consequences, in tissues of major organs such as the liver, heart, pancreas, endocrine organs, 
skin and joints. When organs are overburdened, their ability to function properly is affected and 
disease often ensues. This is the case with haemochromatosis, where accumulation of iron in 
tissues of primary organs has been associated with the development of diseases such as 
diabetes mellitus, cardiomyopathies, impotence, arthritis and skin pigmentation.
1.2 Haemochromatosis: A Historical Review
The first description of haemochromatosis as a clinical or pathological entity was attributed to 
Trousseau in 1865, who used terms like “pigment cirrhosis” and “bronze diabetes”, to describe 
the condition later termed as “haemochromatosis”, by von Recklinghausen in 1889. In later 
years, Troisier (1871) and Hanot and Chauffard (1882) showed agreement with the proposal that 
a distinct connection between iron overload and diabetes exists (Barton & Edwards, 2000).
The theory of haemochromatosis as a heritable disorder was initially put forward by Sheldon, a 
British physician in 1927. Sheldon later published a book entitled “Haemochromatosis”, in which 
the following descriptional monograph of haemochromatosis was contained (1935):
1 The most reasonable explanation of haemochromatosis is that it should be classed as an inborn 
error of metabolism which has an overwhelming incidence in males, and which at times actually 
has a familial incidence’.
However, it should be noted that not everyone of the time shared the opinion of Sheldon, in that 
haemochromatosis can be an inherited disorder. In 1964 MacDonald postulated that 
haemochromatosis and iron overload were consequences of alcoholism and other nutritional 
factors.
1
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Simon et al., (1976) further hypothesized on the genetic nature of the disorder and reported a 
strong association between the gene(s) responsible for haemochromatosis and those of the 
Major Histocompatability Complex (MHC). A later study (Feder et al., 1996) reconfirmed support 
for the role of a novel MHC-like gene in the development of haemochromatosis.
During the 1980’s, several studies were conducted on the relationship of haemochromatosis to; 
arthritis (Mathews & Williams, 1987), hepatic fibrosis (Bassett et al., 1986), cardiovascular 
problems (Olson et al., 1987; Fitchett et al., 1980), and on the linkage of haemochromatosis to 
HLA-H (Bassett et al., 1981). Concurrently, further understanding of the phenotypic expression of 
haemochromatosis was also achieved.
The quest to understand the biochemical and molecular mechanisms in the body underlying iron 
absorption (Halberg et al., 1997; Wood & Han, 1998; Fleming et al., 1999; McKie et al., 2001), 
metabolism (Abboud & Haile, 2000; Eisenstein & Blemings, 1998), and transport (Gunshin et al., 
1997; Vulpe et al., 1999; McKie et al., 2000a), dominated research in the last fifteen years.
Sixty years after its inception, in 1996, Sheldon’s observation was finally confirmed by a research 
team at Mercator Genetics, with their discovery of a novel gene called HFE, found to be 
responsible for hereditary haemochromatosis. Over twenty years had passed between 
localization of the haemochromatosis gene on chromosome 6p (Simon et al., 1975), and its 
molecular identification in 1996. The limited number and availability of genetic markers, 
comparable levels of linkage disequilibrium between markers and the low number of 
recombinants provided by familial studies, are factors suggested to account for this twenty year 
delay or search phase.
In the year 2000, expert review of the disorder by groups at the EASL (European Association for 
the Study of the Liver) International Consensus Conference on Haemochromatosis, resulted in 
the definition of haemochromatosis as; !an inherited disorder resulting from an inborn error of iron 
metabolism which leads to progressive iron loading of parenchymal cells in the liver, pancreas 
and heart’. (Adams et al., 2000).
A guideline on genetic haemochromatosis was compiled in 2000 by Dr. James Dooley and 
Professor Mark Worwood on behalf of the Clinical Task Force of the British Committee for 
Standards in Haematology. The authors conducted a Medline search of world literature to review
2
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existing guidelines. The findings were presented in an open forum at the British Society for 
Haematology meeting in April 1999. In these guidelines genetic haemochromatosis refers mainly 
to the accumulation of iron in the body due to the inheritance of mutations in the HFE gene on 
both copies of chromosome 6. This leads to excessive absorption of iron from food.
1.3 Types of Haemochromatosis
Iron overload is associated with mutations in multiple genes. It is therefore important to note the 
Online Mendelian Inheritance in Man (OMIM) database classification system that follows;
1.3.1 Type 1 or ‘hereditary haemochromatosis’ or ‘HFE-related hereditary haemochromatosis’: 
is an autosomal recessive condition caused by mutations in the HFE gene (chromosome 
6p21.3). Postulated functions of this gene are; interaction with transferrin receptor 1, 
probably facilitating uptake of transferrin-bound iron and possibly the modulation of 
hepcidin expression. The major mutations of HFE are C282Y and H63D. Lesser 
mutations are S65C, C282S, [5569G-A, an intronic polymorphism], VAL53MET, 
VAL59MET, GLN127HIS, ARG330MET, ILE105THR, GLY93ARG. To date, there have 
been 37 allelic variants of the HFE gene reported (Pointon et al., 2000). The OMIM 
number that defines type 1 or hereditary haemochromatosis is 235 200.
1.3.2 Type 2 or ‘juvenile haemochromatosis’: is a rare, autosomal recessive condition 
consisting of two different subtypes. The gene implicated in type 2, subtype A is 
hemojuvelin (HJV) on chromosome 1q21, whose function is not yet confirmed but is 
thought to play a role in the modulation of hepcidin expression. The gene implicated in 
type 2, subtype B is HAMP on chromosome 19q13, which is thought to be involved in the 
down-regulation of iron release by enterocytes, macrophages or placental cells. The 
OMIM number for type 2A is 602 390 and for type 2B is 606 464.
1.3.3 Type 3 haemochromatosis or ‘TFR2-related hereditary haemochromatosis’: is an 
autosomal recessive condition caused by mutations in TFR2, a gene which codes for a 
transferrin receptor isoform and is located on chromosome 7q22. It is thought that this 
gene is possibly involved in the uptake of iron by hepatocytes. The OMIM number for 
type 3 is 604 250.
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1.3.4 Type 4 haemochromatosis or ‘Ferroportm-related iron overload’: is an autosomal 
dominant condition associated with mutations in the ferroportin 1 gene (also called 
IREG1 and MTP10) on chromosome 2q32, which codes for a molecule involved in 
intestinal iron transport (McKusick, OMIM). It’s OMIM number is 606 069.
1.3.5 Type 5 haemochromatosis: is an autosomal dominant condition which is caused by a 
mutation in the H-subunitof the gene for ferritin (Bomford, 2002).
Pietrangelo (2004) concluded that hereditary haemochromatosis should be defined as a unique 
clinical / pathophysiological entity that can be provoked by pathogenic mutations of one of the 
four known haemochomatosis genes, HFE, TfR2, HJV and HAMP.
To ensure clarity, all future references to haemochromatosis and / or iron overload in this review / 
text refers to Type 1 or hereditary haemochromatosis, unless otherwise stated.
1.4 Genetics of Haemochromatosis
1.4.1 Molecular Basis of Haemochromatosis
Haemochromatosis is an inherited disease. Initial studies by Simon et al., (1976) on the linkage 
between a haemochromatosis locus and the major histocompatability complex, and on the 
presence of an ancestral hapiotype (combination of genotypes on the same chromosome that 
tend to be inherited), were of importance in the search for the haemochromatosis gene (Simon et 
al., 1980). In 1996, the gene responsible for hereditary haemochromatosis was isolated (Federet 
al., 1996). Using linkage disequilibrium and full hapiotype analysis, they identified a 250-kilobase 
region more than 3 megabases telomeric of the MHC. It was within this region that they identified 
a gene closely linked to the MHC class I family, which they termed HLA-H, that was responsible 
for hereditary haemochromatosis. The gene was later renamed HFE by the Nomenclature 
Committee of the Genome Database and can be found on the short arm of chromosome 6 of the 
human karyotype.
Genetic disorders can be of three main types; chromosomal, single gene (monogenic), or 
multifactorial (polygenic) diseases. Hereditary haemochromatosis was originally considered a 
monogenic disorder, in that it is caused by mutations in one or both alleles of a single gene, and
4
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involves changes at the nucleotide ievel that disrupt the genes normal function. However, with 
the identification of similar phenotypes associated with mutations in at least four iron-metabolism 
genes, the condition is more multifactorial in nature than initially realized.
Hereditary haemochromatosis is most commonly the consequence of missense mutations of the 
HFE gene. The first mutation at the 845 nucleotide locus causes substitution of tyrosine for 
cysteine in amino acid 282 and is designated as the C282Y (Cys282Tyr) mutation. The second 
mutation is designated as H63D (His63Asp), as it occurs at the 187 nucleotide locus and causes 
substitution of aspartic acid for histidine in codon 63. Hereditary haemochromatosis is 
considered an autosomal recessive disorder, because both copies of the HFE gene (which are 
iocated on the two homoiogues of chromosome 6) need to have a particular mutation in order for 
the disorder to present itself. If an individual has only one HFE-mutated chromosome they are 
known as a heterozygote and the remaining non-mutated copy of the HFE is usually sufficient to 
prevent the onset of symptoms. If a particular mutation (either C282Y or H63D) is present on 
both chromosomes, an individual is said to be homozygous for that mutation, and there is a 
strong likelihood that C282Y homozygotes will develop the phenotypic expression of 
haemochromatosis. When the C282Y mutation is present on one chromosome and the H63D 
mutation is present on the other, individuals are called compound heterozygotes, and there is a 
small possibility that some of these individuals may also develop hereditary haemochromatosis. 
Figure 1.0 shows the different HFE genotypes and inheritance possibilities (Burke et al., 2001). 
Although C282Y and H63D are the major haemochromatosis mutations, two other mutations 
S65C and C282S may also contribute towards abnormal iron metabolism. The S65C mutation 
appears to be in a region implicated in binding the transferrin receptor to the HFE protein, and like 
the H63D mutation is associated with a milder phenotype than that of the C282Y mutation (ARUP 
Laboratories, 2002). The S65C mutation may be inherited in the compound heterozygous state 
with either C282Y or H63D, and is the most clinically significant of the lesser known HFE gene 
mutations, arising in 2-3% of Caucasians (Mura et al., 1999; Wallace et al., 2002). The C282S 
mutation is associated with severe iron overload, when in combination with H63D, but because 
both of the aforementioned mutations have a relatively low frequency, it has been difficult to 
obtain robust data pertaining to them (Rosmorduc et al., 2000).
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Figure 1.0: Examples of HFE Genotypes in families with Haemochromatosis {Source: Burke, Phatak & Weinberg, 
2001]. Permission requested from publisher.
The exact function of the HFE protein in iron metabolism is currently unknown, but it is thought 
that it may act as a receptor for an iron-binding ligand on the basal cell surface. This activity 
could function as a negative feedback control so limiting iron absorption, and therefore an 
abnormality of this protein could result in loss of this negative feedback effect resulting in 
excessive iron absorption. Other suggested functions are; signal transduction of body iron stores 
to the mucosal cell and interaction with immune system components that may influence iron 
metabolism, however these two functions are still purely speculative (Robson et al., 1997).
The HFE protein has an ancestral peptide-binding groove that is too narrow for antigen 
presentation (Lebron et al., 1998), so newly synthesized HFE protein binds to beta2-microglobulin 
facilitating its interaction with the major receptor for transferrin (transferrin receptor 1 or TfR1) 
(Feder et al., 1998; Gross et al., 1998). The C282Y mutation (but not the H63D mutation) of HFE 
prevents formation of a disulphide bridge in the protein product which in turn, prevents it from 
binding with beta2-microglobulin and reaching the cell surface (Feder et al., 1997). Some 
investigators have suggested that the C282Y mutation may result in lower levels of the HFE- 
transferrin receptor complex at the cell surface, which would decrease the uptake of transferrin-
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bound iron and so lower a cells iron status. Enterocytes may not be able to distinguish this low 
iron state from anemia and would therefore stimulate iron absorption, eventually leading to iron 
overload (Waheed et al., 2002; Wood, 2002). Low iron status stimulates increased expression of 
transporters, and to support this, haemochromatosis patients have been shown to over-express 
the iron importer DCT1 (Zoller et al., 1999) and the iron exporter 1REG1 (McKie et al., 2000b). 
The presence of the C282Y mutation in HFE prevents its interaction with TfR1 and leads to iron- 
deficient crypt cells and in turn, iron-deficient daughter cells. These cells are programmed to 
react to iron starvation by hyperactively and persistently absorbing iron from the intestinal lumen 
and transferring almost all of it into the bloodstream, irrespective of the fact that erythropoietic 
needs may be fully satisfied. This theory is known as the ‘crypt-programming model’ and is a 
recently postulated pathogenic model of HFE-related hereditary haemochromatosis (Pietrangelo, 
2004).
1.4.2 Origins, Population Genetics, Gene Frequency & Prevalence
Haemochromatosis has a distinctive geographical distribution that reflects the movements of 
people of northwestern Europe during historic times. This distribution led to the thinking that 
haemochromatosis is the result of a relatively recent mutation (one that has occurred in hundreds 
of generations) in a Celtic I North West European population. For a gene to become so prevalent 
in a population, it must have conferred a selective advantage or survival benefit to the populations 
which they affected e.g. resistance to dietary iron deficiency or certain infectious diseases. 
Because haemochromatosis is rarely associated with disability and death during reproductive 
years, it is unlikely that the disorder would confer a selective disadvantage. It is thought that 
populations of northwestern Europe that show a high prevalence of haemochromatosis, must 
have experienced an earlier period where human dietary iron intake was very limited or been 
areas where populations were repeatedly subjected to blood letting, for example, during war 
(Fairbanks, 2000). Both of these reasons help explain why the ability to absorb iron at an 
accelerated rate would confer a selective advantage to a population. Countries with the highest 
gene frequency for the C282Y mutation include Ireland, Great Britain, The Netherlands, 
Denmark, Germany, Iceland and Norway and are shown in Figure 1.1.
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Figure 1.1: Estimated haemochromatosis gene frequency in Europe and the Mediterranean littoral (principally reflects 
the distribution and allele frequency of the C282Y mutation of the HFE gene).
[Source: Fairbanks, VF. "Haemochromatosis: population genetics', in Barton & Edwards, Hemochromatosis: 
genetics, pathophysiology, cSagnosis and treatment Cambridge University Press 2000; pp 43], Permission 
requested from publishers.
The prevalence of the major haemochromatosis mutation C282Y in European populations is 
estimated at 0.4% for the homozygous state and 9.2% for the heterozygous state (Hanson et al.,
2001). Studies on people of mixed European descent conducted by Beutler et al., (1996) showed 
that 83% of patients with hereditary haemochromatosis were homozygous for the C282Y 
missense mutation. Familial studies conducted by Jawinska et al., (1996) and Jouannolle et al.,
(1996) supported these findings with even higher mutational frequencies of 91% and 100%, 
respectively, being observed. The highest allele frequency On a control population) of 14% for 
the C282Y mutation has been reported in Ireland (Ryan et al., 1998). In this study thirty-one out 
of 109 randomly selected people were heterozygous for the C282Y mutation. This allelic 
frequency of 14% represents a heterozygote or ‘carrier1 frequency of approximately 1 in 4, and 
shows agreement with studies by Merryweather-Clarke et al., (1997a) and Edwards et al., (1988) 
in which a heterozygote frequency of 1 in 5 for the C282Y mutation was observed in Irish people. 
The carrier frequency in the Irish population is generally accepted to be in the range of 1 in 8 to 1 
in 10 people, so the findings by Ryan et al., (1998) of 1 in 5 is extremely high.
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The degree of iron overfoad and the related clinical complications can vary widely in 
haemochromatosis with both acquired (environmental) and genetic factors influencing phenotypic 
expression of the disease. A large proportion of people who may be homozygous for the 
haemochromatosis gene remain undiagnosed because they are either presymptomalic or they 
present with one or more of the many symptoms/manifestations of iron overload that may also be 
ascribed to other, more common conditions. Individuals with hereditary haemochromatosis are 
generally asymptomatic until toxic concentrations of iron have accumulated within the body, a 
process which usually takes several decades (Burke et al., 2001). Once this stage has been 
reached, clinical features such as bronzed skin, joint pain and swelling, diabetes, hypothyroidism 
and cardiomyopathies can present themselves. By this point, the concentration of iron stored in 
many body organs is much higher than the normal levels found, e.g. iron levels in the liver and 
pancreas may be up to 50 to 100 times their normal level. This surplus iron is mainly in the form 
of hemosiderin and can be visualised in tissues when stained with potassium fenrocyanide I Peris 
stain (see Figure 1.2).
Taking into account the existence of the highly prevalent C232Y mutation, it is difficult to explain 
the phenotypic variability of haemochromatosis (Piperno et al., 1996). For example, the iron 
overload phenotype associated with mutations in the gene which encodes transferrin receptor 2 
(TfR2), appears to be very similar, to that of the classic HFE-related haemochromatosis, although 
very few cases have been described to date (Camaschella et al., 2000; Mattman et al., 2002; 
Girelli et al., 2002; Hattori et al., 2003). Both of these forms of the disease are representative of 
adult-onset hereditary haemochromatosis and are characterized by gradual iron loading, with a 
relatively late onset of parenchymal iron deposition and hepatic organ damage (Pietrangelo, 
1998). A study by Laine et al., (2005) reported that excess body mass is commonly associated 
with the lack of phenotypic expression in detected C282Y homozygotes. This should therefore be 
kept in mind with respect to the design and cost-effectiveness of phenotypic screening programs 
for haemochromatosis. A review article by Whittington & Kowdley (2002) reported that 
phenotypic expression of hereditary haemochromatosis appears to be different in different ethnic 
populations. The Healthlron study aims to examine environmental and genetic modifiers of HFE 
gene expression, and as such, should shed some light on the factors that modify the clinical 
severity of hereditary haemochromatosis (Gertig et al., 2005).
1.4.3 Phenotype vs. Genotype
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Figure 1.2: Hepatic micrograph showing iron accumulation (blue) in liver cells (Haemochromatosis) using Peris stain. 
[Source: Burkitt et al. Wheater's Basic Histopathology, a colour atlas and text, 3rd edition (1996), published by 
Churchill Livingstone. Standard Edition ISBN 0-443-05088-0], Permission requested from publishers.
1.4.4 C282Y Homozygosity
Individuals who are diagnosed as homozygous for the C282Y mutation and have hereditary 
haemochromatosis, generally have iron stores that are greatly elevated from ‘normal’ levels. 
There have been relatively few large studies investigating iron status in C282Y homozygotes from 
the general population (Jackson et al., 2001; Burt et al., 1998; Beutter et al., 2000) that have 
included random samples. The study by Jackson et al., (2001) of HFE mutations, iron deficiency 
and overload in 10,500 blood donors, showed that 1 in 147 (72) were homozygous for the C282Y 
mutation. Studies by Beutler et al., (2000) and Burt et al., (1998) demonstrated that both 
transferrin saturation levels and serum ferritin concentration was considerably higher in C282Y 
homozygotes than in their wild-type counterparts. A study by Olynyk et al., (1999), showed that a 
high proportion of C282Y homozygotes had increased hepatic iron levels.
The penetrance of homozygosity for HFE C282Y is low, ranging between 1% and 4%. It remains 
unclear as to why only few patients homozygous for the C282Y mutation develop the full-blown 
form of the disease whilst others do not The variation in penetrance may be due to epigenetic 
mechanisms like the presence of retrotransposons influencing expression nearby, environmental 
factors (such as alcoholism) and genetic modifiers such as mutations in other genes involved in 
iron metabolism (Beutler et al., 2003). However, a study by Lee et al., (2002) suggested that 
mutations in the genes coding for transferrin, ferroportin, TfR1, TfR2, haem-oxygenase 1 and 2, 
NRAMP1, NRAMP2, IRP2, haptoglobin, hepcidin and caeruloplasmin did not contribute to 
manifestation of the disease in patients homozygous for C282Y. Phatak et al., (2005), showed 
that disease expression varied considerably in C282Y homozygotes and that the observed 
variation is not explained by variations in dietary iron, fibre, ascorbic acid or ethanol intake. The
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authors suggest that oiher unknown environmental variables or alternatively, modifier genes, may 
play a role in modulating disease expression in these patients. Candidate genes that could have 
implications for the clinical penetrance of C282Y, are the genes coding for hephaestin, duodenal 
cytochrome b and those of the heavy and light chains of ferritin (Bomford, 2002), as well as the 
gene that causes juvenile haemochromatosis (Roetto et al., 1999). There is no doubt that 
homozygosity for C282Y is a required cause of clinical haemochromatosis but other causal 
factors must also play a role in order to account for the incomplete penetrance of the disorder 
(Beutieretal., 2003).
A study in 2004 (Livesey et al.,) found that the frequency of the 16189 variant of mitochondrial 
DNA, is elevated in individuals with haemochromatosis who are homozygous for the C282Y 
allele, compared with population controls and with C282Y homozygotes who are asymptomatic. 
Homozygosity for the C282Y mutation appears to be the prevailing cause of clinically overt 
hereditary haemochromatosis (Milman et al., 2003). It is important to emphasize that 
homozygosity for C282Y does not confer a diagnosis of haemochromatosis but rather indicates a 
tendency towards iron overload (Whittington & Kowdley, 2002). Non-expression is common, 
especially in women (Crawford et al., 1998). A study in 2002 by van Aken et al., showed that no 
increase in mortality and morbidity was evident for carriers of the C282Y mutation. It is 
noteworthy that a study by Rossi et al., (2004) found that none of the C282Y homozygotes or 
compound heterozygotes expressed the phenotype of iron-overload disease.
1.4.5 C282Y Heterozygosity
Most studies report elevated transferrin saturation levels in C282Y heterozygotes when compared 
to their wild-type counterparts (Burt et al., 1998; Beutler et al., 2000; Datz et al., 1998). A study 
by Distante et at, (1999) supports this statement by reporting that 11% of heterozygotes had 
elevated transferrin saturation compared with 3% of wild-type individuals. Serum ferritin 
concentrations did not appear to differ significantly (Burt et al., 1998; Datz et al., 1998; Rossi et 
al., 2001). To date, there is little data on the prevalence of increased hepatic iron levels in C282Y 
heterozygotes taken from the general population.
A study of 1784 Danes suggested that C282Y heterozygosity may be associated with shorter life 
expectancy, particularly in women (Banthum et al., 2001). One of the main results of a study by 
Chambers et al., (2003) was a falling prevalence of C282Y heterozygosity with increasing age.
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Both of the aforementioned findings are not consistent with those of Beutler et al., (2002 (a), 2002 
(b)) and Waalen & Beutier (2004).
1.4.6 C282Y/H63D Compound Heterozygosity
indices for the iron status of C282Y/H63D compound heterozygotes appear to lie between those 
of C282Y homozygotes and heterozygotes. Beutler et al., (2000) and Rossi et al., (2001) 
reported higher transferrin saturation levels in both male and female compound heterozygotes 
than in their wild-type counterparts. Serum ferritin levels were reported to be higher in men than 
in women also (Beutler et al., 2000). Compound heterozygotes are at increased risk of clinical 
haemochromatosis. Numerous studies have also pointed towards an increased risk of liver 
disease in compound heterozygotes. Rossi et al., (2001) expected a prevalence of around 2% in 
the general population of Australia, yet a study by Bacon et al., (1999a) reported that out of 132 
patients with liver disease, 6% were compound heterozygotes, in 2000, Willis et al., 
demonstrated that individuals with cirrhosis had a prevalence rate of 3% for C282Y/H63D 
compound heterozygosity compared to a prevalence rate of 0.9% (for the same mutationai 
status), in the general population. Results from a study by Aguilar-Martinez et al., (2005) 
highlights that females who are compound heterozygotes for C282Y and H63D, are also at risk of 
developing clinical pictures of iron overload as severe as C282Y homozygous females.
1.4.7 H63D mutations
The H63D mutation (and that of the S65C), are associated with a milder phenotype than that of 
C282Y. H63D has an allele frequency of approximately 16% in the general American population 
(Arup Laboratories, 2002). A study by Gochee et al., (2002), reported elevated transferrin 
saturation levels in individuals with H63D mutations alone (i.e. no C282Y mutation). There was 
no significant differences in serum ferritin levels, although 9% of male H63D homozygotes and 
3% of H63D heterozygotes had increased transferrin saturation and serum ferritin levels 
compared with 0.7% of the wild-type individuals. H63D is the major HFE mutation found in the 
Thai population with an average allele frequency of 3% (Viprakasit et al., 2004). The H63D 
mutation is now widely accepted to have few if any clinical sequelae (Galhenage et al., 2004; 
Burke et al., 2000; Gochee et al., 2002).
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In recent years, a new HFE amino acid variant known as S65C has been reported. This variant 
results in a single base substitution at nucleotide 193 in exon 2 and has been implicated, through 
association, to be involved in the pathogenesis of haemochromatosis (Mura et al., 1999; Barton 
et al., 1999). A study was conducted by Arya et al., (1999) to evaluate the association of S65C 
with iron overload that is unexplained by C282Y. Results showed that the S65C variant is not 
associated with increased transferrin saturation in voluntary blood donors and did not support the 
hypothesis that the S65C allele is associated with a genetic predisposition to iron overload. 
Wallace etal., (2002) investigated the haemochromatosis phenotype of compound heterozygotes 
for C282Y and S65C. They found that some C282Y/S65C compound heterozygotes had 
elevated serum iron indices and iron overload. The penetrance of this genotype is low and it is 
thought that other genetic and environmental factors may influence the expression of iron loading. 
Screening for the S65C mutation may be useful in people with iron overload who are neither 
C282Y homozygotes or C282Y/H63D compound heterozygotes. An allele frequency of 0.013% 
for S65C was reported by Willis et al., (2003), and was similar to that reported by Simonsen et al., 
(0.015%) in 1999. This suggests that the frequency of S65C homozygosity is about one in 5000, 
and that of C282Y/S65C compound heterozygosity is about one in 1400. The S65C mutation has 
a European allele frequency of 0.1-2% (Mura et al., 1999; Arya et al., 1999; Holmstrom et a!., 
2002; Koefoed et al., 2002; Candore et al., 2002; Couto et al., 2003; Willis et al., 2003; Salvioni et 
al., 2003; Pietrapertosa etal., 2003).
1.5 Penetrance
Clinical penetrance may be defined as the extent to which the mutations predict disease. In a 
review by Worwood (2005) it is stated that prior to the discovery of the HFE gene it was assumed 
that every person found homozygous for haemochromatosis would eventually accumulate 
enough iron to cause tissue damage ultimately resulting in morbidity. A recent study has 
suggested that the clinical penetrance of the C282Y mutation may be as low as 1%, however, this 
figure may be underestimated because the studied population was not representative of the 
population as a whole, symptom definition was poor (therefore it may not be reflective of the true 
health status of C282Y homozygotes in general), and because the sample size may have been 
inadequate. It should be noted, however, that the frequency of lethargy, arthralgia and diabetes 
was the same in both the study group and the controls. There was also a small but significant
1.4.8 S65C mutations
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increase in the percentage of individuals with either raised transaminase activity or 
fibrosis/cirrhosis in the C282Y homozygous group (Beutler et al., 2002a). A large study in 
Norway showed iron accumulation in C282Y homozygotes but little morbidity (Asberg et al.,
2002). A study by Jackson et al., in 2001 identified 72 C282Y homozygotes out of a sample 
population of 10,500 blood donors. Most of the men and 45% of the women had elevated 
transferrin saturation levels. Sixty-three of the C282Y homozygotes that were interviewed did not 
show any physical signs of iron overload or were aware of relatives with haemochromatosis. 
Worwood (2005) states that despite much debate about ascertainment bias in family and 
population surveys, it is becoming clear that most men homozygous for C282Y will have raised 
transferrin saturation before the age of thirty, a proportion will have raised serum ferritin levels, 
but only a minority will eventually develop fibrosis and liver cirrhosis. Only around 50% of C282Y 
homozygous women will have raised transferrin saturation. Iron accumulation and tissue damage 
will usually, but not always, occur at a slower rate.
An article by Fodinger and Sunder-Plassmann (2003) stated that almost all iarge-scale studies to 
date, have focused on the clinical penetrance of HFE C282Y homozygosity. Very few studies 
have investigated the clinical penetrance of other HFE mutations like H63D and S65C, and 
compound heterozygosity for C282Y and H63D.
1.6 iron Metabolism in Haemochromatosis
The pathophysiology of hereditary haemochromatosis lies in a defective gene that controls the 
intestinal mucosal barrier to iron absorption. Lifelong absorption of dietary iron results in 
excessive body iron loading and haemochromatosis develops as a consequence. Although an 
essential element in many metabolic and enzymatic body processes (e.g. as an electron carrier), 
iron may also be extremely toxic due to lack of specific excretion pathways for the metal in vivo. 
Except for natural blood loss, maintenance of body iron levels relies on regulation of absorption 
alone. Intestinal absorption of iron that has entered the body via the gastrointestinal tract, can be 
split into three components; mucosal uptake by the enterocyte following iron presentation to the 
cells, intracellular enterocyte transport and storage, and extra-enterocyte transfer (Abdou, 2002; 
Fletcher & Halliday, 2002). Some regulation may occur during each phase. For absorption to 
occur, elemental iron must first be bound to oxygen and exposed to acidic conditions in the 
stomach, where it becomes ferrous iron and is absorbed in the duodenum. Absorbed iron is
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captured by viiii, finger-like projections, on the surface of the intestinal wall and so enters the 
bloodstream, where it is met by transferrin, a transport protein molecule.
Under normal conditions, each transfemn molecule can bind two atoms of Fev  and transports it 
to all tissues, vital organs and bone marrow, where it plays a vital role in metabolism, synthesis of 
DNA and erythropoiesis (Burke et al., 2001). Figure 1.3 shows the cycling of transferrin across 
the cell membrane. Current research has shown that caeruloplasmin and divalent metal transport 
ions (DMTI) are also involved with transferrin and the transport of iron in the blood. Transferrin is 
normally saturated 25 to 35 percent with iron, but when excess iron is present in the blood, 
transferrin becomes oversaturated and its ability to bind iron tightly, decreases. Transferrin 
saturation is a measurement of the amount of iron that transfemn can bind and transport and 
therefore reflects the changeability of iron from its storage form to its utilization. This 
measurement is the most reliable measure of the key process underlying haemochromatosis, as 
it shows the increased saturation of the body’s TIBC (total iron binding capacity) in relation to 
serum iron levels (Haemochromatosis (Inherited) by The Haemochromatosis Society Australia 
Inc., 2000). The role of transferrin and its significance in transcellular transfer has been 
scrutinized. Studies have shown that hypotransferrinaemic mice and humans can develop iron 
overload due to enhanced iron absorption despite low serum transferrin concentrations, and 
hypoxaemic animals with enhanced iron absorption do not have increased mucosal cell 
transfemn, in spite of having increased plasma transferrin concentrations (Simpson et al., 1991; 
Osterloh et al., 1987). Additional studies in man indicate that transferrin may not play a 
controlling roie in transcellular iron transport, as no significant difference was found in duodenal 
mucosal cell transferrin concentrations between iron-deficient patients and normal subjects 
(Whittaker et al., 1989). Mucosal cell transferrin concentration is not correlated with body iron 
stores or with non-haem or haem iron absorption. The concentration of transferrin within mucosal 
cells is probably achieved as a consequence of the ceii’s iron requirements during cellular growth 
and development.
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Figure 1.3: The Transfemn Cycle:
Iran-laden transfemn (Fe2-Tf) binds to transferrin receptors (TfR) on the surface of erythrotd precursors. These complexes 
localize to dathrin-coated pits, which invaginate to form specialized endosomes, A proton pump decreases the pH within the 
endosomes, leading to conformational changes in proteins that result in the release of iron from transfemn. The iron transporter 
DMT1 moves iron across the endosomal membrane, to enter the cytoplasm. Meanwhile, transferrin (Apo-Tf) and transfemn 
receptor are recycled to the cell surface, where each car be used for further cycles of iron binting and iron uptake. In erythrold 
cells, most iron moves into mitochondria, where it is incorporated into protoporphyrin to make heme. In nonerythroid cells, iron is 
stored as ferritin and hemosiderin.
[Source: Andrews NC. Disorders of Iron Metabolism, Review Article, Medical Progress, The New England Journal o f 
Medicine 1999, pp 1987]. Permission requested from publishers.
Absorbed iron that is not needed for metabolism or production of DNA and erythrocytes may be 
stored within hepatocytes as ferritin. This large protein molecule can hold up to 4500 atoms of 
iron and acts as a containment reservoir for the metal when present in plentiful supply, or when 
free iron has the potential to damage ones health. When stored iron is in its soluble, mobile, 
diffuse form it is known as ferritin. The insoluble form is called hemosiderin and may be found as 
aggregated deposits throughout the tissues of the body. In cells, ferritin concentration reflects its 
repository function of sequestering excess cellular iron that has not been absorbed into the 
circulation. Free or unbound iron has toxic potential within the body through, amongst other 
things, its elicitation of free radical activity. Ferritin sequesters iron within the cell and prevents it 
from catalysing potentially cytotoxic free-radical generating reactions. Excessive absorption and 
deposition of iron within organs induces an inflammatory reaction, which in turn can induce organ 
fibrosis. In iron overload, plasma transfemn concentration decreases (transfemn saturation 
increases), while plasma ferritin is greatly elevated; consequently these measurements serve as 
important indicators of disease status. A review on the evaluation of iron overload by Jensen in 
2004 highlighted that although the determination of serum transfemn saturation is commonly
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used as an indication of iron status, and is therefore useful in screening for hereditary 
haemochromatosis, its diagnostic predictive value is higher than that of the serum ferritin test 
(Cook et al., 1976; Worwood et ai., 1997). Serum ferritin, although easy to perform frequently, 
exhibits high variability, but to date, no alternative serum/plasma marker provides a better 
indicator of total body iron. A study, published in 2003, by Guillygomarc’h et al., concluded that 
although circadian variations in transferrin saturation levels exist, the test may be performed at 
any time during the day. O’Hara et al., (2003) concluded that in the absence of a national genetic 
screening programme for haemochromatosis in Ireland, transferrin saturation could be used as 
part of a health-screening panel, to detect individuals prior to the occurrence of organ damage.
Whilst for many years it had been suggested that both total body iron levels and the rate of 
erythropoiesis regulated iron absorption (Bothwell et al., 1958), it is only recently that a number of 
other factors have been proposed that may influence iron absorption. These molecules, called 
iron stores regulators and erythroid regulators, are thought to play an important role in regulatory 
aspects of the absorption pathway (Finch, 1994; Sayers et al., 1994).
1.7 Diagnostic techniques for iron overload
Diagnosis of hereditary haemochromatosis is generally by way of molecular testing. 
Haemochromatosis mutation detection can supplement biochemical measurements like 
transferrin saturation and serum ferritin, to confirm a diagnosis in symptomatic individuals and to 
detect sub-clinical cases. Molecular analysis detects people at risk of developing 
haemochromatosis independent of environmental factors, and consists of testing for the presence 
of the two major mutations C282Y and H63D. Most assay systems are PCR-based, meaning that 
specific gene regions are amplified and the products analysed.
The Polymerase Chain Reaction (PCR) is a technique for selective amplification of a part of DNA 
from the total genome. This technique makes amplification of large quantities of DNA from a DNA 
template, relatively simple and rapid. A task which prior to PCR, was only possible by labour- 
intensive cloning.
The process of PCR faithfully replicates a defined segment of DNA millions of times and is 
dependent on the enzyme Taq polymerase. There are three main steps that make up the 
amplification procedure, and these steps are repeated typically 25 -  35 times. The first step is
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denaturation, a process which involves the separation of the two strands of the DNA double helix. 
Each strand can then be used as a template for the synthesis of a new strand. Denaturation 
occurs by subjecting the DNA to high temperature. The second step involves the annealing of 
DNA primers. Primers are short, synthetic pieces of DNA that match the two end points of a 
defined segment of DNA and bind on to them by complementary base pairing. They mark the 
starting point of the synthesis of the new DNA and prime the amplification reaction from their 3’ 
OH end. The final or third step is extension. Here, single nucleotide bases are inserted to form 
the new DNA strands. It is in this way that the new strand is manufactured with a sequence 
complementary to the original template. At the end of the first cycle of PCR the DNA segment of 
interest has been duplicated. This cycle of three steps is repeated up to 35 times, with each 
subsequent step doubling the number of copies of DNA (See Figure 1.4). The main components 
of polymerase chain reaction are: oligonucleotides, buffers, Taq DNA polymerase, 
deoxyribonucleotide triphosphates, primers and target sequence / DNA (Innis et al., 1990).
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Rgure 1.4: Polymerase Chain Reaction (round 1 amplification). [Source: Rudin, N. and Inman, K. An Introduction to 
Forensic DNA Analysis, 2nd edition, 2001, published by CRC Press, USA]. Permission to use requested from 
publishers.
PCR product can be then be subjected to further analysis, for example to determine the presence 
or absence of genetic mutations.
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The most common method to differentiate between alleles is restriction fragment length 
polymorphism (RFLP) analysis. This method employs restriction enzymes to ‘cut” alleles that 
contain certain mutations (Lyon & Frank, 2001). Variations of this analysis include multiplex 
PCR-SSCP (Polymerase Chain Reaction with Sequence Specific Primers), a simple and rapid 
technique that permits simultaneous detection of C282Y, H63D and S65C mutations (Simonsen 
et al., 1999; Guttridge et al., 1998) and MS-PCR, a method specific enough to distinguish 
between different genotypes of C282Y (Merryweather-Clarke et al., 1997b). Other methods 
include the oligonucleotide ligation assay (Feder et al., 1996) and allele-specific oligonucleotide 
hybridisation (Beutler et al., 1996). Both of the aforementioned methods have disadvantages in 
that they require either sophisticated automated technology or the use of radioisotopes. The 
advantages of using heteroduplex technology to genetically screen for haemochromatosis has 
been described by Jackson et al., (1997). This method involves the construction of a 
heteroduplex generator, by site-directed mutagenesis, which is subsequently used in PCR 
followed by capillary electrophoresis, for the detection of haemochromatosis mutations. 
Advantages to this type of analysis are that it permits rapid processing of large sample numbers 
and has higher specificity than RFLP analysis. A study by Gomez-Llorente et al., (2004) 
presented the first application of a multiplex multicolour assay for the simultaneous detection of 
the three most frequent HFE mutations; C282Y, H63D and S65C. The method is based on single 
base extension followed by competitive alieie-specific PCR, using fluorescent detection and 
capillary electrophoresis. This method will facilitate automated genotyping for routine molecular 
diagnostics and Iarge-scaie genetic studies. Results from a study by Rossi et ai., (1999) 
indicated that, overall, genotyping for the C282Y mutation is a useful test for the diagnosis of 
genetic haemochromatosis in clinical practice.
In this study, PCR for detection of the C282Y haemochromatosis mutation was conducted with 
the forward C282Y primer used by Feder et al., (1996) but a different reverse primer was used. 
The base sequence of the reverse primer that was used by Feder et al., (1996) was: C282YR: 
5’CTC AGG CAC TCC TCA ACC-3’. This primer was discarded for use in this study (as it may 
cause overestimation of C282Y homozygosity) and an alternative one used by Jeffrey et al., 
(1999) was employed. Both the H63D and the S65C haemochromatosis mutations were 
detected using the forward and reverse primers employed by Merryweather et al., (1997a). The 
same set of primers could be used to detect both mutations as they are contained in the same 
region I exon of the HFE gene that is amplified by the aforementioned primers (see Figure 1.5).
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Nucleotide no. 4652
I
gttcacact ctetgcacta cctctteatg ggtgcctcag agcaggacct tggtctttcc ttgtttgaag ctttgggcta cgtggatgac cagctgtteg tgttctatga 
tcatgagagt cgccgtgtga agocccgaac tccatgggtt tccagtagaa tttcaagcca gatgtggctg cagctgagcc agagtctgaa agggtgggat 
cacatgttca ctgttgactt ctggactatt atggaaaatc acaaccacag caag
Rgure 1.5: Exon 2 of the HFE gene and location of the H63D and S65C mutations (in bold) [Source: adapted from 
results of GenBank search on NCBI, http://www. ncbi. nlm. nih.Qoyj.
Restriction endonuclease digestion in conjunction with electrophoresis allows simple 
determination of sample mutational status.
Electrophoresis through agarose (or polyacrylamide) gels is the standard method used to 
separate, identify and purify DNA fragments. The technique is simple, rapid and capable of 
resolving fragmente of DNA that cannot be separated adequately by other procedures, such as 
density gradient centrifugation. The location of DNA within the gel can be determined directly by 
the use of ethidium bromide staining detected under UV light
Agarose gels have lower resolution than their polyacrylamide counterparts, but a greater range of 
separation. DNAs from 200bp to nearly 50kb in length can be separated on agarose gels of 
different concentrations (Sambrook et al., 1989).
Agarose, which is a neutral polysaccharide extracted from seaweed, is a linear polymer whose 
basic structure is:
t
Nucleotide no. 4915
W X W ^ X W W
HN
N H
O
Figure 1.6: Chemical structure of agarose [Source: http://vv\vw.bioloq.de/a036.html].
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Special types of low melting temperature agarose can be used to analyze very small fragments of 
DNA (10-500bp) and have a greater resolving power than gels made with normal agarose.
Agarose gels are cast by melting an amount of agarose in a volume of buffer until a clear, 
transparent solution is achieved. This solution is then poured into a mold and allowed to harden 
or polymerize. On hardening, the agarose forms a matrix, the density of which being determined 
by the concentration of the agarose. When an electric field is applied across the gel, DNA, which 
is negatively charged at neutral pH, migrates toward the anode. The rate of DNA migration is 
determined by the:
- molecular size of the DNA (larger molecules migrate more slowly because of 
greater frictional drag and because they pass through gel pores less efficiently 
than smaller molecules).
- agarose concentration (gels of different agarose concentrations can separate 
linear DNA of different sizes).
- conformation of the DNA (different conformations of DNAs of the same molecular 
weight migrate through agarose geis at different rates)
- applied voltage (migration rate of linear DNA fragments is proportional to the 
voitage applied. For maximum resolution of DNA fragments greater than 2kb in 
size, gels should be run at no more than 5 V/cm.
- direction of the eiectric field
- base composition and temperature
- Presence of intercalating dyes (ethidium bromide is a dye which intercalates 
between stacked base pairs, extending the length of DNA molecules and 
increases their rigidity).
- Composition of the electrophoresis buffer (DNA electrophoretic mobility is 
affected by the composition and ionic strength of the buffer. If there are no ions, 
electrical conductance is minimal and DNA migration is very slow) (Sambrook et 
al„ 1989).
Liver biopsy was once considered essential by many authorities, when the diagnosis of 
haemochromatosis was suspected due to either clinical or biochemical abnormalities (Sallie et al., 
1991; Powell, 1996). The procedure for hepatic biopsy is invasive and may not be advisable in 
reluctant or older patients, or those with other complicating medical conditions. Alternative
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methods that may be of use in the diagnostic evaluation of severe hepatic iron deposition, are 
computed tomography (CT) scanning and magnetic resonance imaging (MRI), but both 
techniques are quite expensive (Bonkovsky et al., 1990; Chezmar et al., 1990).
1.8 Screening
By definition, a screening test is one administered on a single occasion in seemingly normal 
individuals to allow detection of a disease at a time when instigation of appropriate treatment will 
substantially improve outcomes (Prorok, 1992). Haemochromatosis represents the current model 
for genetic screening for disease predisposition followed by preventative therapy. A study by 
Niselle et al., in 2004, investigated the implementation of a workplace-based genetic screening 
programme for haemochromatosis. Results of the investigation showed that widespread 
screening for hereditary haemochromatosis is readiiy accepted in the workplace and a “one-to- 
many” education programme is effective. It was also found that the level of participation varied 
greatly and that the advertising and logistics of the screening programme should be adapted to 
reflect this and suit the specific features of each workplace.
A review on hereditary haemochromatosis by Limdi & Crampton (2004) reiterates that the 
condition meets a number of WHO criteria for population screening (Wilson & Junger, 1968), 
such as a latent period, availability of a screening test, and safe, cost-effective treatment. 
Despite this, there is still much debate as to whether population screening for the 
haemochromatosis mutations is worthwhile. A review by the European & UK Haemochromatosis 
Consortia (2000) highlighted that although there are many epidemiological arguments in favour of 
developing screening programmes for haemochromatosis, the condition of hereditary 
haemochromatosis does not yet fulfill the criteria of Wilson & Junger (1968) for implementation of 
a screening programme,
Serum transferrin saturation (preferably in the fasting state to help eliminate confounding factors 
such as iron fortified preparations or oral contraceptives) is the best initial screening test for 
haemochromatosis (Edwards & Kushner, 1993; George et al., 1995). Although population 
screening studies have traditionally used a transferrin saturation threshold of > 45-75 %, it is 
likely that a value of 55 % gives the best positive predictive value. Following determination of 
transferrin saturation, serum ferritin is usually measured and it is only if concentrations > 300 pg/l 
that genotyping is recommended (Dooley & Worwood, 2000). Results from the HEIRS
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(Hemochromatosis and Iron Overload Screening) study, presented by Adams et al., (2005(b)), 
have suggested that the unbound iron binding capacity (UIBC) be used as an alternative 
biochemical screening test to transferrin saturation to identify individuals with C282Y-linked 
haemochromatosis. An advantage of population screening is that it would permit early
identification of those at risk from iron overload before clinical complications of the disorder occur. 
Disadvantages may be its cost-effectiveness and potential implications for negative bias in health 
insurance and employment (Cifuentes Henderson et al., 2002).
The optimal time for screening is between the ages of 18 and 30, a time when haemochromatosis 
is evident from biochemical tests, but before serious organ damage has occurred (Bacon et al., 
1999b). Screening of children is currently not recommended (Adams et al., 2000).
A recent study by Patch et al., (2005) iookea at factors affecting the uptake of two different 
strategies for screening, i.e. phenotypic versus genotypic. Results showed that the uptake of 
screening with a genotypic strategy was not inferior to that in a phenotypic strategy. A study by 
Gason et al., (2004) on the novel concept of genetic susceptibility screening in schools, indicated 
that it could be a public health success, provided community support was obtained. Allen et al., 
(2005) have presented data that demonstrates that population-based screening, prior to the onset 
of symptoms, is both practicable and acceptable to the community. Of the 11,307 individuals 
they screened, genotyping was completed on 11,287 individuals. Out of the 51 C282Y 
homozygotes identified, 46 have taken steps to treat or prevent iron overload.
Population genetic screening programmes will remain a contentious issue until it can be 
demonstrated that the benefits outweigh any potential harm or costs (Gertig et al., 2003; Yapp et 
al., 2001), and optimal screening strategies are designed to meet various medical, ethical, legal 
and social issues, whilst identifying ‘at risk1 individuals (Adams 2005a; Olynyk et al., 2005; 
Delatycki et al., 2005; Powell, 2005). The roie of HFE genotyping in asymptomatic populations 
has yet to be defined (The European & UK Haemochromatosis Consortia, 2000). Figure 1.7 is a 
typical algorithm for the evaluation of hereditary haemochromatosis.
Cadet et al., (2003) recommend that patients, presenting to hospital clinics with 
haemochromatosis associated conditions, should be screened biochemically for iron overload. 
They also state that patients at greatest risk of having undiagnosed haemochromatosis are those
24
Literature Review
presenting with unstable diabetes, or fatigue and/or arthralgia in the absence of any other 
explanation.
The HEIRS study aims to evaluate the prevalence, genetic and environmental determinants, and 
potential clinical, personal and societal impact of hemochromatosis and iron overload in a 
multiethnic, primary care-based sample of 100,000 adults over a five-year period. Information 
from the study will inform policy regarding the feasibility, optimal approach and potential health 
benefits and risks of primary care-based screening for hemochromatosis and iron overload 
(McLaren et al., 2003).
Figure 1.7: AASLD (American Association for the Study of Liver Disease) algorithm for the evaluation of hereditary 
haemochromatosis. From Tavill AS. Diagnosis and management of haemochromatosis AASLD practice guidelines. 
Hepatology;33:1321-8. Copyright © 2001, Wiley-Liss, Inc. Reproduced with permission of John Wiley & Sons, Inc.
Imperatore et al., (2004) listed the generally accepted criteria for an effective population-based 
screening test The criteria were as follows; the disorder screened for must be well-defined and 
represent an important health problem whose natural history is understood. The prevalence must 
be known and the disorder common enough that population screening is cost-effective. Suitable 
screening tests with known performances must be available, and for individuals identified as 
screen positive, there must be an adequate and acceptable protocol for diagnosis and effective
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treatment There should be adequate facilities available to support screening, diagnosis and 
treatment and costs must have been examined and found reasonable. Above all the approach 
must be considered ethical and must be acceptable to both health care providers and consumers.
1.9 Therapy
1.9.1 Phlebotomy
Therapeutic phlebotomy was the first successful treatment described for iron overload (Davis & 
Arrowsmith, 1952) and is still the preferred treatment for the condition today (Powell et al., 1994; 
Witte et al., 1996). For subjects who have already accumulated iron, the usual treatment is 
phlebotomy carried out at weekly intervals. A record should be kept of the volume or weight of 
blood venesected so that it is possible to calculate the amount of iron removed by treatment 
Guidelines on genetic haemochromatosis compiled on behalf of the British Committee for 
Standards in Haematology recommend the following treatment regime:
! Venesect 450-500 mi blood once weekly until serum ferritin concentration is below 20 yg/l and 
transferrin saturation s under 16%. Haemoglobin levels should be monitored weekly and the rate 
of venesection reduced in the event of anaemia developing. Serum ferritin should be monitored 
on a monthly basis and transferrin saturation measured as the ferritin concentration decreases 
below 50 |jg/1. Calculation of the amount of iron removed by therapy can be achieved by 
weighing the blood bag before and after phlebotomy (density of blood is 1.05 g/ml) and assuming 
that 450 mi blood (Hb concentration = 13.5g/dl) contains 200 mg of iron. If daiiy iron absorption 
of 3 mg is allowed for, the assumption is that 25 weekly venesections will remove 4.5 g of iron ’ 
(Dooley & Worwood, 2000).
Iron depletion by phlebotomy usually alleviates malaise, weakness and ease of fatigue, 
symptoms not attributable to specific organ dysfunction, but which affect approximately 80% of 
patients with iron overload (Powell et ai., 1994; Witte et al., 1996). Therapeutic phlebotomy can 
help resolve many liver-associated abnormalities. Cardiomyopathies and arrhythmias are also 
alleviated by the aggressive removal of stored iron (Cutler etal., 1980; Candell-Riera et al., 1983; 
Rivers et al., 1987). Patients with haemochromatosis, who do not have hepatic cirrhosis, 
diabetes meliitus or cardiomyopathy and who undergo and maintain depletion of iron stores by 
phlebotomy, can expect to have a normal life expectancy. For patients who have these
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aforementioned complications, therapeutic phlebotomy often improves the quality of life and may 
increase longevity (Niederau et al., 1985 & 1996; Powell 1986; Adams et al., 1991(b)). Cirrhosis 
of the liver rarely resolves with venesection therapy (Knauer et al., 1965; Weintraub et al., 1966; 
Powell & Kerr, 1970). De Valk et al., in 2000 stated that phlebotomy treated haemochromatosis 
homozygotes maintain a high and potentially harmful non-transferrin-bound iron (NTBi). 
Haemochromatosis heterozygotes have a higher serum NTBI than normal controls. The reported 
increased risk of cardiovascular events in heterozygous haemochromatosis may be explained by 
NTBI-catalyzed LDL peroxidation (De Valk et al., 2000).
1.9.2 Chelation Therapy
Although phlebotomy is well established for the treatment of haemochromatosis, it requires an 
intact haemopoietic system to maintain its efficacy. Therefore, it is unsuitable for patients with 
genetic and other chronic anaemias who require blood transfusions for their survival, and the only 
available method of protection against consequences of transfusional iron overload for these 
individuals, is chelation therapy (Hershko et ai., 2000). Chelation therapy can be used to achieve 
safe tissue iron concentrations by promoting negative iron balance. The therapy can also serve 
to detoxify excess iron in the body. Chelatable iron is that which comes from the continuous 
catabolism of red cell haemoglobin as well as iron obtained from the breakdown of ferritin within 
lysosomes. Chelation of iron can be achieved by either subcutaneous infusion of deferoxamine 
or oral therapy with deferiprone, see Figure 1.8 (Porter, 2001; Nielsen et al., 2003). The dose 
regime for both forms of chelation therapy involves a balance between the risks of excess iron 
and those of excess chelator. Lower doses, given more continuously are generally more efficient 
and less toxic than larger, more intermittent doses of chelator (Porter, 1997). The efficiency of 
chelation regimes is low, with 90% of subcutaneous deferoxamine (Porter et al., 2000) and 96% 
of deferiprone (Al-Refaie et al., 1995) being excreted without binding iron.
OH
o
OH
Deferoxamine B
0H3
Deferiprone
Figure 1.8 Iron Chelators [Source: http://www.medicinescomplete.com: http://www.lipomed.com1
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1.10 Social & Ethical Issues
Genetic testing for haemochromatosis raises concerns about stigmatisation and discrimination 
which in turn raises concerns about possible breaches of privacy and confidentiality. Diagnosis 
of, or a predisposition to, the condition may lead to possible loss of insurance coverage and 
employment both of which have been reported by Alper et al., (1994). Such instances of 
discrimination in health insurance and employment should be prohibited by law, but as yet have 
not been defined with enough clarity to afford legal protection to those concerned. Once a person 
has been diagnosed with haemochromatosis it is necessary to explain that other family members 
may also be at risk. Genetic testing and counselling should be offered to all first-degree relatives 
of the proband, it is important to note that some but not all insurance companies take the view 
that haemochromatosis, when properly diagnosed and managed, does not justify refusal of 
insurance cover or increased premiums.
1.11 Relationship to other disorders
There may be a high frequency of heterozygosity for haemochromatosis in patients with porphyria 
cutanea tarda (PCT), sideroblastic anaemia and hereditary spherocytosis with iron overload, 
amongst other conditions (Simon, 1985).
A study by Elder & Worwood (1998), showed a high frequency of HLA-A3 in patients with PCT, 
which is suggestive of the presence of a haemochromatosis mutation also. Although patients 
with PCT exhibit some iron accumulation, very few of them have an iron overload which would be 
considered diagnostic for haemochromatosis. Roberts et al., (1997a, 1997b), also showed that 
PCT patients demonstrated a high frequency of HLA-A3 in addition to a high frequency of 
D6S265-1, D6S105-8 and D6S1260-4, all of which are allelic markers associated with the 
ancestral haplotype for haemochromatosis. A study by Sampietro et ai., (1998) showed findings 
opposite to that of these two studies, in that PCT patients did not show an increased frequency of 
the C282Y mutation. The study did, however, demonstrate a significant increase in the frequency 
of the H63D mutation when compared to the control population or other patients suffering with 
viral hepatitis. The relationship between PCT and haemochromatosis can be summarized by 
stating that; haemochromatosis per se does not precipitate PCT (Brissot et al., 1978) and 
inheritance of the haemochromatosis gene is an important susceptibility factor for sporadic PCT,
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but the coexistence of the two conditions needs further investigation (Roberts et al., 1997a, 
1997b).
A review by George et al., (1999) provides evidence that mild to moderate iron ioading due to 
either homozygosity or heterozygosity for the haemochromatosis mutations, acts as a 
hepatotoxin by aggravating liver damage from other causes of liver disease, like non-alcoholic 
steatohepatitis, chronic hepatitis C, PCT and possibly primary liver cell cancer.
Co-inheritance of heterozygosity or homozygosity for haemochromatosis with that for beta- 
thalassaemia, may increase the rate at which iron overload occurs (Rees et al., 1997). 
incidences have been reported where patients with sideroblastic anaemias have expressed HFE 
mutations (Yaouanq et al., 1997; Cotter et al., 1999). Results from a study by Jazayeri et al., 
(2003), suggested that the mutations C282Y and H63D are more frequent in Iranian beta- 
thalassemia minor patients than in the normal population but cause no significant changes in 
serum ferritin level.
In Wilson’s disease, genetic mutations cause excess copper to accumulate in the liver or brain 
and because there is increasing evidence for an interaction between copper and iron metabolism, 
it is reasonable to assess iron indices in Wilson’s disease sufferers in order to detect iron 
overload (Erhardt et al., 2002).
it has been suggested that if iron plays an important role in the pathogenesis of atherosclerosis 
and ischaemic heart disease, subjects homozygous or heterozygous for haemochromatosis might 
be expected to experience high rates of the disease (Burtet al., 1993; Sempos & Looker, 1999). 
However, systemic reviews do not support the existence of strongly positive or strongly negative 
epidemiological associations between iron status and cardiovascular disease (Kelly, 2002). 
Worwood (2002) stated that heterozygosity for either C282Y or H63D does not appear to be a 
risk factor for common conditions like diabetes, liver and cardiovascular disease. Hetet et al., 
(2001) reviewed three association studies between the haemochromatosis gene and the risk of 
cardiovascular disease. None provided consistent evidence supporting the hypothesis that HFE 
mutations are associated with an increased risk of cardiovascular disease and with the 
development of arteriosclerosis. A case-eontrol study by Claeys et al., (2002) also reported no 
association between genetic haemochromatosis and myocardial infarction. No evidence to 
support an association between haemochromatosis and atherogenesis was found, when a study
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into the prevalence of haemochromatosis in premature atherosclerotic vascular disease was 
conducted by Franco et al., in 1998.
Iron is potentially carcinogenic as it has a catalytic effect on the formation of hydroxyl radicals 
(initiation), it is an essential nutrient for tumour cells (promotion) and it has the potential to 
suppress the activity of immune cells. Based on epidemiological surveys, the possibility of a 
positive association between measures of iron status and cancer, in the general population, has 
been proposed (Knekt et al., 1994; Stevens et al., 1988 & 1994). The evidence relating iron to 
cancer and cardiovascular disease risk is inconsistent and equivocal for the general population 
(Kelly, 2002).
1.12 Summary of mutational incidence (worldwide)
The figures presented below (Figures 1.9 to 1.14) summarise the incidence of HFE mutational 
genotypes in 25 clinically diagnosed populations versus 64 general populations. In clinically 
diagnosed proband populations (those with haemochromatosis), the commonest mutational 
genotype was C282Y homozygosity followed by C282Y/H63D compound heterozygosity (see 
Figure 1.9). The reverse was the case, when general (control) populations were screened (see 
Figure 1.7). The Reference Code for the information compiled below is as follows:
* = Rivard et al., (2000).
# = http://www.cdc.gov/genomics/hugenet/reviews/tables/HFE_Tables.htm
= Milmanetal., (2003).
A = Imperatore et al., (2003)
$ = Guix et al., (2002)
+ = Beutler et al., (2002a)
£ = Jackson etai., (2001)
> = Deugnier et al., (2002)
< = Cadet etal., (2003)
! = Rossi et al., (2004)
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Figure 1.9: incidence of C282Y homozygosity & C282Y/H63D compound heterozygosity in clinically
diagnosed proband populations.
Of the data presented for 25 countries/regions, the frequency of (a) C282Y homozygosity in 
clinically diagnosed proband populations, ranged from 43.8% in Canada’s Saguenay-Lac-Saint- 
Jean (SLSJ) region to 100% in each of Australia, New Zealand and England (Eastern). The 
frequency in Ireland was reported at 89.7%. (b) C282Y/H63D compound heterozygosity in 
clinically diagnosed proband populations, ranged from 0% in England (Eastern), New Zealand, 
Canada (Ontario) and Australia, to 9.6% in France (Brittany). The frequency in Ireland was 
reported at 3.8% (see Figure 1.9).
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Figure 1.10: Incidence of C282Y homozygosity & C282Y/H63D compound heterozygosity in general
populations.
Of the data presented for 25 countries/regions: the frequencies of C282Y homozygosity in 
general populations, ranged from 0% in 12 out of 25 countries/regions to 1.4% in Denmark 
(n=219), the frequency in Ireland was reported at 0%, and C282Y/H63D compound 
heterozygosity in general populations, ranged from 0% in Denmark (n=219), USA (Connecticut- 
Caucasians) and France (n=9396), to 4% in the UK (n=101). The frequency of C282Y/H63D 
compound heterozygosity in Ireland and Northern Ireland was reported at 3.7% and 2.5%, 
respectively (see Figure 1.10).
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Figure 1.11: Incidence of H63D homozygosity, C282Y heterozygosity & H63D heterozygosity in clinically
diagnosed proband populations.
Of the data presented for 20 countries/regions: the frequencies of H63D homozygosity in clinically 
diagnosed proband populations, ranged from 0% in 5 out of 20 countries/regions to 12.5% in 
Canada (SLSJ), and the frequency in Ireland was reported at 0%. The frequencies of C282Y 
heterozygosity in clinically diagnosed proband populations, ranged from 0% in 4 out of 20 
countries/regions to 14.9% in USA (Alabama), and the frequency in Ireland was reported at 2.6%. 
The frequencies of H63D heterozygosity in clinically diagnosed proband populations, ranged from 
0% in 3 out of 20 countries/regions to 13.4% in France (Brittany), and the frequency in Ireland 
was reported at 1.3% (see Figure 1.11).
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Figure 1.13: Incidence of C282Y heterozygosity in general populations.
Of the data presented for 47 countries/regions, the frequency of C282Y heterozygosity in general 
populations, ranged from 0.5% in South Africa to 28.4% in Ireland (see Figure 1.13).
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Figure 1.14: Incidence of H63D heterozygosity in general populations.
Of the data presented for 56 countries/regions, the frequency of H63D heterozygosity in general 
populations, ranged from 1.1 % in Australia (Vanuatuan) to 43.1% in the Chuetas (Majorcan jew) 
population. The frequency in Ireland was reported at 24.8% (see Figure 1.14). It should be 
noted, however, that sample population sizes differed in each country/region presented in Figures
1.9 to 1.14.
As discussed previously, results from studies of HFE mutations in North African populations have 
revealed that the C282Y mutation is extremely rare. Sassi et al., (2004) reported allele 
frequencies for C282Y and H63D in aTunisian population to be 0.09% and 15.17%, respectively. 
Similar allele frequencies for C282Y and H63D (13.2% and 0.9%) were reported in individuals 
with a North African ancestry, but who were living in Southern France (Aguilar-Martinez et al., 
2001).
A study by Guix et al., (2000) reported a C282Y mutation frequency in Majorcans of 2.62 ± 0.8%. 
Another study Guix et al., (2002) on the prevalence of C282Y and H63D mutations in the Balearic 
Islands showed the populations were not homogeneous. The C282Y chromosomal frequency 
was very low in Minorca (1.2%) when compared to the other islands of Majorca (4.7%) and Ibiza
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(6.5%). The heterozygote frequency of the H63D mutation in all three islands was similar and 
quite high (27.5%, 34.9% and 31.4%, respectively).
The frequency of the haemochromatosis C282Y mutation was reported to be 2.59 ± 1.25% in 
Hungarians, and 1.07 ± 1.20% in Romanies, living in eastern Hungary (Szakony et al., 1999). 
Miedzybrodzka et al., (1999) reported high allele frequencies for C282Y (8%) and H63D (15.7%) 
in North-East Scotland. In Sweden, a study by Cardoso et al., (1998) showed the chromosomal 
frequency for C282Y in the control population was 3.8%, and for the H63D mutation was 12.4%. 
An allele frequency of 4.8% for C282Y was found in control subjects from Northern Germany 
(Nielsen et al., 1998). In comparison to these results, Murphy et al., (1998) estimated allele 
frequencies of 9.9% and 14.10% for the C282Y and H63D mutations, respectively in an Irish 
population.
The first global population analysis of 2978 people showed a prevalence for C282Y of 1.9% and 
for H63D of 8.1% (Merryweather-Clarke et al., 1997a). A high C282Y allele frequency of 9.44% 
has been reported for a population from western Brittany (Jezequel et al., 1998). A review by 
Mortimore et al., (1999) details that the C282Y mutation is virtually absent in African, Asian and 
indigenous Australasian populations and has a very low frequency (generally below 1.4%), on the 
Indian subcontinent and in indigenous Americans. The highest C282Y allele frequency was 
found in Irish samples and was approximately 10% (Merryweather-Clarke et al., 1997a).
The H63D mutation is frequently observed in European populations at frequencies ranging 
anywhere between 6.7 and 30.4% (Merryweather-Clarke et al., 1997a). The same mutation was 
also detected at high frequencies (6.5-9.2%), in North Africans (Roth et al., 1997), Mexicans and 
Asian Indians. Low frequencies for H63D (between 0.6 and 2.8%) were observed in the following 
populations; Sub-Saharans, Jamaicans, Vancouver island Indians, Hong Kong Chinese, 
Indonesians and Vanuatuans. There was a complete absence of the H63D mutation in the 
following populations; Senegalese, Taiwanese, Australian Aboriginals and indigenous people 
form Papua New Guinea and Colombia (Merryweather-Clarke et al., 1997a). Another study by 
Cullen et al., (1998) reported findings of very low mutational frequencies for C282Y (< 1.07%) in 
Australian Aboriginal, Melanesian and Polynesian populations. It also reported an absence of the 
C282Y mutation in Chinese, Javanese, Micronesian and Nepalese individuals.
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The first description of diabetes is usually credited to Arataeus of Cappadocia in Asia Minor in the 
first century AD, who was also responsible for giving the disease its name. However, the greatest 
figure in the history of diabetes in the first half of the nineteenth century was undoubtedly Claude 
Bernard, who discovered that the liver stored glycogen and secreted a sugary substance into the 
biood. In 1879, Von Mering, a German physician discovered that removing the pancreas caused 
diabetes. This showed that the pancreas contained an antidiabetic substance later known as 
insulin. Insulin was first crystallized in 1926 by J.J. Abel (Alberti et al., 1997).
Classification of Diabetes
Diabetes mellitus is a syndrome or a collection of disorders that have hyperglycaemia and 
glucose intolerance as their hallmarks. The contemporary classification of diabetes was 
developed by the National Diabetes Data Group of the National Institutes of Health, USA (1979) 
and later endorsed by the World Health Organization (WHO) Expert Committee on Diabetes 
(1980), and the WHO Study Group on Diabetes Mellitus (1985). These groups recognized two 
main types of diabetes, insulin dependent diabetes mellitus (IDDM, type I diabetes) and non­
insulin dependent diabetes mellitus (NIDDM, type II diabetes).
Criteria for the diagnosis of Diabetes Mellitus is as follows;
(1) Classic symptoms of diabetes and plasma glucose concentration >11.1 mmol/L (200 
mg/dL) regardless of the time of the preceeding meal
(2) Fasting (no calorific intake for at least 8 hours) plasma glucose level of > 7 mmol/L (126 
mg/dL)
(3) 2-hour postioad plasma glucose concentration of > 11.1 mmol/L during the oral glucose 
tolerance test (200 mg/dL) (American Diabetes Association, 1997)
Diabetes occurs either because of a lack of insulin or because of the presence of factors that 
oppose the action of insulin. Diabetes is diagnosed by way of a glucose tolerance test The two 
most common forms of diabetes are discussed below.
Type I Diabetes (Insulin Dependent Diabetes Mellitus/IDDM):
This form of diabetes is generally characterized by abrupt onset of severe symptoms and 
dependence on exogenous insulin to sustain life. Type I diabetes is due to the destruction of 0-
1.13 Diabetes: A  brief history & Classification
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cells in the pancreatic islets of Langerhans, which in turn results in loss of insulin production, it is 
generally thought that a combination of environmental and genetic factors cause an autoimmune 
attack on the (S-cells. The highest incidence of type I diabetes is in Scandinavia, of medium 
incidence in Europe and the USA and lowest in Oriental or tropical regions (Diabetes 
Epidemiology research International Group (1990). It is now apparent that type I diabetes is a 
chronic autoimmune disorder that develops gradually over time, with suggestions that both MHC 
Class II genes and T lymphocytes are important in the pathogenesis of islet B-cell destruction 
(Mordes et al., 1987; Rossini et al., 1984). The main defect in type I diabetes appears to be 
related to the activation of T lymphocytes which then mediates the destruction of the islets. T-cell 
activation through gene rearrangement may be a close step to the development of type I diabetes 
in an individual who is genetically predisposed to the disease, and environmental factors may act 
by triggering or selecting the appropriate T-cell receptor rearrangement (Hoover & Capra, 1987; 
Ito et al., 1988; Millward et al., 1987). Environmental agents could play several roles in type I 
diabetes in that they may function as initiating factors i.e. factors which begin or continue the 
aetiologic processes, which eventually terminate in type I diabetes. Alternatively, they may act as 
factors that convert pre-clinical diabetes into clinical disease (Bosi et al., 1987; Gamble, 1980).
Type H Diabetes (Non-Insulin Dependent Diabetes Melfitus /  NIDDM /  Adult-onset diabetes):
Type II diabetes constitutes approximately 90% of all cases of diabetes. People with type II 
diabetes are not dependent on exogenous insulin for the prevention of ketonuria but they may 
require insulin for correction of fasting hyperglycemia. The underlying mechanism of this form of 
diabetes is due either a diminished insulin secretion or increased hepatic glucose output As 
many as 98% of cases of Type II diabetes are ‘idiopathic’, meaning no specific causative defect 
of the condition has yet been identified. Type li diabetes has a strong genetic basis as evidenced 
by its frequent familial pattern of occurrence, high prevalence in certain ethnic groups and genetic 
admixture studies (Kaprio et al., 1992; Newman et al., 1987), however the gene(s) causing most 
cases of Type II diabetes remain obscure. It is thought that the causes of Type II diabetes lie in 
environmental and lifestyle factors superimposed on genetic susceptibility (Harris and Zimmet 
1997).
Figure 1.15 demonstrates the role of insulin in development of diabetes. The figure shows that if 
the body is functioning normally, it is insulin that permits glucose entry to cells where it is 
subsequently used to provide energy. In the case of Type I diabetes, no insulin is being 
produced by the body and glucose is therefore not able to enter cells. With Type II diabetes,
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insulin is being produced by the body but in insufficient quantities to allow adequate glucose entry 
to the cells.
How our bodies use 
insulin and glucose
NORMAL FUNCTIONING  
In su lin  15 th e  k e y  to  
lettin g  t h e  g lu c o s e  e n te r  
Che c e ll . G lu c o s e  In ttie  
cell is  tra n s fo rm e d  Into 
e n e r g y  f o r  t h e  b o d y.
T Y P E  I D l  A U l £  T E  3  
In  T y p e  I d ia b e te s  
th e  p a n c r e a s  is n ot  
p ro d u cin g  in su lin ; 
th e r e fo r e  th e  g lu c o s e  
is  n o t a b le  to  e n te r  
th e  ceil.
T Y P E  II D l  A O  
In  T y p e  IE d ia b e te s  
th e  p a n c r e a s  still 
p ro d u c e s  in su lin , 
b u t n o t e n o u g h  
to  h elp  a d e q u a te  
a m o u n ts  o f  g lu c o s e  
into t h e  cells .
glucose I I insulin J cell
Figure 1.15: Type I & Type II Diabetes Mellitus [Source: http://www.diabetes-and-diabetics.com] Accessed on 
25/05/2005.
1.14 Genetics of Diabetes
The main information used to support the hypothesis that diabetes mellitus is a hereditary 
disorder is its familial incidence. Diabetic individuals have an increased family history of the 
disease with the frequency of diabetics having positive family histories ranging from 25 to 50%. 
The relative frequency of a positive family history in non-diabetics is less than 15% (Rimoin & 
Schimke, 1971). Studies on twins have also confirmed the importance of genetic factors in the 
aetiology of diabetes. Most investigators have reported a concordance rate of between 45 and 
96% for monozygotic twins (i.e. twins that share all genes), and 3-37% for dizygotic twins (twins 
that share half of their genes), when clinical diabetes was used as the criterion. The theory of 
genetic heterogeneity proposed in 1967 by Rimoin, was backed up by the following indirect 
evidence;
- the existence of distinct genetic disorders that have glucose intolerance as one of their features 
(Rotter et al., 1992).
- genetic heterogeneity exhibited in diabetic animal models
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- the ethnic variability in prevalence rate and clinical features
- the clinical variability between individuals e.g. thin, ketosis-prone insulin-dependent juvenile 
diabetes vs. obese, non ketotic, insulin-resistant adult-onset diabetes
- physiologic variability i.e. in the plasma insulin levels of individuals.
Direct evidence for genetic heterogeneity came from clinical genetic studies, the results of which 
suggested that insulin-dependent and non-insulin dependent patients differed genetically within 
families (Rotter et al., 1978a; Simpson, 1976).
Clinical and genetic evidence from twin and familial studies eventually led to the separation of 
type I and type II diabetes. Physiologic studies further supported this separation and 
immunologic studies highlighted the importance of immune mechanisms in the aetiology of Type I 
diabetes, but not Type II diabetes. Finally, the major argument for aetiologic differences between 
the two types of diabetes is the consistent association of Type I diabetes with HLA antigens, with 
approximately 95% of Type I diabetes patients having DR3 or DR4 or both (Nerup et al., 1977; 
Maclarenetal., 1988; Platzetal., 1981; Rotter etal., 1983; Wolfet al., 1983).
1.14.1 Genetics of Type I Diabetes Mellitus
There is no consensus as to which gene or combination of genes in the major histocompatability 
complex is responsible for HLA-related susceptibility to diabetes, or other genes outside the HLA 
region that are involved. Difficulties in analyzing the genetics of Type I diabetes include the 
reduced penetrance of the disorder, the confounding effect of linkage and association and the 
heterogeneity within the disorder (Rotter & Rimoin, 1978b). Genetic determinants are important 
risk factors for Type I diabetes, especially certain histocompatability antigens (HLA) located on 
chromosome 6. Studies have shown that in Europe and North America around 95% of young 
Type I diabetes patients have either HLA DR3 or HLA DR4 or both, compared to only 20% of the 
general population (Nerup, 1976; Cudworth & Woodrow, 1976). Other MHC genes like DPA1 
and DPB1 may act as candidate susceptibility determinants for type I diabetes. A positive 
association has been found between a DPB1 polymorphism and diabetes in a European 
population but not in other races (Eastel et al., 1990). Susceptibility to Type I diabetes has been 
associated with the C4A3 allele of the C4 complement locus and an increase in the frequency of 
C4AQ0/C4BQ0 (null) alleles (Thomsen et al., 1988; White, 1989). It has even been suggested 
that single gene copies of the C4 genes were a common feature of diabetes-associated
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haplotypes (Serguado et al., 1992). Other non-HLA genes that are candidates for susceptibility to 
type I diabetes include the insulin gene and T-cell receptor genes. Results from comparative 
mapping studies using animal models of Type I diabetes, propose that a gene residing on 
chromosome 11q23 might cause susceptibility to type I diabetes in women. This gene was 
designated as human IDDM2 by the Eleventh International Workshop on Human Gene Mapping 
(Junien & van Heyningen, 1991). Support has come from animal models of diabetes, for the 
importance of non-HLA region genes in susceptibility to Type I diabetes. The availability of large 
numbers of multiple-case pedigrees (Bain et al., 1990; Lernmark et al., 1990) allowed type I 
diabetes to be one of the first complex disorders subjected to a systematic search for 
susceptibility loci, using PCR or automated DNA technology. A landmark study by Morton et al., 
in 1983 confirmed the dominance of MHC-encoded susceptibility (called IDDM1) to type I 
diabetes. Linkages of Type I diabetes mellitus to chromosomes 11q and 6q were confirmed by 
replication studies (Hashimoto et al., 1994; Field et al., 1994; Pociot & Nerup, 1993; Barbosa et 
al., 1982).
1.14.2 Genetics of Type II Diabetes Mellitus
Evidence of a genetic contribution to Type II diabetes mellitus has come from animal studies 
which suggest that diabetes can be modified by genes other than those directly responsible for 
obesity and/or diabetes in mice (Coleman, 1982; Coleman & Hummel, 1973; Zhang etai., 1994). 
Several studies have shown that in populations with a high prevalence of Type II diabetes, the 
distribution of glucose tolerance may be bimodal. This means that fasting giucose levels appear 
to be distributed around two distinct mean values. Interpretation of this suggests that there is a 
major gene which influences glucose tolerance (Elston et al., 1974; Raper et al., 1984; Rushforth 
et al., 1971; Zimmet & Whitehouse, 1978). However, it should be noted that in most populations, 
blood giucose values are unimodally distributed due to their heterogeneous nature. Twin and 
familial studies have long suggested a strong ‘genetic’ susceptibility to Type II diabetes. Studies 
in monozygotic twins demonstrate almost complete concordance for Type II diabetes (Pyke, 
1979; Barnett et al., 1981), yet the aggregation of clinical disease or glucose levels in families is 
not consistent with a single, simple mode of inheritance (Rotter & Rimoin, 1981). The most likely 
explanation for this would be genetic heterogeneity, although environmental factors are known to 
be important as well. Several studies have suggested that impaired insulin secretion is an early 
defect in the development of Type II diabetes (Cerasi & Luft, 1967; O’Rahilly et al., 1986; 
Polonsky et al., 1988; Mitrakou et al., 1992). Genetic susceptibility appears to be the primary
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determinant for development of Type II diabetes and in all probability, at least some forms of 
Type II diabetes require the presence of one or more gene defect to cause clinical diabetes. 
Genetic defects couid influence any of the many steps in glucose metabolism and these defects, 
alone or in concert with other defects, could result in Type II diabetes mellitus. This makes 
studying the genetics of Type II diabetes problematic, as this extensive etiologic heterogeneity 
underlies the disease (Scheuner et al., 1997).
1.15 Summary of incidence (worldwide)
A large number of studies support the theory that the ‘diabetes epidemic’ is to continue well into 
the future (King et al., 1998; Wild et al., 2004; International Diabetes Federation 2003; Lefebvre 
2002; Amos et al., 1997; Zimmet et al., 2001; Larkin, 2001). Results of a study by Wild et al., on 
the global prevalence of diabetes were published in 2004. This study utilized data on diabetes 
prevalence by age and gender from a limited number of countries, to extrapolate to all World 
Health Organization member states. The data was subsequently applied to United Nations 
population estimates, to calculate diabetes prevalence for the year 2000 and to make projections 
of prevalence for the year 2030. The authors estimated the prevalence of diabetes to be 2.8% in 
2000 and 4.4% in 2030. This means, that the overall number of people with diabetes is projected 
to rise from 171 million in 2000 to 366 million in 2030. Given that these figures will continue to 
rise even if obesity levels associated with diabetes mellitus were to remain constant, it is likely the 
prevalence of diabetes may be underestimated as obesity is on the increase. In 2003 the 
International Diabetes Federation (iDF) also released estimates of numbers of people with 
diabetes for 2003 and forecasts for 2025 of 194 million and 334 million, respectively.
Studies on the Irish population (King et al., 1998) estimated a diabetes prevalence of 1.8% for 
Ireland in the year 1995 and 2000 which would rise to 2.3% in 2025.
1.16 Haemochromatosis and Diabetes
A large number of mutations have been mapped to chromosome 6 (McKusick et al., OMIM, 
2006). Most of these mutations can be found on 6p (the short arm of chromosome 6), which is 
also the area where the HFE gene is localized. It is presumed that only genes on 6p may be in 
linkage disequilibrium with HFE, but most interestingly the gene causing insulin dependent / type I 
diabetes (IDDM1), is in close proximity. The chromosomal location of both disorders is band
43
Literature Review
p21.3 of chromosome 6 (i.e. 6p21.3), however exact locational status of the IDDM1 gene remains 
elusive, and the status of other genes associated with type 1 diabetes on the long arm of 
chromosome 6 (6q) remain provisional.
A conclusive answer as to whether the HFE gene is associated with or linked to other disease 
causing genes on chromosome 6 cannot be obtained until positional cloning of the candidate 
genes e.g. IDDM1 is conducted. Even though subjects I individuals with haemochromatosis have 
not been examined prospectively for other chromosome 6 genetic disorders, no suggestion for an 
association or linkage of the haemochromatosis allele to any other disorder on chromosome 6, 
other than that concerning diabetes mellitus, has been reported (Sheldon, 1935; Bassett et al., 
1981,1984; Simon et al., 1977,1980,1987; Edwards et al., 1981,1982,1988; McKusick et al., 
OMIM; Saddi et al., 1981; Kravitz et al., 1979; Cartwright et al., 1979; Beaumont et al., 1979; 
Valberg et al., 1980; Dadone et al., 1982; Lalouel et al., 1985; Milman et al., 1994; Borwein et al., 
1983,1984; Bulaj et al., 1996).
Early studies have reported an almost 80% prevalence of diabetes mellitus in haemochromatosis 
(Finch & Finch, 1966). Studies conducted later reported the prevalence to be about 50 -  60% 
(Niederau et al., 1985).
Although diabetes meilitus may be common in people with haemochromatosis (it is the most 
commonly observed endocrine disorder), it does not affect everyone. However, in late-stage 
haemochromatosis, iron deposition is often visible in the pancreas which leads invariably to 
pancreatic fibrosis. The severity and frequency of pancreatic dysfunction depends on the degree 
of iron overload within the body (Milman, 1991), and particularly the proportion of excess iron 
deposited in the islets of the pancreas. In 1995, a review by Yaouanq indicated that patients with 
haemochromatosis, who were diagnosed in the preclinical or early iron-loading phase, exhibited a 
lower prevalence of diabetes mellitus and less severe diabetes than patients with symptomatic 
iron overload. The clinical spectrum of diabetes mellitus in haemochromatosis is variable, having 
no consistent pattern of presentation and can range from latent diabetes to non-insulin dependent 
diabetes to insulin dependent diabetes. Such a wide spectrum of clinical manifestations favours 
the view that the severity of pancreatic dysfunction and diabetes may be related to the severity of 
iron deposition in the pancreatic islet cells, and therefore body iron overload (Milman, 1991). This 
view is supported by the observation that 40-50% of haemochromatosis patients with diabetes
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show improved carbohydrate tolerance following phlebotomy therapy. Insulin resistance is also 
markedly improved after this therapy (Dymock et al., 1972; Stremmel et al., 1988).
The prevalence of diabetes in people with clinically overt haemochromatosis has been reported 
as 40-55% (Milman, 1991; Niederau et al., 1985; Yaouanq et al., 1990), whereas it was only 13- 
17% in people with biochemical evidence of haemochromatosis without clinical signs (Yaouanq et 
al., 1990; Adams et al., 1991b). Homozygosity for the C282Y mutation occurs with a presumed 
prevalence of 0.4 - 0.5% and type 1 diabetes mellitus occurs with a similar lifetime cumulative 
prevalence of approximately 0.4% (Bain et al., 1997). This, combined with the high prevalence of 
diabetes in patients with haemochromatosis, meant that it seemed reasonable to postulate a 
genetic linkage between the two conditions (Dymock et al., 1972; Balzercak et al., 1968; Pozza & 
Ghidoni, 1968; Saddi & Feingold, 1974). Although there is no documented evidence of a linkage 
between the haemochromatosis locus and the IDDM1 gene, the disorder is strongly associated 
with HLA-hapiotypes known as ‘low-risk’ markers for type i diabetes, and there is even a 
suggestion that HLA-A3, B7 may have a protective effect against type I diabetes through its 
significant association with the aforementioned markers.
The close association between diabetes and haemochromatosis is well established (Fernandez- 
Real et al., 2002) with hepatic cirrhosis, damage to pancreatic beta-cells and genetic 
predisposition being the major causal factors of impaired glucose tolerance and diabetes in 
haemochromatosis (Niederau et al., 1981, 1984,1985; Saddi & Feingold, 1974; Strohmeyer et 
al., 1976; Saudek, 1980). Yaouanq’s study in 1990 showed that diabetics have twice as much 
mobilisable iron as non-diabetic patients. The decreased prevalence of haemochromatosis- 
associated diabetes over the last few decades is mainly due to higher numbers of people being 
diagnosed in the early stages, when glucose metabolism is still normal or only slightly abnormal. 
The prevalence of unrecognized haemochromatosis in diabetics has been estimated at 5-8 cases 
per 1000 in Europe (O’Brien et al., 1990; Czink & Tamas, 1991; Singh et al., 1992) and 9.6 cases 
per 1000 in Australia (Phelps et al., 1989), therefore it has been recommended that people with 
diabetes should also be evaluated for the possible presence of haemochromatosis.
Non-insulin dependent diabetes mellitus (NIDDMI Type II diabetes) is a common complication of 
diseases of iron overload such as haemochromatosis, with 53-80% of individuals with 
haemochromatosis developing diabetes (Witte et al., 1996). Salonen et al., (1999) conducted a 
study which showed an association between body stores of iron and the incidence of diabetes.
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Their data supported the theory that increased iron stores even in the range not considered to be 
associated with haemochromatosis, contribute towards development of Type II diabetes.
A study by Tuomainen et al., (1997) proposed that three mechanisms may associate between an 
elevated iron status and an increased risk of type II diabetes; (a) the effect of iron on insulin 
synthesis and excretion and the pancreatic cells, (b) the oxidation of free fatty acids by free 
radicals leading to decreased utilization of glucose by muscle tissue, which in turn leads to 
increased insulin resistance and (c) accumulation of iron in the liver, which interferes with its 
capacity to remove insulin from the blood.
In 1999, a large study was conducted by Ford & Cogswell, to investigate whether non- 
haemochromatotic individuals with elevated iron levels had a higher risk of type II diabetes. It 
reported an increased risk of newly diagnosed diabetes in both sexes, with elevated serum ferritin 
concentrations. However, the cross-sectional nature of this study, compounded by the fact that 
both risk factor and outcome were measured at the same time point means it is impossible to 
determine whether it is the elevated serum ferritin (an acute phase protein) causing the diabetes, 
or diabetes-induced inflammation causing elevated serum ferritin.
Niederau et al., (1985) reported that patients with hereditary haemochromatosis are at increased 
risk of type II diabetes and are seven times more likely to die from diabetes than the general 
population. However, there is conflicting evidence as to whether there is an increased risk of type 
II diabetes in C282Y heterozygotes (Salonen et al., 2000). A study by Jiang et al., (2004) showed 
that higher iron stores (reflected by an increased ferritin concentration and a lower ratio of 
transferring receptors to ferritin), are associated with an increased risk of type II diabetes in 
healthy women independent of known diabetes risk factors. A study in 2001 evaluated a possible 
association between HFE mutations and either chronic liver disease or type II diabetes. Three 
hundred and twenty seven individuals were tested for the C282Y, H63D and S65C mutations of 
haemochromatosis. One hundred individuals from this tested population had type II diabetes. 
Genotypic analysis of this group (n = 100), showed that 3% were homozygous for H63D, 27% 
were heterozygous for H63D, 1% were heterozygous for S65C and the remaining 69% had none 
of the three haemochromatosis mutations tested for (Campo et al., 2001).
Prior to the era of HFE gene testing, the most convincing data in support of screening a diabetic 
population for haemochromatosis was published by Phelps et al., (1989). The biochemical based
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screening strategy employed in their study, revealed a prevalence rate for hereditary 
haemochromatosis of 9.6 per 1000 in diabetic individuals. A similar but separate study 
conducted in the U.K reported a prevalence rate of 0.5% (5 per 1000), in diabetics tested (George 
et al., 1995). Subsequent to the availability of HFE testing numerous case-control studies have 
investigated the prevalence of HFE mutations among diabetic patients, compared to gender- and 
age matched non-diabetic controls (Dubois-Laforgue et al., 1998; Frayling et al., 1998; Sampson 
et al., 2000; Braun et al., 1998; Fernandez-Real et al., 1999 and Florkowski et al., 1999). The 
Spanish study (Fernandez-Real et al., 1999), found a significantly increased prevalence of the 
H63D allele in diabetics and serum ferritin levels were also significantly higher in type II diabetics 
that carried HFE mutations. A study by Kwan et al., (1998) found that there was an increased 
prevalence of the C282Y mutation in type II diabetics compared to individuals with type I diabetes 
(reported incidence rates of 21.9% versus 11.7%). In 2001, Moczulski et al., conducted a study 
on the role of C282Y and H63D mutations in the development of type II diabetes and diabetic 
nephropathy. Their results showed a significantly increased frequency of the C282Y mutation in 
diabetics when compared to the controls. They also observed an increased frequency of the 
H63D mutation in diabetics with microalbuminuria, which suggests that this mutation may play a 
role in susceptibility to diabetic nephropathy. Ellervik et al., (2001) concluded from a recent, iarge 
retrospective study in Denmark, that all individuals with late-onset type I diabetes should be 
screened for hereditary haemochromatosis.
Serum ferritin levels are increased in individuals with type II diabetes (in the absence of a 
reciprocal decrease of soluble transferrin receptor levels), thereby suggesting that the elevated 
ferritin levels seen in diabetics are a result of an inflammatory mechanism rather than due to iron 
overload (Hernandez et al., 2004).
Some ‘typical’ symptoms of haemochromatosis like diabetes and arthritis may be no more 
common in C282Y homozygotes than in matched controls (Adams, 2005c).
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Tables 1.0 & 1.1 below, show the incidence of HFE mutations in both diabetic populations and in 
populations without diabetes (controls), and conversely, the prevalence of diabetes mellitus in 
haemochromatotic populations. Figure 1.16 illustrates the survival rates of individuals with each 
permutation of the two conditions i.e. haemochromatosis and diabetes mellitus.
Table 1.0: Screening studies of HFE mutations in diabetics compared with controls [Source: DuBois & Knowdley, 
Alimentary Pharmacology & Therapeutics 2004;20(1 ): 1-14]
Author Year Sample size (N) Population HFE mutations
Sampson et al., 2000 - 220 normal subjects
- 220 type II diabetes 
mellitus (DM2)
England No difference
Femandez-Real et 
a l.
1999 -108 normal subjects 
-170 DM2
Spain No difference in C282Y; 
increased frequency of 
H63D allele in DM2 (22.64 
± 4.4 % versus 15.7 ±  0.9
%)
DuBois-Laforgue 
et a l.
1998 - 87 normal subjects 
-184 DM2
France No difference
Frayling et a l. 1998 - 215 normal subjects 
-238 DM2
England No difference
Kwanetal, 1998 -103 type I diabetes mellitus 
(DM1)
-105 DM2
Canada Increased C282Y 
frequency in DM2: (21.9% 
D M 2,11.7% DM1)
Florkowski et a l. 1999 -1064 normal subjects 
-230 DM2
New Zealand No difference
Braun et a l. 1998 - 355 normal subjects 
-401 DM2
Germany No difference
Table 1.0 shows that only two out of seven studies reported a difference in the incidence of HFE 
mutations in individuals with diabetes compared to that of control individuals. One study reported 
an increased H63D aliele frequency in individuals with type II diabetes mellitus (Fernandez-Real 
et al., 1999). Other workers have reported an increased C282Y frequency in individuals with type 
II diabetes mellitus (Kwan et al., 1998).
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Table 1.1: Prevalence of diabetes mellitus in primary haemochromatosis [Source: Strohmeyer & Niederau. Diabetes 
mellitus and haemochromatosis in Barton & Edwards Haemochromatosis: Genetics, pathophysiology, diagnosis and 
treatment. Cambridge University Press 2000]. * Indicates review from previous literature.
Reference Year Number of patients (n) Prevalence of diabetes 
(% of patients)
Sheldon 1935 311* 82
Butt & Wilder 1938 30 87
Finch & Finch 1966 707* 78
Wohler 1964 1500* 76
Dymock & Williams 1971 115 63
Stocks & Powell 1973 33 63
Saddi & Feingold 1974 96 69
Strohmeyer et al., 1976 40 70
Niederau et al., 1981 74 62
Niederau et al., 1985 163 55
Yaouanqetal., 1990 & 1995 474 40
Niederau et al., 1996 251 48
Adams et al., 1991a 85 21
Table 1.1 shows that between 21 and 87% of individuals with haemochromatosis have diabetes 
mellitus also.
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diabetes mellitus and the normal population i.e. individuals that do not suffer with haemochromatosis or diabetes or 
both. [Adapted from Niederau et al. Long-term survival in patients with hereditary hemochromatosis. 
Gastroenterology 1996;110:1107-19. by Niederau & Strohmeyer. Survival in hemochromatosis in Barton & Edwards 
Hemochromatosis: genetics, pathophysiology, diagnosis and treatment. Cambridge University Press 2000}.
Figure 1.16 shows that patients with haemochromatosis have cumulative survival rates lower 
than those of the normal population. It also shows that non-diabetic haemochromatosis -affected 
individuals have higher cumulative survival rates than those of diabetic haemochromatosis -  
affected individuals (over a 30 year period).
Although the pancreas is a site of heavy iron deposition in haemochromatosis, the diabetes that 
occurs in haemochromatosis is the result of inherited genetic factors and cirrhosis as well as islet 
cell dysfunction due to iron overload (Stocks & Powell, 1973). A review by George & Powell
(1997) states that there is a definite trend towards increased haemochromatosis rates in diabetic 
populations. Prevalence rates between 1 in 100 and 1 in 200 have been confirmed by liver 
biopsy (George et al., 1995) but proving statistical significance between the two conditions is 
difficult.
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1.17 Information on incidence of haemochromatosis and diabetes in Ireland
Ireland has a reported C282Y homozygote frequency of 1 in 83 (Ryan et al., 2000, Gleeson et al., 
2004).
Although the biochemical expression of the C282Y mutation is high in individuals with hereditary 
haemochromatosis, the clinical expression has not been fully investigated. A study by Gleeson et 
ai., (2004), was conducted to determine the clinical, biochemical and histological penetrance of 
the C282Y homozygous mutation in Irish individuals originally identified by family screening. 
Results showed that 43.4% of males and 23.3% of females had elevated transferrin saturation 
and ferritin levels. Approximately one third (32.3%) of male subjects also exhibited abnormal liver 
enzyme levels and diabetes was noted in 2.8% of males.
Research into haemochromatosis by Kelleher et al., (2004) stated that genetic variability (i.e. 
polymorphisms), within the DMT 1 gene, are not responsible for phenotype variability in 
hereditary haemochromatosis.
A study by Ryan et al., (1998) showed that thirty-one out of 109 randomly sampled individuals 
from a hospital were heterozygous for the C282Y mutation when tested. This correlates to a 
C282Y allele frequency of 14% and a heterozygote or ‘carrier’ frequency of approximately 1 in 4. 
This is the highest allele frequency reported in a control population and supports the theory of a 
Celtic origin for the genetic condition. The prevalence of C282Y was assessed in a cohort of 
thirty haemochromatosis patients and 404 normal controls. Ninety per cent of the 
haemochromatosis patients were homozygous for C282Y and there was an increased frequency 
of the C282Y mutation in the normal population (17.3%), which was also reflected in the higher 
frequency of C282Y homozygotes (1.24%), (Murphy et al., 1998).
Merryweather-Clarke et al., (1997(a)) found the highest global prevalence of the C282Y allele in 
45 Irish individuals (10%). They also found a high H63D prevalence of 30.4% in 28 Basque 
individuals.
A study on the genetics and pathophysiology of hereditary haemochromatosis in Ireland was 
completed by Valerie Byrnes in 2002. The study analysed a random sample of neonates 
(n=1000) from the Irish population, for genotypic and phenotypic frequencies of hereditary
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haemochromatosis. Genotypic results for 800 neonates reported C282Y and H63D allele 
frequencies of 10.7% and 15.1 %, respectively. The allele frequency of approximately 11 % is the 
highest globally reported result to date. The study also reported that 1 % of the sample population 
had the genetic susceptibility to develop the phenotype of hereditary haemochromatosis. If this 
figure is extrapolated to represent the Irish population in general, an estimate of 1 in every 83 
Irish people is genetically susceptible to developing iron overload. The high C282Y allele 
frequency in the Irish population and its close linkage to hereditary haemochromatosis indicate 
that C282Y genotyping is the preferred screening strategy for the disease in Ireland (Byrnes et 
al., 2001).
Taking the following factors into account; (a) that Ireland has the highest C282Y allele frequency 
reported worldwide, (b) that there is repeated suggestion of an association of the 
haemochromatosis allele and diabetes and (c) that the prevalence of diabetes in individuals with 
haemochromatosis is high, it is reasonable to propose an investigation into the potential 
interrelatedness of the two conditions be conducted.
1.18 Research Question I Objectives of the Study
(1) To determine the incidence of the C282Y, H63D & S65C haemochromatosis mutations in 
a population from the North West of Ireland.
(2) To determine if there is an increased incidence of these mutations in a diabetic 
population from the same region.
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2.0 MATERIALS & METHODS
Materials
2.1 Materials
DAM Purification
Wizard™ Genomic DNA Purification Kit:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Cat # A1120. 
Eppendorf Safe-Lock Microtubes, 1.5ml capacity, PCR clean:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: Z60,631-6 (1000 
each).
PCR
Human Genomic DNA:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Cat.# G3041.
This DNA is sourced from multiple anonymous donors. The genomic DNA is purified by the method 
described by Sambrook et a/., (1989). Greater than 90% of the DNA is longer than 50kb in size as 
measured by pulsed-field gel electrophoresis. The DNA is suitable for Southern Blot hybridisations, 
genomic analyses (including PCR), and genomic fibrary construction. Concentration: 173 pg/ml.
Human Placental DNA Ultrapune:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: D 4642.
42 % GC; Tm 87°C, purified by equilibrium buoyant density ultracentrifugation in caesium chloride, 
dialysed against a solution of 1mM sodium chloride, 1mM EDTA and 1mM Trizma HCI, pH 7.5 and 
lyophilised at a concentration of approximately 2 units per ml. Approximately 20 A260 unite per mg 
DNA. % GC is the percentage of G/C base pairs. Tm is the temperature at the midpoint of the 
thermal denaturation profile. The DNA quality and integrity are evaluated using pulsed field gel 
electrophoresis and visualisation after ethidium bromide staining. The DNA is free of RNA and 
contaminants that might interfere with restriction endonuclease digestion. Mol wt 10 MDa (=16 kb).
Mineral Oil for molecular biology:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: M 5904.
Suitable for overlaying aqueous reactions and centrifuge gradients, free from DNase, RNase, 
protease, density of 0.84 g/ml.
ReadyMix™ Taq PCR Reaction Mix wittiout MgChkit.
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght, Dublin 24, Ireland. Product Code: P4475.
ReadyMix Taq PCR Reaction Mix is a prepared solution containing everything needed for a PCR 
reaction except the specific primers and template. The mix includes Taq DNA Polymerase, 99% pure 
deoxynucleotides and buffer in a 2x optimized reaction concentrate. For reaction set-up, add the 
ReadyMix (25 pi) to the primers, template and water (total volume 50 |j|). Using ReadyMix Taq PCR 
Reaction Mix reduces pipetting steps and risk of contamination. This saves time and reduces errors 
while still providing the great performance of Sigma’s Taq Polymerase.
• Amplifies targets up to 7 kb in length
• A separate vial of 25 mM MgCh is provided for optimization with the ReadyMix Taq PCR 
Reaction Mix without MgCh.
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• ReadyMix Taq PCR Reaction Mix offers the same performance as Taq DNA Polymerase in a 
more convenient design.
Supplied with a vial of PCR grade water for dilution. Unit definition: one unit incoiporates 10 nmol 
of total dNTP’s into acid-piecipitable DNA in 30 min. at 74°C, Concentration is 1.5 units/reaction 
(50 pi reaction volume). The kit contains:
• PCR Ready-Mix solution, Product No. P 0351, contains 20mM Tris-HCI (pH 8.3), 100mM 
KCI, 0.4mM dNTP mix (dATP, dCTP, dGTP, dTTP), stabilizers, 60 units Taq 
Polymerase/ml. Provided as 20 reactions, 5 x 20 reactions.
• 25mM Magnesium Chloride, Product No. M 8787, provided as 1 vial
• Sterile Water, Product No. W 1754, provided as a 1.5ml vial.
PCR Master Mix:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Cat # M7502.
PCR Master Mix includes Nuclease-Free Water and PCR Master Mix, 2X. PCR Master Mix is a 
premixed, ready-to-use solution containing Taq DNA Polymerase, dNTP’s, MgCl2 and reaction 
buffers at optimal concentrations for efficient amplification of DNA templates by PCR. PCR Master 
Mix, 2X contains 50 units/ml of Taq DNA Polymerase supplied in a proprietary reaction buffer (pH 
8.5), 400pM dATP, 400pM dGTP, 400pM dCTP, 400|jM dTTP, 3mM MgCb.
Primers
The following primers were manufactured by TAGN Ltd., Unit 11b Station Approach, NE11 OZF, 
Gateshead, U.K.
C282YF: 5’-TGG CAA GGG TAA ACA GAT CC-3’
C282YR: 5’-TAC CTC CTC AGG CAC TCC TC-3’
H63DF: 5’-ACA TGG TTA AGG CCT GTT GC-3’
H63DR: 5’-CTT GCT GTG GTT GTG ATT TTC C-3’
See Appendix 1 for Certificate of Analysis.
Thermo Hybaid Omne E thermal cycler
Hybaid Ltd., 111-113 Waldegrave Road, Teddington, Middlesex TW II8LL, United Kingdom.
Restriction Endonuclease Digestion
Nde II, restriction endonuclease:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Product Code: R7291. 
Source: Neisseria dentrificans,
Recognition sequence: 5J...Y GATC...3’
3’...CTAGA...5’
Rsa I, restriction endonuclease:
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Pnomega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Product Code: R6371. 
Source: Rhodopseudomonas sphaeroides,
Recognition sequence: 5’...GTT AC...3’
3\..CAA TG...5’
Hint I, restriction endonuclease:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Product Code: R6201. 
Source: Haemophilus influenzae Rf(1)
Recognition sequence: 5’... GT ANT C... 3’
3’...C TNAA G...5’
PCR tubes, 0.2ml thin-walled tubes with flat caps, RNase, DNase, DNA and pyrogen free. Molecular 
Bioproducts, San Diego, California, USA. Product Code: 3412.
Contois
Positive control samples for C282Y homozygosity and C282Y/H63D compound heterozygosity were 
supplied by the Haematology Department of Sligo General Hospital. Positive control samples for 
S65C heterozygosity and S65C/H63D compound heterozygosity were supplied by Dr. Sharon Barrett 
(Centre for Liver Disease, 55 Eccles Street, Dublin 7).
Agarose Gel Electrophoresis
Water:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: W 4502. 
Molecular Biology reagent, CAS # 7732-18-5, EC no. 231-791-2,0.2 pm filtered, DNase and RNase 
free.
TBE Buffer, 10X (Tris-borate-EDTAy.
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Cat #H5241.
TBE buffer, 10X (pH 8.3), is used for polyacrylamide and agarose gel electrophoresis and has been 
optimized for use in DNA applications. Composition: 890 mM Tris-borate, 890 mM boric acid, 20 mM 
EDTA.
Agarose:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: A 9539.
Molecular Biology reagent CAS # 9012-36-6, EC no. 232-731-8. Agarose is ideal for routine 
analysis of nucleic acids by gel electrophoresis or blotting (Northern or Southern) and is also suitable 
for protein applications such as Ouchterlony and radial immunodiffusion (RID), has low ethidium 
bromide and SYBR Green background staining, < 10 % water, < 1.0 % ash, DNase and RNase free, 
EEO of 0.09-0.13 and a gel point of 36°C (± 1,5°C),
50 bp DNA Step Ladder:
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Product Code: G4521. 
The 50 bp DNA Step Ladder consists of 16 DNA fragments ranging from 50 bp to 800 bp in exactly 
50 bp increments. The 800 bp band appears 2-3 times more intense than all other bands, which are 
of approximately equal intensity. Concentration: 0.34 pg/pl.
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Lambda DNA Hind III digest buffered aqueous solution (for molecular biology):
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: D 9780. 
Concentration: 334pg/ml, Contains 8 fragments, 125-23,130 bp, solution in 10 mM Tris-HCI, pH 8.0, 
1 mM EDTA,
Blue/Orange Loading Dye, 6X\
Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin, USA. Product Code: G1881. 
Blue/Orange Loading Dye, 6X, is a marker dye containing 0.4% orange G, 0.03% bromophenol blue, 
0.03% xylene cyanol FF, 15% FicolKs) 400,10 mM Tris-HCI (pH 7.5) and 50mM EDTA (pH 8.0). It is 
provided in a premixed, ready-to-use form. The dye is used for loading DNA samples into gel 
electrophoresis wells and tracking migration during electrophoresis. In a 0.5-1.4% agarose gel in 
0.5X TBE, xylene cyanol FF migrates at approximately 4kb, bromophenol blue at approximately 300 
bp and orange G at approximately 50 bp.
Ethidium bromide:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: E 8751.
(2, 7-Diamino-10-ethyl-9-phenylphenanthridinium bromide; EtBr; 3, 8-Diamino-5-ethyl-6- 
phenylphenanthridinium bromide; Homidium bromide, [1230-45-8], C2iH2oN3Br, FW = 394.3), 
Ethidium bromide (EtBr) is a nucleic acid intercalating agent and frameshift mutagen. It can also be 
used in conjunction with acridine orange to differentiate between viable, apoptotic and necrotic cells. 
It is the most commonly used nucleic acid stain for PAGE or agarose gel electrophoresis. EtBr 
intercalates double-stranded DNA and RNA. The fluorescence of EtBr increases 21-fold upon binding 
to double-stranded RNA and 25-fold on binding double-stranded DNA so that destaining the 
background is not necessary with a low stain concentration (10 pg/ml). EtBr has been used in a 
number of fluorimetric assays for nucleic acids. It has been shown to bind to single-stranded DNA 
and triple-stranded DNA. For staining a gel after electrophoresis, dilute a sample of stock solution to
0.5 pg/mi with water and incubate the gei for 15-30 min. Destaining is usually not needed but can be 
earned out in water for 15 min if decreased background is necessary. The DNA bands can then be 
detected on a UV light box (254 nm wavelength). EtBr can also be incorporated into the get and 
running buffer at 0.5 |jg/ml and visualised immediately after electrophoresis.
Electrophoresis Power Supply, EPS-250 Series II:
C.B.S. Scientific Co. Inc., Del Mar, California, USA.
Horizontal Electrophoresis unit (Maxi):
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: Z33,882-6.
Comb, 28 Sample wells, 1.0mm, for 20cm tray:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght, Dublin 24, Ireland. Product Code: Z33,934-2. 
Syngene DigiGenius Documentation System:
Syngene, Beacon House, Nuffield Road, Cambridge C4ITF, United Kingdom.
Consumables
Pipette Tips (for Hamilton SoftGrip pipettes, precision pipette tips):
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland.
56
Materials
• 1 ml volume, Product Code: P6733 (1000 each),
• 200pl volume, Product Code: P5983 (1000 each),
• 300|jl volume, Product Code: P6358 (1000 each),
• 10p I volume, Product Code: P5608 (1000 each),
• 10pl volume, filter tips, Product Code: P5858 (1pkg)
Decontamination/  Contamination Prevention
DNA Away:
Molecular Bioproducts, San Diego, California, USA. Product Code: 7010
Ethidium bromide extraction:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght, Dublin 24, Ireland. Product Code: Z361569-2 EA. 
An extractor device manufactured by Schleicher & Schuell as a way to safely remove ethidium 
bromide from nucleic acid staining buffer waste for easy disposal. It consists of two layers of 
specially formulated activated carbon filters sealed into a polypropylene housing. Using a simple 
vacuum filtration procedure, >99% of ethidium bromide is removed from up to 10 liters of staining 
solution through adsorption to the activated carbon matrix. The decontaminated filtrate can then be 
safely disposed of down the drain.
Marigold™ Suretouch vinyl gloves:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland. Product Code: Z30,163-9 
Small, powder-free with low chloride, sulphur and sodium ion levels, they provide minimum 
particulate contamination with good sensitivity, grip and tear resistance.
instrumentation /  Apparatus
Hamilton SofiGrip Pipettes:
Sigma-Aldrich Ireland Ltd., Airton Road, Tallaght Dublin 24, Ireland.
Micro-Centrifuge
Sanyo MSE Micro Centaur, Sanyo Biomedical (previously Sanyo Gallenkamp), 1062 Thomdale 
Avenue, Bensenville, Illinois 60106, USA.
Incubators (37°C and 65°C)
Memmert Model 600, MemmertGmbH +Co. KG-91107 Schwabach, Germany.
57
Methods
2.2 Study Design
In the initial stages of study design, a statistician was consulted to determine the appropriate 
population sample size. Using the sample size formula for a single proportion or percentage, 
which allows for 80% power and a 5% two-sided significance, and an increase I decrease of 
100% from the prevalence documented for the general Irish population (Kelleher & Crowe, 2001), 
N was calculated to be 1530 individuals I subjects (N=765, for each of the ‘control’ and diabetic 
groups). In actuality, the population sample size employed in the study, was N=500. The main 
reasons for deviating from the calculated N value, were limitations on the time period for analysis, 
available personnel and equipment constraints and lack of willing participants. The original study 
design was aimed at genotypic analysis for two haemochromatosis mutations, C282Y and H63D, 
but plans for analysis of a third mutation (S65C) were incorporated at a later date. 
Randomisation of study subject’s for both populations, was achieved as a result of both the 
volunteer nature for study participation and the method of sample selection.
2.3 Ethics
Prior to study initiation, full ethical approval for the study was obtained from the Ethics Committee 
of Sligo General Hospital by submission of the requisite application (see Appendix A).
2.4 Research Subject Recruitment
Initial recruitment of research subjects (diabetic population) took place in the diabetic clinic of the 
Out Patient department of Sligo General Hospital and participation was on a volunteer basis. 
Study participation was by way of informed, documented consent (following review of an 
information sheet about the study by individuals, and by their subsequent signature of consent 
forms -  See Appendix A). The following inclusion criteria for subjects was also applied; aged 
greater than 20 years, residence in the North West region of Ireland, and of a Celtic/North 
European ancestry or origin. Patients who had recent excessive blood loss or blood transfusion, 
were pregnant aged less than 20 years or of a non-Celtic/North European ancestry were 
excluded from the study. Due to project time constraints and the limited availability of suitable 
collection personnel, only twenty six diabetic subjects were recruited in this manner (n=26), it was 
therefore decided that the only way to increase the sample size of the test population to
__________________________________Methods__________________________________
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significant levels was to include 224 blood samples sent to the laboratory (for routine HbA1c 
testing) from patients with diabetes mellitus.
‘Control’ subject samples were obtained by selecting (N= 250), randomly from blood samples
entering the aforementioned laboratories for routine haematological testing. All details regarding
samples obtained in this manner were anonymous and were blind to the tester, save for their 
hospital number (blinded to the researcher), which ensured duplication of samples did not occur 
during analysis.
2.5 Blood /  Serum Samples
Peripheral biood samples were collected by qualified hospital personnel in 
accordance/compliance with routine clinical procedures in place at Sligo General Hospital. The 
blood was collected into EDTA-coated tubes during routine attendance of research subjects at 
Out Patient departments in Sligo General Hospital. All blood samples underwent routine 
processing procedures on arrival at Sligo General Hospital Laboratories. Whole blood samples, 
which were to be used in the study, were subsequently located and stored frozen at -20°C in a 
designated area, prior to future genotypic analysis. The 250 whole blood samples collected from 
each of the diabetic and ‘control’ populations were numbered sequentially from 1 to 250 and C1 
to C250, respectively. The purpose of this was to permit identification of samples in the two 
populations.
2.6 TBE Buffer Preparation
Tris-Borate EDTA (TBE) Buffer at a 1X concentration and with an ethidium bromide concentration 
of 0.5 Mg/ml was used in this study: (a) as a running buffer for gel electrophoresis and (b) for gel 
preparation. The buffer was supplied from the manufacturer as a 10X concentrate and a 1:10 
dilution was therefore necessary before usage. Two litres of buffer was prepared freshly at 
various intervals, as required during analysis. This was performed by adding 200 mis of 10X TBE 
concentrate and 100 |jl of ethidium bromide (stock solution concentration 1 mg/ml) to 1799.9 mis 
of molecular grade water in a 2000 mi volumetric flask. A homogenous solution was then 
ensured by inverting the flask at least 30 times to mix the contents thoroughly. By incorporating 
ethidium bromide at this stage it eliminated the need for staining and destaining of gels after 
electrophoresis. TBE Buffer was subsequently stored at room temperature.
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2.7 Agarose Gel Preparation
Agarose gels of two different concentrations were used in this study and were prepared in the 
following manner:
- 1% Agarose Gels: were prepared by the dissolution of 3.5 grams of molecular grade 
agarose in 350 millilitres of 1X TBE buffer (see Section 2.5) in a clean beaker. Heat in 
the form of a hotplate and continuous stirring was utilized to ensure a homogenous 
solution. The agarose gel was ready to pour when it went completely clear in colour. 1 % 
agarose gels were used in Quantitation of DNA Yield post DNA purification procedure.
- 2% Agarose Gels: were prepared by the dissolution of 7 grams of molecular grade 
agarose in 350 millilitres of 1X TBE buffer (see Section 2.5) in the same manner as that 
employed for the preparation of 1% gels (see above). 2% agarose gels were used in 
PCR Optimisation procedures and Restriction Enzyme Digestion Analysis.
2.8 Molecular Weight Marker Preparation
Two molecular weight markers were employed in this study to help identify restriction fragments 
of varying sizes during mutational analysis. The markers were a 50 bp DNA Step Ladder 
(Promega) and a Lambda Hind III digest. Before use the markers were prepared in the following 
way:
(a) DNA Step Ladder: 5 |jl of a 50 bp DNA Step Ladder was added to 1 pi of 6X gel loading 
dye (as per manufacturers instructions) and was mixed by gentle pipetting. 2 pi of the 
resultant mixture was added to each of two wells of the gel at varying positions to 
function as a molecular weight marker.
(b) Lambda Hind III Digest 5 pi of Lambda Hind ill Digest was added to 5 pi of molecular 
grade water and 2 pi of 6X gel loading dye. The solution was mixed by gentle pipetting 
and 5 pi of the resultant mixture was added to each of two wells of the gel at varying 
positions to function as a molecular weight marker.
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2.9 Primer Stock Solution & Working Solution Preparation
Primers were supplied from the manufacturers in a lyophilized form. Prior to usage all four 
primers (a forward and reverse primer for each of C282Y and H63D), were made into 1 pg/pl 
stock solutions in the following way:
C282Y Forward Primer (C282YF): 315.6 pg* was dissolved in 315.6 pi of molecular grade
water.
C282Y Reverse Primer (C282YR): 348.6 pg* was dissolved in 348.6 pi of molecular grade
water.
H63D Forward Primer (H63DF): 258 pg* was dissolved in 258 pi of molecular grade
water.
H63D Reverse Primer (H63DR): 309.5 pg* was dissolved in 309.5 pi of molecular grade
water.
All solutions were mixed thoroughly to ensure homogeneity.
* = quantity of lyophilized primer supplied by the manufacturer
For PCR, primer working solutions of a concentration of 5 picomoles/pl were required. These 
working stock solutions of each primer were prepared in the following way at various intervals 
when required during analysis (calculations were based on primer molecular weight).
C282YF: 20 pi of C282YF stock solution (1 pg/pl) was added to 596 pi of molecular grade
water.
C282YR: 20 pi of C282YR stock solution (1 pg/pl) was added to 618 pi of molecular grade
water.
H63DF: 20 pi of H63DF stock solution (1 pg/pl) was added to 598 pi of molecular grade
water.
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H63DR: 20 pi of H63DR stock solution (1 pg/pl) was added to 544 pi of molecular grade
water.
All solutions were mixed thoroughly to ensure homogeneity (see Appendix B for Primers 
Certificate of Analysis).
2.10 DNA Purification
Whole blood samples were thawed completely at room temperature before use. Each tube was 
inverted gently to ensure thorough mixing of the contents prior to use. DNA was extracted or 
‘purified’ from these whole blood samples using Promega’s Wizard™ Genomic DNA Purification 
Kits (Cat. # A1120) and in accordance with the following procedure from product inserts.
The Wizard™ Genomic DNA Purification Kit is designed to isolate genomic DNA from white biood 
ceils. The procedure is based on a four-step process. The first step is lysis of red blood cells 
using Cell Lysis Solution (which leaves white blood cells intact). The second step is lysis of the 
white blood cells and their nuclei, and their solublisation in the Nuclei Lysis Solution. The third 
step removes cellular proteins by salt precipitation, leaving only high molecular weight genomic 
DNA in solution. In the final step the genomic DNA is concentrated and desalted by isopropanol 
precipitation.
According to the manufacturer, the following procedure consistently yields in the range of 5-15 pg 
of DNA per 300 pi of whole blood. This procedure involves no organic extractions or proteinase 
digestions. DNA purified using this system is suitable for amplifications, restriction endonuclease 
digestion and membrane hybridisation. Promega has tested the performance of genomic DNA 
isolated from fresh whole blood collected in EDTA-, heparin- and citrate-coated tubes and has 
detected no adverse effects upon subsequent manipulations of the DNA including PCR.
The manufacturer recommends that the DNA isolated from the purification procedure should be 
quantitated by agarose gel electrophoresis method. This method is more accurate than the 
spectrophotometric method of DNA quantitation.
Procedure for Genomic DNA Purification from Whole Blood (300 ul sample volume):
1. Add 900 pi of Cell Lysis Solution to a sterile 1.5 ml microcentrifuge tube.
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2. Gently rock the tube of blood until thoroughly mixed; then transfer 300 pi of blood to the 
tube containing the Cell Lysis Solution. Invert the tube 5-6 times to mix.
3. Incubate the mixture for 10 minutes at room temperature (mix once during the incubation) 
to lyse the red blood cells. Centrifuge for 20 seconds at 13,000-16,000 x g at room 
temperature.
4. Remove and discard as much supernatant as possible without disturbing the visible white 
pellet Approximately 10-20 pi of residual liquid will remain in the tube.
Frozen samples may require repeat of Steps 1-4 until the pellet is white. There may be 
some loss of DNA from frozen samples.
Note: Some red blood cells or red ceil debris may be visible aiong with the white blood 
cells. If the pellet appears to contain only red blood cells, add an additional aliquot of 300 
pi of Cell Lysis Solution after removing the supernatant above the cell pellet Then 
repeat Steps 3-4.
5. Vortex the tube vigorously until the white blood cells are resuspended (10-15 seconds).
Note: To obtain efficient cell lysis, it is essential that the white blood cells are completely 
resuspended.
6. Add 300 pi of Nuclei Lysis Solution to the tube containing the resuspended cells. Pipette 
the solution 5-6 times to lyse the white blood cells. The solution should become very 
viscous. If clumps of cells are visible after mixing, incubate the solution at 37°C until the 
clumps are disrupted. If the clumps are still visible after 1 hour, add an additional 100 pi 
of Nuclei Lysis Solution and repeat the incubation.
7. OPTIONAL STEP: Add 1.5 pi of RNase Solution to the nuclear lysate and mix the 
sample by inverting the tube 2-5 times. Incubate the mixture at 37°C for 15 minutes. Cool 
the sample to room temperature before proceeding.
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8. Add 100 pi of Protein Precipitation Solution to the nuclear lysate and vortex vigorously 
for 10-20 seconds. Small protein clumps may be visible after vortexing.
Note: if it was necessary to use additional Nuclei Lysis Solution in Step 6, add a total of 
130 pi of Protein Precipitation Solution.
9. Centrifuge at 13,000-16,000 x g for 3 minutes at room temperature. A dark brown pellet 
should be visible.
10. Transfer the supernatant to a clean 1.5 ml microcentrifuge tube containing 300 pi of 
room temperature isopropanol.
Note: Some supernatant may remain in the original tube containing the protein pellet 
Leave this residual liquid in the tube to avoid contaminating the DNA solution with the 
precipitated protein.
11. Gently mix the solution by inversion until the white thread-like strands of DNA form a 
visible mass.
12. Centrifuge for 1 minute at 13,000-16,000 x g at room temperature. The DNA will be 
visible as a small white pellet
13. Decant the supernatant and add 300 pi of room temperature 70% ethanol to the DNA. 
Invert the tube gently several times to wash the DNA pellet and the sides of the 
microcentrifuge tube. Centrifuge for 1 minute at 13,000-16,000 x g at room temperature.
14. Carefully aspirate the ethanol using either a drawn Pasteur pipet or a sequencing pipette 
tip. The DNA pellet is very loose at this point and care must be used to avoid aspirating 
the pellet into the pipet. invert the tube on clean absorbent paper and air-dry the pellet for 
10-15 minutes.
15. Add 100 pi* of DNA Rehydration Solution (10mM Tris-HCI/1mM EDTA, pH 7.4) to the 
tube and rehydrate the DNA by incubating at 65°C for 1 hour. Periodically mix the
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solution by gently tapping the tube. Alternatively, rehydrate the DNA by incubating the 
solution overnight at room temperature (a  later changed to 50 pi).
16. Store the DNA at 2-8°C (prior to amplification by PCR etc).
Quantitathn o f the DNA (Yield Get)
1. Mix 3.5 pi of the DNA solution prepared by the above method with 0.7 |jl of gel loading 
dye and centrifuge at 12,000 x g for 2 seconds in a microcentrifuge. [5:1 ratio for volume 
of DNA to that of the loading dye].
2. Prepare a 1 % agarose gel (see section 2.6).
3. Load the sample into one of the wells. In the adjacent wells, load equal volumes of a 
series of DNA concentration standards in the range 25-500 ng/|jl.
4. Run the gel at 5V/cm. When the bromophenol blue tracking dye has migrated at least 2 
cm from the wells, the run can be stopped.
5. Examine the gel on an ultraviolet light transiiiuminator. Intact DNA will be visible as a 
band near the wells. A smear extending from the well to the dye front indicates that the 
DNA has been fragmented. Visualize the gel under UV light and document the results 
through photography.
6. From the photograph, estimate the quantity of DNA in the test samples by comparison to 
the DNA concentration standards.
The yield should be in the range of 5-15 pg of DNA per 300 pi of fresh whole blood with an 
average size of >50kb. It should be noted that DNA yield may decrease with prolonged storage 
and repeated freeze-thaw cycles.
At the end of the purification procedure, sufficient DNA should be obtained for use in the 
Polymerase Chain Reaction (PCR).
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A second method of DNA purification was also tried and is detailed below.
Chelex DNA Extraction from Whole Blood (Walsh et al.. 1991).
1. Pipet 1 ml of sterile distilled water into a sterile 1.5-ml microcentrifuge tube. Add 3 pi of 
whole blood and mix gently.
2. Incubate at room temperature for 15 -  30 minutes. Mix occasionally by inversion or 
gentle vortexing.
3. Spin in a microcentrifuge for 2 -  3 minutes at 10,000 -15,000 x g.
4. Carefully remove the supernatant (all but 20 -  30 pi) and discard.
5. Add 5% Chelex to a final volume of 200 pi.
6. Incubate at 56°C for 15 -  30 minutes.
7. Vortex at high speed for 5 -1 0  seconds.
8. Incubate in a boiling water bath for 8 minutes.
9. Vortex at high speed for 5 -1 0  seconds.
10. Spin in a microcentiifuge for 2 -  3 minutes at 10,000 -15,000 x g.
11. The sample is now ready for the amplification process, it is recommended that 20 pi of 
the supernatant be added to the PCR mix.
12. Store the remainder of the sample at 2° - 8°C or frozen. To re-use, repeat Steps 9 -1 1 .
Methods
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PCR is a method used to amplify a specific DNA sequence in vitro by repeated cycles of 
synthesis using specific primers and DNATaq polymerase enzyme. Optimised PCR components 
and run parameters ensure successful PCR. The DNA product obtained from the optimised PCR 
process can subsequently be analysed in a variety of different ways, but in this case restriction 
enzyme digestion was employed for mutational analysis of haemochromatosis for C282Y, H63D 
and S65C.
2.11.1 Optimisation of PCR
It is necessary to carry out optimization experiments in order to establish optimal conditions for 
each procedure. The following factors should be investigated during the optimization process 
because all may influence the specificity, fidelity and yield of the desired product
(a) Enzyme Concentration
The concentration of Taq DNA polymerase required for use in PCR can vary with respect to 
target templates or primers. Too high a concentration of enzyme and background products may 
accumulate but with too low a concentration, an insufficient amount of desired product is made.
(b) Deoxynucieotide Triphosphates (dNTP’s)
The four dNTP’s should be used at equivalent concentrations to minimize misincorporation errors. 
Low dNTP concentrations minimize mispriming at nontarget sites and reduce the likelihood of 
extending misincorporated nucleotides (Innis et al., 1988). Working stock solutions of 1 mM for 
each dNTP are recommended.
(c) Buffer
Buffers generally recommended for PCR are Tris-HCI orTris-borate based buffers (pH 8.3 - 8.8). 
Optimal buffer conditions are required to help facilitate primer annealing and to optimize Taq DNA 
polymerase activity.
(d) Magnesium Concentration
The magnesium ion concentration may affect; primer annealing, strand dissociation temperatures 
of template and PCR product product specificity, enzyme activity and fidelity and formation of
2.11 PCR
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primer-dimer artifacts. I aq DNA polymerase requires free magnesium on top of the amount 
generally bound by template DNA, primers and dNTP’s.
2.11.2 Optimisation of PCR in terms ofMgCh Concentration
As initial attempts at PCR were conducted using Readymix™ Taq without MgCi2, it was 
unnecessary to optimize in terms of enzyme and dNTP concentration or buffer capacity. The 
product is supplied as a ready-prepared mixture of Tris-HCI, KCi, dNTP’s and Taq DNA 
polymerase, and the product insert recommends a volume of 25 |jl of PCR Readymix be used in 
each PCR reaction. This means that there is a final concentration of 1.5 unite of Taq polymerase 
and 0.2 mM dNTP’s per reaction within the optimum pH range.
It was however necessary to optimize in terms of magnesium chloride (MgCb), when using the 
aforementioned Sigma-Aldrich product The exact protocol employed in this optimization is 
detailed below.
Procedure for Optimization of Magnesium Chloride (MgCh) Concentration:
1. PCR tubes were set up according to Table 2.0 below.
2. Varying volumes of MgCb were added to each tube to give finai magnesium chloride 
concentrations of: 0 mM, 0.5 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM and 4 
mM.
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Table 2.0: Preparation of Tubes for Optimisation of PCR in terms of Magnesium Chloride
Concentration.
Tube Number
Tube Contents 1 2 3 4 5 6 7 8 9
DNA Template 1 Ml 1 Ml 1 Ml 1 Ml 1 Ml 1 M' 1 Ml 1 Ml 1 Ml
C282YF*
(5 picomoles/pl stock solution)
2.5 pi 2.5 Ml 2.5 Ml 2.5 pi 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml
C282YR*
(5 picomoles/pl stock solution)
2.5 pi 2.5 Ml 2.5 pi 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml
MgCfe
(25 mM stock solution)
OmI t Ml 2 Ml 3 Ml 4 Ml 5 Ml 6 Ml 7 Ml 8 Ml
Readymix™ Taq polymerase 25 Ml 25 Ml 25 Ml 25 Ml 25 Ml 25 Ml 25 Ml 25 Ml 25 Ml
Ultrapure / Molecular biology jade water 14 Ml 13 Ml 12 Ml 11 Ml 10 Ml 9 Ml 8 Ml 7 Ml 6 Ml
Final Volume 50fjl 50 fjl 50 y ! 50 y l 50 y  1 50 y  1 50 y l 50 y  1 50 y  1
* see section 2.9
3. The contents of each of the iubes above were over layed with PCR mineral oil prior to 
PCR to prevent sample evaporation.
4. All tubes underwent PCR under the following conditions: Initiai dénaturation at 95°C for 5 
minutes -*■ Dénaturation at 94°C for 45 seconds —> Annealing at 55°C for 45 seconds 
—► Extension at 72°C for 45 seconds (30 cycles).
5. Following PCR, 10 |jl of each PCR product was removed to a set of new tubes and 2 pi 
of 6X gel loading dye was added to each. The solution was then mixed by gentle 
pipetting.
6. 5 pi of each of the resultant mixtures was then loaded into wells of a 2% agarose gel 
(see section 2.7).
7. Molecular weight markers were prepared and used as detailed in section 2.8.
8. The agarose gel underwent electrophoresis at a rate of 5V/cm for 3 hours, after which 
time it was visualized over UV light on a transilluminator. All results were photographed 
and archived using the Syngene DigiGenius Documentation System.
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(e) PCR Run Conditions
(i) Dénaturation Time and Temperature: Incomplete dénaturation of the target template and/or the 
PCR product is the most likely cause for failure of a PCR. Incomplete dénaturation of DNA, 
results in the inefficient use of template in the first cycle of PCR and a poor yield of PCR product 
will be obtained.
It is generally accepted that an initial dénaturation step of an incubation at 95°C for 1-3 minutes 
be performed for templates with GC contents of 50% or less. For GC-rich templates this 
incubation period should be extended for up to 10 minutes. For the initial dénaturation step, Taq
DNA polymerase should only be added to the initial reaction mixture if the incubation period is no
longer than 3 minutes and the temperature is not greater than 95°C otherwise the enzyme’s 
stability decreases (Sambrook et al., 1989).
Because the PCR product synthesized in the first round of amplification is considerably shorter 
than the template DNA (and is completely denatured under these conditions), a dénaturation step 
of 0.5-2 minutes at 94-95°C is sufficient for PCR (MBI Fermentas, 2002-2003).
2.11.3 Optimisation of PCR in terms o f Primer Annealing Temperature
(ii) Primer Annealing: The length of time and temperature required for primer annealing is 
dependant on the base composition, length and concentration of the amplification primers. 
Annealing temperature is generally 5°C below the true Tm of the primer-template DNA duplex. 
The melting temperature (Tm) can be calculated by the following equation (Hybaid Omne E 
thermal cycler, user instruction manual, 1994):
Tm = 2 x ( A + T ) + 4 x ( C + G )
Where: A is the number of adenine bases in the primer
T is the number of thymine bases in the primer 
C is the number of cytosine bases in the primer 
G is the number of guanine bases in the primer
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Annealing temperatures in the range of 55 to 72°C generally yield the best results. Incubation for
0.5 -  2 minutes is usually sufficient, but if nonspecific PCR products are obtained in addition to 
the expected product, the annealing temperature may need to be increased.
The following forward (F) and reverse (R) primer pairs were used to detect the two major 
haemochromatosis mutations C282Y and H63D.
C282YF: 5’-TGG CAA GGG TAA ACA GAT CC-3’
C282YR: 5’-TAC CTC CTC AGG CAC TCC TC-3’
H63DF: 5’-ACA TGG TTA AGG CCT GTT GC-3’
H63DR: 5’-CTT GCT GTG GTT GTG ATT TTC C-3’
Calculation of primer melting temperature was as follows and was based on the equation above;
Tm of C282YF = 2x(7 + 3 )+ 4 x ( 4  + 6) = (2x10)+(4x10)  = 20 + 40 = 60°C 
TmofC282YR = 2x(3 + 5)+4x(10 + 2) = (2x8 )+ (4x12)  = 16 +48 = 64°C 
Tm of H63DF = 2 x ( 4 + 6 ) + 4 x ( 4 + 6 )  = (2x10)+(4x10) = 20 +40 = 60°C 
TmofH63DR = 2x(1 +11 ) +4x(  4 + 6) = (2x12) +(4x10) = 24 + 40 = 64°C
The melting temperatures indicated on the manufacturers Certificate of Analysis for the primers 
were; 57.3°C for C282YF, 61.4°C for C282YR, 57.3°C for H63DF and 58.4°C for H63DR. By 
applying the hypothesis that the optimum annealing temperature is 5°C below the melting 
temperature, it can be said that the optimum annealing temperature for C282YF is somewhere 
between 52.3'C and 55°C. Using the same principle, the optimum annealing temperature for 
C282YR is between 56.4°C and 59°C, for H63DF is between 55°C and 55.3°C and for H63DR is 
between 53.4°C and 59°C. The following temperatures were therefore decided on for 
optimization work: 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61 °C, 62°C, 64°C 
and 70°C,
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1. Thirteen tubes were prepared for PCR by adding the following reagents together.
DNA Template I 3.2 pi
Genomic DNA [50ng/pl]
C282YF primers 2.5 pi
[5 pmoles/pl stock]
C282YR primer* 2.5 (Jl
[5 pmoles/pl stock]
PCR Master Mix 25 pi
Molecular Grade Water 16.8 pi 
Final Volume 50 pi
Procedure for Optimization of Annealing Temperature:
2. The contents of each of the tubes above were over layed with PCR mineral oil prior to 
PCR to prevent sample evaporation.
3. One tube was subjected to PCR at each of the 13 annealing temperatures listed above 
for a cycle time of 45 seconds. All other PCR conditions remained as determined i.e. 
Initial dénaturation at 95°C for 5 minutes —*■ Dénaturation at 94°C for 45 seconds —► 
Annealing (at each relevant temperatures above) for 45 seconds —*• Extension at 72°C 
for 45 seconds (30 cycles).
4. Following PCR, 10 ¡jl of each PCR product was removed to a new set of tubes and 2 pi 
of 6X gel loading dye was added to each. The solution was then mixed by gentle 
pipetting.
5. 5 pi of each of the resultant mixtures was then loaded into wells of a 2% agarose gel 
(see section 2.7).
6. Molecular weight markers were prepared and used as detailed in section 2.8.
7. The gel then underwent electrophoresis at a rate of 5V/cm for 3 hours, after which time it 
was visualized over UV light on a transilluminator. All results were photographed and 
archived using the Syngene DigiGenius Documentation System.
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♦ A second set of 13 tubes was prepared using the H63D forward and reverse primers and 
annealing temperature was optimized by the same method. See section 2.9 for primer solution 
preparation.
(iii) Cycle Number: The optimum number of cycles to use for PCR depends mainly on the amount 
of starting/template DNA and on the expected yield of the PCR product For less than 10 copies 
of the template, 40 cycles should be performed, but if the initial quantity of template is higher, 25- 
35 cycles is usually sufficient Too many cycles can increase the amount and complexity of 
nonspecific background products, yet too few will give a poor product yield. Based on published 
literature, a cycle number of 30 was utilized for PCR.
2.11.4 Optimisation of PCR in terms of Primer Concentation
(iv) Primers: Typical primers are 18 to 28 nucleotides long and have a GC content of between 50 
and 60%. Primers are used at concentrations between 0.1 and 0.5 pM for optimal results. Higher 
concentrations may promote accumulation of nonspecific product mispriming and the probability 
of primer-dimers occurring (MBI Fermentas, 2002-2003).
Procedure for Optimization of Primer Concentration:
1. From the stock solutions of the C282YF and C282YR primer, working solutions of the 
following concentrations were prepared: 0.1 pmole/pl, 0.01 pmole/pl, 1 pmole/pl, 4 
pmole/pl, 1 nmole/pl, 0.1 nmole/pl, 0.01 nmole/pl, 1 pmole/pl and 5 pmole/pl.
2. Nine tubes were set up for PCR according to Table 2.1. Each of the 9 tubes used primer 
working solutions of a different concentration (see above). A volume of 2.5 pi of each of 
the forward and reverse primer was used for each PCR reaction. A different set of tubes 
was prepared in the same manner for the H63D primer pair.
73
Methods
Table 2.1: Preparation of tubes for Optimisation of PCR in terms of Primer Concentration
Tube Number
1 2 3 4 5 6 7 8 9
Tube Contents 1 0.1 0.01 1 0.1 0.01 1 5 4
jjmole/(jl (jmole/pl pmole/pl nmole/pl nmole/pl nmole/pl pmole/pl pmote/pl umole/|jl
primer primer primer primer primer primer primer primer primer
working working working working working working working working working
solution solution solution solution solution solution solution solution solution
DNA Template 1 pi 1 pi 1 pi 1 pi 1 pi 1 pi 1 pi 1 pi 1 pi
C282YF* 2.5 pi 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml
C282YR» 2.5 pi 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml 2.5 Ml
MgCI2
(25 mM stock 
solution)
3 pi 3 pi 3 pi 3 pi 3 pi 3 pi 3 pi 3 pi 3 pi
Readymix™ Taq 
polymerase
25 pi 25 pi 25 pi 25 pi 25 pi 25 pi 25 pi 25 pi 25 pi
Ultrapure/ 
Molecular biology 
grade water
16 pi 16 pi 16 pi 16 pi 16 pi 16 pi 16 pi 16 pi 16 pi
Final Volume 50 y! 50 ill 50 fil 50 fil 50 ¡il 50 fil 50 fil 50 pi 50 ill
■ or H63DF and H63DR primers (see section 2.9 for primer solution preparation)
3. The contents of each of the tubes above were over layered with PCR mineral oil prior to 
PCR to prevent sample evaporation.
4. All tubes underwent PCR at the following conditions: 95°C for 5 minutes —> Dénaturation 
at 94°C for 45 seconds —► Annealing at 55°C for 45 seconds —► Extension at 72°C for 
45 seconds (30 cycles).
5. Following PCR 10 pi of each PCR product was removed to a set of new tubes and 2 pi 
of 6X gel loading dye was added to each. The solution was then mixed by gentle 
pipetting.
6. 5 pi of each of the resultant mixtures was then loaded into wells of a 2% agarose gel 
(see section 2.7).
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7. Molecular weight markers were prepared and used as detailed in section 2.8.
8. The gel then underwent electrophoresis at a rate of 5V/cm for 3 hours, after which time it 
was visualized over UV light on a transilluminator. All results were photographed and 
archived using the Syngene DigiGenius Documentation System.
In order to ensure PCR was continuously and reproducibly conducted at optimized conditions in 
terms of enzyme, magnesium chloride and dNTP concentrations, and to minimize possible 
sources of error, it was decided to utilize Promega’s PCR Master Mix for all subsequent PCR 
work. This product has been optimized for use in routine PCR reactions for amplifying DNA 
template in the range of 0.2-2kb.
2.11.5 Optimisation of PCR in terms of Template DNA Concentration
Optimisation of Template DNA Concentration
1. Eight tubes (labeled 1 -8) each containing the following PCR components were prepared:
Forward Primer [5 picomoles/pl] 2.5 pi
Reverse Primer [5 picomoles/pl] 2.5 pi
PCR Master Mix (Promega) 25 pi
2. Varying voiumes of DNA template (i.e. product from Wizard Extraction procedure) was 
added to each of the nine tubes as follows (see Table 2.2):
Table 2.2: Preparation of tubes for Optimisation of PCR in terms of Template DNA
Concentration
Tube Number 1 2 3 4 5 6 7 8
Volume of Wizard product added (pi) 10 12 15 16 17 18 19 20
Volume molecular biology grade 
water added (pi)
10 8 5 4 3 2 1 0
Final PCR volume (pi) 50 50 50 50 50 50 50 50
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3. A negative control for PCR was also included. It contained every component above 
excluding the DNA (i.e. it contained forward and reverse primer, PCR master mix and 
20pl of molecular biology grade water).
4. The contents of each of the tubes above were over layered with PCR mineral oil prior to 
PCR to prevent sample evaporation.
5. All tubes underwent PCR at the following conditions: 95°C for 5 minutes —► Dénaturation 
at 94°C for 45 seconds —>• Annealing at 55°C for 45 seconds —>■ Extension at 72°C for 
45 seconds (30 cycles).
6. Following PCR 10 pi of each PCR product was removed to a set of new tubes and 2 |jl 
of 6X gel loading dye was added to each. The solution was then mixed by gentle 
pipetting.
7. 5 pi of each of the resultant mixtures was then loaded into wells of a 2% agarose gel 
(see section 2.7).
8. Molecular weight markers were prepared and used as detailed in section 2.8.
9. The gel then underwent electrophoresis at a rate of 5V/cm for 3 hours, after which time it 
was visualized over UV light on a transilluminator. All results were photographed and 
archived using the Syngene DigiGenius Documentation System
Procedure for Optimised Polymerase Chain Reaction (PCR):
1. For each DNA sample, a sterile tube with the following contents was prepared:
DNA Template 20 pi
(Product from Wizard Extraction procedure)
Forward Primer [5 picomoles/pl] 2.5 pi
Reverse Primer [5 picomoles/pl] 2.5 pi
PCR Master Mix (Promega) 25 ul
FINAL VOLUME 50 pi
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2. A separate set of tubes for each primer was prepared, i.e. the first set is set up for all 
samples using C282Y forward and reverse primers and the second set using H63D 
forward and reverse primers (see section 2.9 for primer solution preparation).
3. A negative control for PCR was also included. It contained every component above 
excluding the DNA.
4. The contents of each of the tubes above were over layered with PCR mineral oil prior to 
PCR to prevent sample evaporation.
5. All tubes underwent PCR at the following conditions: 95°C for 5 minutes —*• Denaturation 
at 94°C for 45 seconds —► Annealing at 55°C for 45 seconds —► Extension at 72°C for 
45 seconds (30 cycles).
6. Following PCR, samples were stored frozen at -22*C for future analysis. Samples were 
completely thawed, immediately prior to use in restriction endonuclease digestions.
On random occasions one tube (for each set of primers) was prepared as above, but Promega 
Human Genomic DNA was utilized instead of DNA obtained via the Wizard® extraction 
procedure. This acted as a positive PCR/DNA control, in that it ensured that DNA obtained via 
the Wizard® kit method was of a comparable quantity and quality to that of Promega’s human 
genomic DNA and therefore that which is required for subsequent analysis.
PCR was performed in a Hybaid Omn-E thermal cycler.
Following PCR, DNA or ‘product is available for subsequent genetic manipulation. In this study, 
product obtained from PCR was subjected to restriction enzyme digestion analysis in order to 
determine the presence/absence of the three main mutations responsible for hereditary 
haemochromatosis; C282Y, H63D and S65C.
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Restriction enzymes (also called restriction endonucleases), are enzymes that recognize short 
specific DNA sequences. They cleave double-stranded DNA at specific sites that are within or 
adjacent to their recognition sequences. Isoschizomers are enzymes isolated from different 
sources that cleave within the same target sequences.
Each restriction enzyme has specific requirements to achieve optimal activity. Ideal storage and 
assay conditions favor the most activity and highest fidelity in a particular enzyme’s function. 
Conditions such as temperature, pH, enzyme cofactor(s), salt composition and ionic strength 
affect enzyme activity and stability.
Restriction enzyme digestions should be carried out as per manufacturers instructions, as each 
manufacturer has optimized reaction conditions for their own enzymes.
In this study, the restriction enzymes Rsa I, Nde I! and Hinf I were used to identify the three major 
haemochromatosis mutations C282Y, H63D and S65C respectively, following amplification by 
PCR. Nde II, is an isoschizomer of Mbo I, both of which have the following recognition sequence; 
jGATC. The recognition sequence of Rsa I is GT|AC and that of Hinf I is GJ.ANT C. Both Nde II 
and Rsa I restriction enzymes are examples of Type II enzymes, which means that they are 
binary in nature, consisting of a restriction endonuclease that cleaves a specific sequence of 
nucleotides and a separate methylase that modifies the same recognition sequence.
Following amplification, PCR products of 393bp were obtained using the C282Y primers 
mentioned earlier and were digested:
(1) with Rsa I, to give fragments at
•  247bp and 146bp for normal non-mutated DNA (wild-type)
•  247p, 146bp, 117bp and 29bp for a C282Y carrier I heterozygote and
•  247bp, 117bp and 29bp for a mutant C282Y homozygote (Feder et al., 1996 &
Jeffrey et al., 1999)
2.12 Restriction Endonuclease Digestion
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PCR products of 294bp are obtained using H63D primers and are digested:
(2) with Nde II, to give fragments a t
•  138bp, 99bp and 57bp for normal non-mutated DNA (wildtype)
•  237bp, 138bp, 99bp and 57bp for a H63D carrier I heterozygote and
•  237 bp and 57bp for a mutant H63D homozygote (Merryweather-Clarke et al.,
1997a)and
(3) with Hinf I, to give fragments a t
•  147 bp and 80 bp for normal non-mutated DNA (wildtype)
•  227 bp, 147 bp and 80 bp for a S65C carrier I heterozygote and
•  227bp and 80 bp for a mutant S65C homozygote (correspondence with Kathryn Robson, 
Oxford, 2006).
All restriction endonucleases employed were used in accordance with the information supplied by 
the manufacturer (Promega), which recommends that
Analytical scale restriction enzyme digests are performed in a volume of 20 pi on 0.2-1.5 pg of 
substrate DNA, using a 2- to 10-fold excess of enzyme over DNA. If an unusually large volume of 
DNA or enzyme is used, aberrant results may occur and may or may not be readily recognized.
The following is an example of a typical restriction enzyme digest. In a sterile tube, assemble in 
order:
Sterile, deionized water 16.3 pi
Restriction Enzyme 10X Buffer 2.0 pi
Acetylated BSA, 10 pg/pl 0.2 pi
DNA, 1 pg/pl 1.0 pi
Mix by pipetting, and then add:
Restriction Enzyme, 10 u/pl 0.5 ul
Final Volume 20 pi
Mix gently by pipetting, close the tube and centrifuge for a few seconds in a microcentrifuge. 
Incubate at the optimum temperature for 1-4 hours.
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Add 4 pi of 6X loading buffer and proceed to gel analysis. Note that overnight digests are usually 
unnecessary and may result in degradation of the DNA.
Experimental controls are important and the following controls were employed to help identify, 
understand and explain problems or inconsistencies in results:
(i) uncut experimental DNA
(ii) digest of commercially supplied control DNA
(iii) no-enzyme “mock” digest
(iv) 1 or 2 different size markers in more than 1 lane per gel.
Procedure for Restriction Enzyme Digestion for Mutational Analysis:
Following PCR, products were digested with Rsa I for C282Y mutational analysis, Nde ¡1 for 
H63D mutational analysis and Hint I for S65C mutational analysis, in accordance with the 
following procedure.
1. For each DNA sample to be analysed a separate tube was prepared by assembling (in 
order) the following reagente:
Sterile, deionized water 12.3 pi
Restriction Enzyme 10X Buffer 2.0 pi
Acetylated BSA [10pg/mi] 0.2 pi
DNA Template* 5.0 pi
Mix by pipetting, and then add:
Restriction Enzyme 0.5 ul
(Rsa UNde \\IHinf\)
FINAL VOLUME 20 ul
* DNA Template refers to the products obtained for each sample following PCR with the relevant 
primers.
2. A ‘control’ which contained all components except the restriction enzyme was also 
prepared.
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3. The tubes were then closed and centrifuged in a microcentrifuge for a few seconds. Ali 
tubes were incubated at 37°C for 4 hours.
4. Following incubation, 4 pi of 6X gel loading dye was added to each tube and the tube 
contents mixed by gentle pipetting.
5. 20 pi from each tube was loaded into different wells of a 2% agarose gel (see section 
2.7).
6. Molecular weight markers were prepared and used as detailed in section 2.8.
7. The gel then underwent electrophoresis for 1 hour and 50 minutes at 155 volts (130 
milliamps), after which time it was visualized under UV light on a transilluminator. All 
results were photographed and archived using the Syngene DigiGenius Documentation 
System
The same procedure was conducted for H63D and S65C mutation analysis. In the case of H63D 
and S65C analyses, the restriction enzymes used were Nde II and Hinf I, respectively.
2.13 Agarose Gel Electrophoresis
Agarose gels were prepared as detailed in section 2.7 and were used in both quantitation of DNA 
yield and in Restriction Endonuclease Digestion analysis for the haemochromatosis mutations 
C282Y, H63D and S65C.
Before usage, the previously prepared gels (in their units), were overlaid with the same TBE 
buffer used in gel preparation. Samples and molecular weight markers were then loaded into the 
wells and the gel underwent electrophoresis at either:
- 155 voits (130 milliamps) for 1 hour and 50 minutes (Restriction Enzyme Digestion 
Analysis).
Or
- 5V/cm until the bromophenol blue tracking dye has migrated at least 2 cm from the wells 
(Quantitation of DNA Yield).
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Ethidium bromide stained gels were visualized under UV light (365nm) on a Syngene DigiGenius 
documentation system (see Figure 2.0). The location of restriction fragments was compared 
visually to the 50bp-800bp fragments/increments of the 50bp DNA stepladder in order to 
determine the mutational status of each sample. A Lambda Hind III digest was used as a second 
molecular weight marker.
2.14 Gel Analysis & Documentation
Figure 2.0: Syngene DigiGenius Documentation system. (http://www.svnQene.com). Website accessed on 25s' April 
2005.
A number of samples (N=15) were also sent to external facilities for verification of results. The 
two external facilities that conducted genotyping were NUI Galway and the Centre for Liver 
Disease in Dublin. Both facilities use highly automated technologies such as real time PCR (RT-
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PCR) for analysis of genetic mutations, which allows high sample throughput Some results of 
external analysis conducted in Dublin are presented in Figures 3.13 to Figure 3.17.
2.15 Biochemistry Analysis
The following biochemical parameters; serum iron, UIBC, ferritin, HbAic, glucose, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were assayed at Sligo General 
Hospital. Only samples that had documented were assayed. Details of the methods employed 
for routine testing of the aforementioned biochemistry parameters are outlined below.
Serum Iron:
Serum iron is greatly increased in haemochromatosis. Numerous photometric methods have 
been described for the determination of iron. All have the following common features;
- liberation of Fe3+ ions from the transferrin complex using acids or detergents
- reduction of Fe3* ions to Fe2+ ions
- reaction of the Fe2+ ions to give a coloured complex.
Analysis of iron in this study was based on the BM-lron Ferrozine Method for the BM/Hitachi
“Modular” clinical chemistry analyzer. This is a colorimetric assay which does not involve 
deproteinization. Each blood sample is first added to a buffer/detergent and then to an 
ascorbate/FerroZine solution which initiates the reaction. Under acidic conditions, iron is 
liberated from transferrin. Lipemic samples are then clarified by the detergent Ascorbate causes 
the reduction of released Fe3* ions to Fe2+ ions, which then react with FerroZine to form a 
coloured complex (see Figure 2.1). The colour intensity is directly proportional to the iron 
concentration and can be measured photometrically (Siedel et al., 1984).
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pH < 2.0
Transferrin-Fe-complex —> apotransferrin + Fe3*
ascofbate
Fe3* - > Fe2+
FerroZine+Fe2+ —> coloured complex
Figure 2.1: Summary of reaction for the determination of iron by the BM-lron FenoZine Method (Siedel et al., 1984).
UIBC:
Transferrin is generally only 25 to 30 percent saturated with iron. The additional amount of iron 
that can be bound is the unsaturated iron binding capacity (UIBC). The sum of the serum iron 
and UIBC represents the total iron binding capacity (TIBC). UIBC is determined directly by 
saturating the transferrin at an alkaline pH with a known, but excess amount of iron. The excess 
iron is quantitated in the same manner as serum iron but at a pH above 7.5. The UIBC is 
determined by subtracting the amount of excess iron from that of the iron added. This procedure 
is a modification (by Roche) of the method of Goodwin (1966).
Serum is first added to an alkaline buffer/reactant solution containing a known concentration of 
iron to saturate the available binding sites on the transferrin. The FerroZine chromogen reacts 
only with Fe2+; therefore, an iron reductant is added to ensure that ali iron is present in the ferrous 
state. The excess unbound divalent iron reacts with FerroZine chromogen to form a magenta 
complex which is then measured spectrophotometrically (see Figure 2.2). The UIBC is equal to 
the difference measured in the concentrations of the added iron solution and the excess unbound 
iron. The TIBC is equal to the sum of the serum iron and the UIBC (Goodwin et al., 1966).
Alkaline buffer
Fe2+ + T ransferrin —► T ransferrin-Fe23* + Fe2+ (excess)
Fe2++ 3 FerroZine —> Fe (FerroZine)32+
Figure 2.2: Summary of reaction for determination of UIBC (Goodwin et al., 1966).
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Ferritin.
Serum ferritin concentrations reflect the level of storage iron in the body. The Abbott 
ARCHITECT™ Ferritin assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the 
quantitative determination of ferritin in human serum and plasma. In the first step the sample is 
combined with anti-ferritin coated paramagnetic microparticles. Any ferritin present in the sample 
binds to the anti-ferritin coated microparticles. In the second step, anti-ferritin acridinium labeled 
conjugate is added (after washing). Pre-Trigger and Trigger solutions are then added to the 
reaction mixture and the resulting chemiiuminescence is measured as relative light units (RLUs). 
A direct relationship exists between the amount of ferritin in the sample and the RLUs detected by 
the ARCHITECT / optical system (Abbott Laboratories, List No. 6C11 ,66-9281/R1).
HbAic /  Glycated haemoglobin:
HbAk levels were determined in accordance with standard operating methods for the Menarini 
‘Hi-Auto A1c’ Analyzer System at Sligo General Hospital. The principle of the test is that each 
sample of whole blood is first diluted by the autosampler, where it is separated by high-pressure 
liquid chromatography into HbAlab, HbF, HbA1c, HbAO, HbS and HbC fractions. The eluted 
fractions are examined with a chromatic colorimeter, and the results analyzed by a 
microprocessor. The identification and the amount of the fractions (as peak ratios) are presented 
in the form of a print out (see Figure 2.3).
1
o 3
Figure 2.3: Typical Format of Result Printout from the Menarini Hi-Auto A1c analyser (HbA1c).
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Aspartate aminotransferase (AST) & Alanine aminotransferase (ALT):
In this study, the following tests (which can be indicative of liver function) were conducted in 
accordance with standard methods for the Roche Modular Analyser and as per manufacturers 
instructions: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).
Analysis of AST is based on the following test principle (Bergmeyer et al., 1986). When the 
sample is added to reagent 1 (buffer/coenzyme/enzyme) and a-ketoglutarate, the following 
reaction occurs
AST
a-ketoglutarate + L-aspartate «-» L-glutamate + oxaloacetate
The enzyme AST catalyses this equilibrium reaction. The increase in oxaloacetate is determined 
in an indicator reaction catalysed by malate dehyrogenase
MDH
Oxaloacetate + NADH + H+ «-► L-malate + NAD+
NADH is oxidized to NAD+. The rate of the photometrically determined NADH decrease is 
directly proportional to the rate of formation of oxaloacetate and thus the AST activity.
Analysis of ALT is based on the following test principle (Bergmeyer et al., 1986). When the 
sample is added to reagent 1 (buffer/coenzyme/enzyme) and a-ketoglutarate, the following 
reaction occurs
ALT
a-ketoglutarate + L-alanine <-► L-glutamate + pyruvate
The enzyme ALT catalyses this equilibrium reaction. The increase in pyruvate is determined in 
an indicator reaction catalysed by lactate dehyrogenase
LDH
Oxaloacetate + NADH + H+ <-» L-malate + NAD+
NADH is oxidized to NAD+. The rate of the photometrically determined NADH decrease is 
directly proportional to the rate of formation of pyruvate and thus the ALT activity.
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Gel and running buffer preparation involved use of ethidium bromide at a concentration of 0.5 
yg/ml. Extreme caution was taken when working with this substance as it is a mutagen. Gloves 
were worn when handling gels or solutions containing this dye. Safety glasses were also used 
during gel and buffer preparation.
Gels were visualised on an ultraviolet transilluminator. When working with the aforementioned 
equipment, a full face UV protection shield was always worn. Excessive exposure to UV light can 
be carcinogenic.
Gloves were worn when handling blood I serum samples and waste materials contaminated with 
blood products were treated and disposed of as biohazardous waste.
2.16 Risk Assessment
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Frequencies for genotypes and alleles (see Table 3.4) were calculated manually from the results 
presented in this thesis (Tables 3.0, 3.1 and 3.2) and in accordance with standard statistical 
formulae. Before comparing the allele frequencies of the two populations (diabetic and ‘control’), 
calculations were performed to determine whether both populations were in Hardy-Weinberg 
equilibrium. A goodness-of-fit (Chi square) test was also used (a) to allow comparison between 
the observed and expected frequencies for both populations and (b) to allow comparison of 
genotype frequencies between the two populations. Appendix E contains all calculations done as 
part of the statistical analysis for this study. The data analysis conducted in this thesis matches 
statistical analysis done in recently published literature on haemochromatosis mutations (Malecki 
etal., 2003; Halsall etal., 2003).
2.17 Statistics /  Data Analysis
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2.18 Row Diagram of Analysis for Present Study
Ethics Application
1
Approved Study
i
Subject Recruitment / Sample Collection
i
1
DNA Purification & I Quantification
1 
i
PCR (Optimised)
I
Restriction Digestion I Mutational Analysis 
& Electrophoresis
I--------
1
Rsal
I
i
C282Y
i
— I—  
1
Ndell
i
i
H63D
i
Hinfl
i
1
S65C
I
Biochemistry I Haematology Testing* 
1 
i
I----------
1
Iron Indices
 !--------------------------------------------- !
I 4
AST & ALT HbA1c
‘ Access to 'consenting' individuals results only
Figure 2.4: The diagram above shows the pathways of analysis for both genotype analysis (in 
blue) and biochemistry I haematology analysis (in red) of samples. Genotypic analysis was 
conducted in Research laboratories in the Institute of Technology, Sligo and Biochemistry I 
Haematology analysis was conducted in laboratories in Sligo General Hospital.
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3.0 RESULTS
Results
In order to conduct genetic analysis for the haemochromatosis mutations C282Y, H63D and S65C, it 
was first necessary to purify DNA from the subject’s samples. DNA was extracted from 500 whole 
blood samples using a Wizard™ Genomic DNA Purification Kit from Promega (Cat # A1120). 
Purified DNA could then be quantified against DNA standards, to help ensure sufficient template was 
available for PCR.
3.1 DNA Purification & Quantitation from Whole Blood
m m m
1 2 3 4 5 6 7 3
Figure 3.0: Quantitation of DNA Yield from whole blood post purification with Wizard™ 
Genomic DNA Purification kit.
Lanes 1 -  8 contain a range of DNA standards made from commercially available Human genomic DNA (Promega). The 
concentration range is as follows; 1-, 2-, 5-, 10-, 20-, 25-, 50- and 75 ng/pl (from left to right). Lanes 9 & 13 contain 
Lambda Hind III digest, which functions as a molecular weight marker. Lanes 10, 11 and 12 each contain 50 bp DNA 
Step Ladder for use as a molecular weight marker also. Lanes A to S represent 19 different whole blood samples that 
underwent the purification process. Comparison of the band intensities of samples, against those of the DNA standards, 
allows quantification of DNA yield post purification with Wizard™ Genomic DNA Purification kit.
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3.2.1 Optimisation of PCR
DNA obtained from the purification procedure serves as a template I source for PCR. A PCR 
reaction should be optimised in terms of (a) component concentrations (i.e. Taq polymerase, 
dNTP, MgCb, primer and template concentrations), (b) buffer levels and (c) run conditions 
(e.g. annealing and extension temperatures and times, cycle numbers etc.). Results for 
some of the components and run conditions that were optimised, are shown below.
3.2.2 Optimisation of PCR in terms of Magnesium Chloride (MgCk) concentration
In initial stages of PCR analysis, a Readymix™ Taq preparation (Sigma-Aldrich), was 
employed. As this product contains all the necessary components for a standard PCR 
reaction (with the exception of magnesium chloride I MgCk and DNA template), it was 
unnecessary to optimise in terms of enzyme and dNTP concentrations or buffer capacity. It 
was however, essential to optimise in terms of MgCb concentration. Results for the 
optimisation of magnesium chloride concentration are shown below (Figure 3.1). PCR was 
not successful at magnesium chloride concentrations below 1.5mM. It was successful at 
MgCi2 concentrations between 2 mM and 4mM, however, it was decided to utilise a 
concentration of 1.5mM per PCR reaction to help minimise problems (like PCR inhibition) 
that can occur as a result of employing too high a concentration of magnesium chloride.
3.2 Genetic Analysis
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Figure 3.1: Optimisation of PCR in terms of Magnesium Chloride (MgCh) 
concentration.
Lanes 1 -  9 contain PCR reactions prepared with a range of magnesium chloride concentrations. The 
concentration range is as follows; 0-, 0.5-, 1-, 1.5-, 2-, 2.5-, 3-, 3.5- and 4 mM MgCb per reaction (from left to 
right). Lanes A & B contain 50bp DNA Step Ladder to function as a molecular weight marker. Lane C contains 
Lambda Hind III digest to function as a second molecular weight marker. Lanes 10 and 11 are empty. Results 
presented above represent PCR carried out using the C282Y primer pair. (Note: Resolution of markers was not 
optimised at the time of image capture).
3.2.3 Optimisation of PCR in terms of Primer Annealing temperature
Another PCR parameter that was optimised was primer annealing temperature. Optimisation 
of annealing temperature ensures that specific primers bind optimally to template DNA. 
Results of experiments on optimisation of annealing temperature are shown in Figure 3.2 
below. The optimum annealing temperature for the C282Y primer pair shown below, was 
55°C (Lane 3). Identical optimisation work carried out on the H63D primer pair (not 
presented) reported an identical optimum annealing temperature for the aforementioned 
primer pair.
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Figure 3.2: Optimisation of PCR in terms of Primer Annealing Temperature.
Lanes 1 to 11 contain PCR reactions performed (with Human genomic DNA), over a range of different primer 
annealing temperatures. The primer annealing temperature range was as follows; 50-, 54-, 55-, 56-, 57-, 59-, 
61-, 63-, 65-, 68- and 70°C (from left to right). The data presented, pertains to optimisation of annealing 
temperature for the C282Y primer pair. Lane A contains 50bp DNA Step Ladder to function as a molecular 
weight marker. The size of the C282Y PCR product is 393 bp.
3.2.4 Optimisation of Primer Concentration & Template DNA Concentration
Similar experiments were run to determine optimum DNA concentrations and primer 
concentrations for PCR. Results from optimisation of primer concentration are not shown 
due to loss of photographic data from the documentation system. However, results of this 
optimisation were recorded in the lab notebook at the time of experimentation and optimum 
primer concentration for PCR was found to be 5 picomoles. The results below show that a 
volume of 20|jl of product (obtained from extraction of DNA from whole blood, using 
Wizard™ Genomic DNA Purification kit), provided sufficient template DNA for successful 
PCR.
93
Results
393 b p  — ►
Figure 3.3: Optimisation of PCR in terms of Template DNA Concentration.
Lane A contains 50bp DNA Step Ladder to function as a marker of size. Lane B contains Lambda Hind III 
digest to function as a second marker of size. Lanes 1 to 8 represents PCR reactions that were conducted 
using varying volumes of 'extracted' template I DNA. The varying volumes of template used in PCR were; 10-, 
12-, 15-, 16-, 17-, 18-, 19- and 20 |jl. (Results presented above are representative of PCR carried out using 
C282Y primer pair only).
3.2.5 PCR Master Mix versus ReadyMix™ kit
During the course of optimisation procedures, it was decided to change from the Readymix™ 
PCR mix without MgCh (Sigma-Aldrich), to a new product by Promega. The new product 
called PCR Master Mix is optimised in terms of all reaction components (except the 
template), and its use would therefore minimise the potential for error in PCR formulation that 
may arise with use of the previous product. From Figure 3.4 below, it is evident that both 
products produce comparable results.
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Figure 3.4: Comparison of PCR carried out with two different component preparations; PCR 
Master Mix (Promega) & Readymix™ (Sigma-Aldrich).
Lanes A and D contain Lambda Hind III digest which functions as a molecular weight marker. Lanes B and C contain 50 
bp DNA Step ladder which functions as a molecular weight marker also. Lanes 5,6,7 and 8 contain PCR reactions that 
were conducted using Readymix preparation (Sigma-Aldrich). Lanes 1,2,3 and 4 contain PCR reactions that were 
conducted using PCR Master Mix (Promega). DNA from four different individuals (from the diabetic population), was also 
used for PCR. DNA used in PCR reactions represented in lanes 1 & 5, came from sample number 4, those in lanes 2 & 6 
came from sample number 5, those in lanes 3 & 7 came from sample number 8, and those in lanes 4 & 8 came from 
sample number 10.
3.2.6 Restriction Endonuclease Digestion I  Mutational Analysis
Following PCR, the product was subjected to restriction endonuclease digestion with Rsa I, Nde II 
and H in fl, which detected the presence I absence of the haemochromatosis mutations C282Y, H63D 
and S65C, respectively. All 250 samples from both the diabetic and 'control' populations were 
genotyped for the C282Y and H63D mutations. A selected group of 125 samples from each of the 
diabetic and ‘control1 populations underwent analysis for the S65C mutation.
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(a) Restriction Digestion for the C282Y mutation using Rsa I
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19 20
117 bp
146 bp ->■
247 bp -►
393 bp
Figure 3.5: Typical Restriction Fragment Pattern indicating absence of the C282Y mutation
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp 
DNA Step Ladder which also functions as a molecular weight marker. Lane 8 contains a C282Y homozygote 
positive control demonstrating restriction fragments at 247 bp and 117 bp (the 29 bp fragment is not visible). Lanes 
2, 4, 5,10 -  16,18 & 19 contain samples that lack the C282Y mutation (Restriction fragments at 247 bp and 146 
bp). Lane 9 contains a negative control for PCR. Lanes 3 and 7 contain non-enzyme digested controls (undigested 
product fragment size of 393 bp). Results In Lanes 6 and 17 are unclear due to under-efficient purification (and as 
such were re-extracted and retested at a later date). Lanes 1 and 20 are empty.
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Figure 3.6: Typical Restriction Fragment Pattern indicating a C282Y heterozygote
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp 
DNA Step Ladder which also functions as a molecular weight marker. Lane 7 contains a C282Y homozygote 
positive control demonstrating restriction fragments at 247 bp and 117 bp (the 29 bp fragment is not visible). Lane 8 
contains a C282Y positive heterozygote control demonstrating restriction fragments at 247 bp, 146 bp and 117 
bp (the 29 bp fragment is not visible). Lanes 10, 11, 13, 14 and 19 contain samples that are C282Y 
heterozygotes. Lanes 2, 3,4, 5,6,15 and 17 contain samples that lack the C282Y mutation (Restriction fragments 
at 247 bp and 146 bp).' Lane 9 contains a negative control for PCR. Lanes 12, 16 and 18 contain non-enzyme 
digested controls (undigested product fragment size of 393 bp). Lanes 1 and 20 are empty.
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Figure 3.7: Typical Restriction Fragment Pattern indicating a C282Y homozygote
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp 
DNA Step Ladder which also functions as a molecular weight marker. Lane 7 contains a C282Y heterozygote 
positive control demonstrating restriction fragments at 247 bp, 146 bp and 117 bp (the 29 bp fragment is not visible). 
Lanes 2 and 12 contains C282Y heterozygotes. Lane 11 contains a C282Y homozygote (restriction fragments at 
247 bp and 117 bp ( the 29 bp fragment is not visible). Lanes 1, 3, 5, 6, 8,10,13,14,15 and 16 contain samples 
that lack the C282Y mutation (Restriction fragments at 247 bp and 146 bp). Lane 18 contains a negative control for 
PCR. Lanes 4,9 and 17 contain non-enzyme digested controls (undigested product fragment size of 393 bp).
98
Results
(b) Restriction Digestion for the H63D mutation using Nde II
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Figure 3.8: Typical Restriction Fragment Pattern indicating absence of the H63D mutation
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp DNA 
Step Ladder which also functions as a molecular weight marker. Lane 10 contains a H63D heterozygote positive control 
demonstrating restriction fragments at 237 bp, 138 bp, 99 bp and 57 bp. Lanes 2 and 17 contain H63D heterozygotes. 
Lanes 4, 5, 6, 7, 13, 15, 16 and 19 contain samples that lack the H63D mutation as they demonstrate restriction 
fragments at 138 bp, 99 bp and 57 bp. Lane 11 contains a negative control for PCR. Lanes 3,14 and 18 contain non­
enzyme digested controls (undigested product fragment size of 294 bp). Results In Lanes 8 and 9 are unclear due to 
under-efficient purification (and as such were re-extracted and retested at a later date). Lanes 1 and 12 are empty.
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Figure 3.9: Typical Restriction Fragment Pattern indicating a H63D heterozygote
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp DNA 
Step Ladder which also functions as a molecular weight marker. Lane 10 contains a H63D heterozygote positive control 
demonstrating restriction fragments at 237 bp, 138 bp, 99 bp and 57 bp. Lanes 11 and 15 contain H63D 
heterozygotes. Lanes 13,14, 17 and 19 contain samples that lack the H63D mutation as they demonstrate restriction 
fragments at 138 bp, 99 bp and 57 bp. Lane 16 contains a negative control for PCR. Lanes 12 and 18 contain non­
enzyme digested controls (undigested product fragment size of 294 bp). Lanes 1 and 20 are empty. Note: Results in 
Lanes 2,3,4,5,6,7,8 and 9 pertain to S65C analysis that was run on the same gel.
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Figure 3.10: Typical Restriction Fragment Pattern indicating a H63D homozygote
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp DNA 
Step Ladder which also functions as a molecular weight marker. Lane 10 contains a H63D homozygote positive control 
demonstrating restriction fragments at 237 bp and 57 bp. Lane 7 contains a H63D homozygote. Lanes 4,12,14 and 
18 contain H63D heterozygotes. Lanes 2, 5,6, 8, 9,16,17 and 19 contain samples that lack the H63D mutation as they 
demonstrate restriction fragments at 138 bp, 99 bp and 57 bp. Lane 13 contains a negative control for PCR. Lanes 3,11 
and 15 contain non-enzyme digested controls (undigested product fragment size of 294 bp). Lanes 1, 20 and 21 are 
empty.
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(c) Restriction Digestion for the S65C mutation using H infl
Figure 3.11: Typical Restriction Fragment Pattern indicating absence of the S65C mutation
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp DNA 
Step Ladder which functions as a molecular weight marker also. Lane 10 contains a S65C heterozygote positive control 
demonstrating restriction fragments at 80 bp, 147 bp and 227 bp. Lane 11 contains a negative control for PCR. Lanes 2, 
3, 4, 5, 7, 8, 9, 12, 13, 15 and 17 contain samples, which lack the S65C mutation (restriction fragments at 80 bp 
and 147 bp). Lanes 6,14 and 16 contain non-enzyme digested controls. Lanes 1 and 18 are empty.
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Figure 3.12: Typical Restriction Fragment Pattern indicating a S65C heterozygote
Lane A contains Lambda Hind III digest which functions as a molecular weight marker. Lane B contains a 50 bp DNA 
Step Ladder which functions as a molecular weight marker also. Lane 8 contains a S65C heterozygote positive control 
demonstrating restriction fragments at 80 bp, 147 bp and 227 bp. Lane 9 contains a negative control for PCR. Lane 5 
contains a S65C heterozygote sample. Lanes 1, 2, 3, 4, 6, 7, 10,12,13,14 and 15 contain samples, which lack the 
S65C mutation (restriction fragments at 80 bp and 147 bp). Lanes 11 and 16 contain non-enzyme digested controls. 
Lane 17 is empty.
The following Tables (Tables 3.0 -  3.4), record the incidence of the three haemochromatosis 
mutations in both the diabetic and 'control' populations.
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Table 3.0: Incidence o f C282Y mutations in the Diabetic and Control Populations.
Mutational Status Sample Identification h umbers at each genotype
Diabetic Population Control Population
C282Y homozygous 164.
(N = 1)
C48, C92, C184. 
(N = 3)
C282Y heterozygous 3, 4, 32, 34, 35, 57, 58, 63. 67,71, 72. 81,86, 88, 90,103,104, 
113,117,122,139,152,156,161,167,171,182,191,196,205, 
206,212,215,219,225,238.250,
(N = 37)
C8, C10, C11, C25, C28, C30, C33, C46, C47, C58, C66, C73, C79, 
C80, C100, C103, C104, C107, C108, C128, C130, C134, C156, C157, 
C158, C159, C162, C177, C181, C185, C192, C198, C211, C214, 
C219, C222, C229, C236, C237, C238, C239, C242, C244, C246, 
C249.
(N -  45)
No C282Y mutation 1,2, 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, 
23, 24, 25, 26, 27,28, 29,30, 31,33,36, 38,39, 40, 41, 42, 43, 
44, 45, 46, 47, 48, 49, 50,51,52, 53, 54, 55,56, 59,60,61, 62, 
64, 65,66, 68, 69,70, 73,74,75,76,77,78, 79, 80,82, 83, 84, 
85, 87,89, 91,92, 93,94, 95,96,97, 98,99,100,101,102,105, 
106,107,108,109,110,111,112,114,115,116,118,119,120, 
121,123,124,125,126,127,128,129,130,131,132,133,134, 
135,136,137,138,140,141,142,143, 144,145,146,147,148, 
149,150,151,153,154,155,157,158,159,160,162,163,165, 
166,168,169,170,172,173,174,175,176,177,178,179,180, 
181,183,184,185,186,187,188,189,190,192,193,194,195, 
197,198,199,200, 201,202, 203, 204,207,208,209, 210,211, 
213,214,216,217,218,220,221,222,223,224,226,227,228, 
229,230,231,232,233,234,235, 236,237,239,240,241,242, 
243,244,245,246,247,248,249.
(N = 211)
C1, C4, C5, C6, C7, C9, C12, C13, C14, C15, C16, C17, C18, C19, 
C20, C21, C22, C23, C24, C26, C27, C29, C31, C32, C34, C35, C36, 
C37, C38, C39, C40, C41, C42, C43, C44, C45, C49, C50, C51, C52, 
C53, C54, C55, C56, C57, C59, C60, C61, C62, C63, C64, C65, C67, 
C68, C69, C70, C71, C72, C74, C75, C76, C77, C78, C81, C82, C83, 
C84, C85, C86, C87, C88, C89, C90, C91, C93, C94, C95, C96, C97, 
C98, C99, C101, C102, C105, C106, C109, C110, C111, C112, C113, 
C114, C115, C116, C117, C118, C119, C120, C121, C122, C123, 
C124, C125, C126, C127, C129, C131, C132, C133, C135, C136, 
C137, C138, C139, C140, C141, C142, C143, C144, C145, C146, 
C147, C148, C149, C150, C151, C152, C153, C154, C155, C160, 
C161, C163, C164, C165, C166, C167, C168, C169, C170, C171, 
C172, C173, C174, C175, C176, C178, C179, C180, C182, C183, 
C186, C187, C188, C189, C190, C191, C193. C194, C195, C196, 
C197, C199, C200, C201, C202, C203, C204, C205, C206, C207, 
C208, C209, C210, C212, C213, C215, C216, C217, C218, C220, 
C221, C223, C224, C225, C226, C227, C228, C230, C231, C232, 
C233, C234, C235, C240, C241, C245, C247, C248, C250.
(N =199)
Table 3.0 shows the incidence of C282Y mutations in the Diabetic and Control Populations. The Individual genotypes exhibited by all samples that were tested, is also detailed In 
the Table above. Results were unavailable for Sample Number(s): 37 (Diabetic Population); C2, C3 and C243 (Control Population). Therefore only 249 diabetic samples and 247 
control samples were analysed for C282Y Instead of250 samples for each group (see Discussion).
Table 3.1: Incidence ofH63D mutations in the Diabetic and Control Populations.
Mutational Status Sample Identification Numbers at each genotype
Diabetic Population Control Population
H63D homozygous 14,44,50,55,60,97,109,114,173,183,189,202,228. 
(N = 13)
C4, C5, C17, C26, C121, C148, C213, C234, C240.
(N = 9)
H63D heterozygous 7, 8,11,12,18,20,21, 23,24,26, 29,30,36, 40, 45, 46,48,51, 
54, 57, 59, 62, 64, 69, 74, 76, 80, 83, 106, 107, 110, 113,120, 
122,124,127,131,142,145,146,149,163,165,166,174,176, 
179,181,186,193,196,198, 209,218,222,227,230,236,237, 
240,241,242,248.
(N = 63)
Cl, C7, C12, C23, C34, C38, C42, C44, C45, C53, C58, C63, C67, 
C69, C71, C73, C75, C85, C86, C87, C91, C94, C99, C110, C112. 
C116, C117, C123, C125, C126, C127, C132, C135, C137, C138. 
C141, C142, C145. C151, C156. C164, C165, C171, C173, C179, 
C180, C190, C191, C194, C197, C201, C215, C223, C229, C236, 
C238, C242.
(N = 57)
No H63D mutation 1,2,3,4,5,6,9,10.13,15,16,17,19,25,27,28,31,32,33,34, 
35. 37, 38, 39, 41, 42, 43, 47, 49,52,53,56,58, 61, 63, 65,66. 
67. 68, 70, 71, 72,73,75,77,78,79,81,82,84. 85, 86,87,88. 
89, 90, 91, 92. 93, 94, 95, 96, 98, 99, 100, 101, 102, 103,104, 
105,108,111,112,115,116,117,118,119,121,123,125,126, 
128,129,130,132,133,134,135,136,137,138,139,140,141, 
143.144,147,148,150,151,152,153,154,155,156,157,158, 
159,160,161,162,164,167,168,169,170,171,172,175,177, 
178,180,182,184,185,187,188,190,191,192,194,195,197, 
199,200,201,203,204,205,206,207,208,210.211.212,213. 
214,215,216,217,219,220,221,223,224,225,226,229,231, 
232,233,234,235,238,239,243,244,245,246,247,249,250.
(N =173)
C2, C3, C6, C8. C9, C10, C11, C13, C14, C15, C16, C18, C19, C20, 
C21, C22, C24, C25, C27, C28, C29, C30, C31, C32, C33, C35, C36, 
C37, C39, C40, C41, C43, C46, C47, C48, C49, C50, C51, C52, C54, 
C55, C56, C57, C59, C60, C61, C62, C64, C65, C66, C68, C70, C72, 
C74, C76, C77, C78, C79, C80, C81 C82, C83, C84, C88, C89, C90, 
C92, C93, C95, C96, C97, C98, C100, C101, C102, C103, C104, 
C105, C106, C107, C108, C109, C111, C113, C114, C115, C118, 
C119, C120, C122. C124. C128, C129, C130, C131, C133, C134, 
C136, C139, C140, C143, C144, C146, C147, C149, C150, C152, 
C153, C154, C155, C157, C158, C159, C160, C161, C162, C163, 
C166, C167, C168, C169, C170, C172, C174, C175, C176, C177, 
C178, C181/C182, C183, C184, C185, C186, C187, C188, C189, 
C192, C193, C195, C196, C198, C199, C200, C202, C203, C204, 
C205, C206, C207, C208, C209, C210, C211, C212, C214, C216, 
C217. C218, C219, C220, C221, C222, C224, C225, C226, C227, 
C228, C230, C231, C232, C233, C235, C237, C239, C241, C243, 
C244, C245, C246. C247. C248, C249, C250.
(N B 184)
Table 3.1 shows the incidence of the H63D mutations in the Diabetic and Control Populations. The individual genotypes exhibited by all samples that were tested, is also detailed 
in the Table above. Results were unavailable for Sample Number: 22 (Diabetic Population). Therefore only 249 diabetic samples analysed for H63D instead of 250 (see 
Discussion)
Table 3.2: Incidence o f S65C mutations in the Diabetic and Control Populations.
Mutational Status Sample Identification humbers at each genotype
Diabetic Population Control Population
S65C homozygous
<N = 0) (N s 0)
S65C heterozygous 54
(N = 1)
08,078,0124, C145.
(N = 4)
No S65C mutation 1,2,3,6,7,10,11,13,15,16,18,21,22,26,27,28,31,32,35, 
36,38,39, 41, 42, 43, 44, 45, 50,51, 52, 56,59, 63,64,65, 66, 
69,70,71,72,74,77,80,81,85,88,89,90,92,94,97,99,100, 
102,103,106,107,110,113,114,117,118,120,122,123,127, 
128,129,131,132,133,134,137,138,140,143,144,146,147, 
150,151,152,156,157, 159,161,163, 166,167,168,172,173, 
176,177,179,183,184,186,190,194,195,198,199,200,203, 
204,209, 210,211,218,219,223, 228,230,233,235,236,241, 
243, 246,249,250.
(N =123)
C1, C4, C5, C9, C12,014, C17, C20,024, C25, C29, C30, C33, C34, 
C37, C40, C46, C47, C49, C53, C55, C57, C58, C60, C61, C62, C67, 
C68,073, C75,076, C79, C82, C83, C84, C86, C87,091, C93, C95, 
C96, C98, C101, C104, C105 C108, C109, C111, C112, C115, C116, 
C119, C121, C125, C126, 0130, 0135, C136, C139, 0141, C142, 
C148, C150, G153, 0154, C155, C158, C160, 0162, C164, C165, 
C169, 0170, 0171, C174, C175, C178, C180, C181, 0182, C183, 
C187, C188, 0189, C191, C192, 0193, 0196, C197, C201, C202, 
C205, 0206, C207, C208, 0212, C213, C214, 0215, C216, C217, 
0220, 0221, C222, C224, C225, C226, C227, C229, C231, 0232, 
0234,0237, C238, C239,0240, C242,0244, C245, C247,0248.
(N = 121)
Table 3.2 shows the incidence of the S65C mutations in the Diabetic and Control Populations. The individual genotypes exhibited by all samples that were tested, is also detailed 
in the Table above. One sample was inadvertently analysed in duplicate (18), this meant that only 124 diabetic samples were analysed for S65C instead of 125 (see Discussion).
Table 3.3: Incidence o f compound heterozygosity for Ihe haemochromatosis mutations C282Y, H63D and 565C in the Diabeù'c &
‘Control’ Populations
Genotype Sample Identification Number, Number & Frequency at each Genotype
Diabetic Population Control Population
C282Y/H63D compound heterozygotes 57,113,122,196 C58, C73, C156, C229, C236, C238, C242
(NM) (N=7)
Frequency = 0.8% Frequency = 1.41%
C282Y/S65C compound heterozygotes C8
(N=1) 
Frequency = 0.27%
H63D/S65C compound heterozygotes 54 C145
(N=1) (N=1)
Frequency = 0,27% Frequency = 0.27%
Table 3.3 (above) shows the incidence of C282Y/H63D-, C282Y/S65C- and H63D/S65C- compound heterozygosity in both the Diabetic and Control 
Populations. The various samples at each genotype are identifiable by their sample identification numbers (sample numbers are also included and 
are in parentheses). The frequency of each genotype in the two populations is also reported.
Table 3.4: Allele & Genotype Distribution of the HFE gene in the Diabetic & ‘Control’ populations
Allele Frequency Genotype Frequency
Codon 282 wt C282Y X2 = 0.58* & 0.0643* wt/wt wt/C282Y & 
C282Y/C282Y
1df 
p = <0.05*4
Diabetic Population* 459(92.2%) 39 (7.8%) 211 (84.74%) 38 (15.26%)
‘Control" Population* 443 (89.7%) 51 (10.3%) 199 (80.57%) 48 (19.43%)
Codon 63 wt H63D x2 = 4.74* & 2.805* wt/wt WVH63D & H63D/H63D
1df
p = >0.05* & p = <0.05*
Diabetic Population* 
‘Control1 Population*
409(82,1%)
425(85%)
89 (17.9%) 
75(15%)
173 (69.48%) 
184(73.6%)
76 (30.52%) 
66 (26.4%)
Codon 65 wt S65C x2= 0.5091 *& 0.033*
1df 
p = <0.05**
wt/wt wt/S65C & S65C/S65C
Diabetic Population* 246 (99.19%) 2(0.81%) 123(99,19%) 1 (0.81%)
'Control'Population* 246 (98.4%) 4(1.6%) 121 (96.8%) 4(3.2%)
Table 3.4 shows the allele frequencies of the three haemochromatosis mutations in both the Diabetic and Control Populations (indicated by the 
codon where the mutation occurs; i.e. the C282Y mutation occurs in codon 282, the H63D mutation occurs in codon 63 and the S65C mutation 
occurs in codon 65). The Table also details the genotype frequencies for each of the three mutations in the two populations, Appendix E contains all 
statistical calculations. No statistically significant differences in the HFE genotype frequencies were found between the two populations.
wt=wildtype 
x? = chi-squared 
df = degrees freedom
Table 3.5 Results of External Genetic Testing
Sample Number Genotype
34 C282Y/Normal*
37 Normal/Normal*
38 Normal/Normal*
41 Normal/Normal*
49 Normal/Normal*
50 H63D/H63D*
53 Normal/Normal*
56 Normal/Normal*
64 H63D/Normal*
108 Normal/Normal*
C8 S65C/C282Y compound heterozygote*
C54 S65C heterozygote*
C78 S65C heterozygote*
C124 S65C heterozygote*
C145 S65C/H63D compound heterozygote*
Results were validated by re-testing of 15 samples at two external genetic facilities. Both facilities are accredited for testing and use highly 
automated technologies such as lightcyclers for analysis of genetic mutations. Some results of external analysis conducted by Dublin are presented 
in Figures 3.13 to 3.17.
Key: * = Genotyping was carried out by the Cytogenetics Unit in the National University of Ireland (NUI), Galway.
*  = Genotyping was carried out by the Centre for Liver Disease, Eccles Street Dublin (c/o Dr. Sharon Barrett).
3.3 Biochemistry Analysis
Table 3.6 which follows, details the results of the various biochemistry parameters that were analysed in individuals who gave written consent for 
study participation (N=26 individuals from the Diabetic Population).
Table 3.6: Results of Biochemistry analysis for individuals who consented to study participation (N = 26).
Sample
Number
Gender Age
years
Iron (Fe)
fjmole/L
TIBC
ymole/L
Transferrin
Saturation
%
Ferritin
m n
AST
M L
ALT
IU/L
HbA1c
%
Genotype
67 F 68 18 51.7 35 21.4 38 31 8.6 C282Y heterozygote«
77 M 58 14 50.4 28 171.9 21 39 8.1 Wiidtype •
60 M 59 15 54,9 27 128.9 26 37 7.1 H63D homozygote«
37 M 67 12 46.3 26 145.8 20 17 9.7 WildlypeA
39 F 76 13 62.3 21 72.5 39 37 7 Wiidtype#
54 M 77 17 43.5 39 97.7 27 21 9.1 H63D/S65C compound 
heterozygote*
52 M 51 27 57.4 47 161.4 21 27 7 Wildtype»
47 M 82 15 62.8 24 52 26 19 6.9 Wiidtype«
34 M 50 37 54.6 68 196.6 18 23 9.2 C282Y heterozygote«
38 F 51 12 55.5 22 22,4 24 18 7 Wildtype»
72 F 46 28 44.9 62 43.2 16 24 9.5 C282Y heterozygote»
175 M 40 15 68.4 22 119.6 - - 11.6 Wildtype«
74 M 65 14 40.2 35 73.9 21 30 7.8 H63D heterozygote»
Table 3.6 continued
68 M 71 21 48.5 43 260.8 23 28 7.9 Wildtypea
76 M 72 11 71.2 15 111.5 31 38 8.3 H63D heterozygote«
55 M 76 12 42.2 28 115.1 20 18 7.5 H63D homozygote«
66 M 61 14 58.1 24 13.4 26 33 8.9 Wildtype«
56 F 55 19 54.6 35 95.4 36 37 6.4 Wildtype»
42 F 53 14 55.4 25 32.3 26 30 8.5 Wildtype«
51 F 74 21 50.1 42 88.1 34 38 7.7 H63D heterozygote«
78 M 76 22 52.5 42 436.4 24 21 6.1 Wildtype«
222 M 73 - - - - 15 16 7 H63D heterozygote«
49 M 68 20 57.9 35 59.2 21 18 8.2 Wildtype«
41 F 52 16 68.7 23 46 21 24 8.2 Wildtype«
50 M 20 17 49.5 34 41.5 23 20 9.2 H63Dhomozygote«
46 M 50 16 61.5 26 141.2 27 42 9.1 H63D heterozygote«
Results Range 11-37 40.2-
68.7
15-68 13.4-
436.4
15-39 16-39 6.4-11.6
Mean of All Results 16.92 52.43 31.85 105.7 24 26.39 8.14
Mean of Mala Results 16.61 51.11 31.28 112.56 21.67 24.83 8.26
Mean of Female Results 17.63 55.4 33.13 52.66 29.25 29.88 7.86
Reference Range 
(Sligo General Hospital)
■10 -  75 2 ! S I — 274 GS 5 — 37 5 - 4C 51 * 
•
Key; * DCCT aligned
■ Genotyped for the C262Y & H630 mutations only ▲ Genotyped for the H63D mutation only.
•  Genotyped for the C282Y, H63D & S65C mutations Male Reference Range = §{j Female Reference Range =
Table 3.7: Mean Values for iron indices for each haemochromatosis genotype exhibited in the 26 consenting diabetic individuals that
underwent biochemistry analysis.
Iron
(pmolefL)
TIBC
(ytttole/L)
Transferrin
Saturation
(%)
Ferritin
(M0/L)
AST
(IU/L)
ALT
(IU/L)
HbA1c
(%)
C282Y heterozygote
(N=3)
iSamole numbers: 67,34,72j
27.67 50.4 55 87.07 24 26 9.1
H63D homozygote 
(N=3)
[Sample numbers: 60,55,50]
14.67 48.87 29.67 95.17 23 25 7.93
H63D heterozygote
(N=6)
[Sample numbers 54,74,76,51,222, 
4SI
15.8* 53.3* 31.4* 102.48* 25.83 30.83 8.17
Wildtype
(N=14)
[Sample numbers 77,37,39,52,47,
38,175,68,66,56.4Z 78,49,411
16.71 55.63 29.79 120.65 25.23« 26,77* 7.96
Table 3.7 shows the mean values for iron indices exhibited by each haemochromatosis genotype.
* = only 5 out of 6 individuals had test results available, therefore results presented are a mean of 5 values.
*  = only 13 out of 14 individuals had test results available, therefore results presented are a mean of 13 values.
Note: One S65C/H63D compound heterozygote was identified within this group. This individuals iron indices values were included when calculating the mean values for the H63D 
heterozygote genotype (row three above). No mean results for the S65C heterozygote genotype are presented, as there was only one S65C heterozygote identified.
Figure 3.13: Lightcycler I RT«PCR graph for C282Y amplification (Examples of External Results / Analysis conducted by Centre for Liver
Disease, Dublin).
The figure below shows results of 5 samples that were amplified for C282Y mutation analysis in duplicate. The sample numbers corresponding to 
each line are detailed on the left-hand side of the printout (inside the blackened box). Results of approximately 45 cycles of amplification are shown.
=lle: C:\UgMCyaler3\UsersWdmlnlstrjrtcr\Oata\SLIQO.ABT Program: amplification Run By: Admfnletrator 
iu n  Data: Jul 24, ZOOS 09:20 Print Oaie:
7 .6 -
7 .0 -
8.5-
e.o-
6 .5 -
5 .0 -  
4 5 -
4 . 0 -  
3 5 -  
3,0 —
C y e le  ¡¡:!uimlb®ir
Start cunon 0:00:30.9 Stop cukoi: 0:49:27.05
eo
Ifcw
LL•tel?
n
E
8
eD
3
U=
Color Compensation: 
c« 29 .06.05. occ
Figure 3.14: Lfghtcycler/ RT-PCR graph for H630 amplification (Examples of External Results / Analysis conducted by Centre for Liver
Disease, Dublin).
The figure below shows results of 5 samples that were amplified for H63D mutation analysis in duplicate. The sample numbers corresponding to 
each line are detailed on the left-hand side of the printout (inside the blackened box). Results of approximately 45 cycles of amplification are shown.
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Figure 3.15: Lightcycier I RT-PCR graph for H63D negative sample (Examples of External Results I Analysis conducted by Centre for
Liver Disease, Dublin).
The figure below shows results of an amplification carried out on a sample that was negative for the H63D mutation. The sample number and name 
corresponding to the H63D negative sample is 11 NEG (inside the blackened box on the left-hand side). The temperature range over which the test 
was mn is shown on the X axis.
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Figure 3,16: Llghtcycler / RT-PCR graph for sample C54 [C282Y amplification] (Examples of External Results I Analysis conducted by
Centre for Liver Disease, Dublin).
The Figure below shows results of an amplification for C282Y, of an individual sample (sample number C54). The sample in question was found to 
lack the C282Y mutation.
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Figure 3.17: Lightcycler I RT-PCR graph for sample C54 [H63D amplification] (Examples of External Results / Analysis conducted by the
Centre for Liver Disease, DubHn).
The Figure below shows results of an amplification for H63D, of an individual sample (sample number C54). The sample in question was found to 
lack the H63D mutation.
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The objectives of this study were to establish P C R  a ssa y s  for C 282Y, H63D  and S 6 5 C  mutations in 
Ihe H F E  (hereditary haemochromatosis) gene, to determine the incidence of the three main genetic 
mutations for hereditary haemochromatosis in the North W est popuiation of ireland and to establish 
whether there is an increased frequency of these mutations in diabetic individuals from the sam e 
region.
The importance of this study lies in the feet that it will provide baseline data, which can be used to 
a s se s s  whether there is a need to implement a regional screening program for haemochromatosis, a 
condition that once diagnosed, is fully treatable and manageable. Early diagnosis (even before 
phenotypic expression) can help avoid development of complications such a s  diabetes and arthritis 
and decrease morbidity. Taking into account the co-existence of diabetes in haemochromatosis and 
vice versa (diabetes occurs at a relatively high rate in individuals with haemochromatosis) and the 
fact that som e of the highest levels of iron in drinking water are found in the North W est region 
(N W H B Reports, 2001), it is reasonable to propose an investigational study into the 
haemochromatosis mutation levels in the region.
The main finding of the study w as that there w as no significant difference in the incidence of HFE 
genotypes between the Diabetic and Control populations. C 2 8 2 Y  and H 63D  allele frequencies in the 
control popuiation were favourably comparable to other studies on similar populations. A  higher 
incidence of H63D  heterozygosity w as found in diabetic individuals than in controls. Unexpectedly, 
the incidence of the S 6 5 C  mutation (in controi individuáis) reported in the present study is higher than 
that reported in the general Irish population.
4.1 Sample Collection
The first stage in the study w as recruitment of research subjects, which took place in the Out Patient 
department of Sligo General Hospital. Individuals attending the Diabetic Clinic were approached, 
given an information sheet about the study and asked if they were interested in participating. Those 
people that consented to participation signed consent forms recording their decision to do so  and 
also gave blood samples, which were taken by phlebotomist, registrar or Medical consultant. Due to
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time constraints, a limited number of willing participants for this phase of the study and the limited 
number of people (with concurrent heavy work loads) available for subject recruitment, only 26 
diabetic sam ples were obtained in this manner. The majority of these were enlisted by the project 
Researcher. It w as therefore decided to decrease total sample size from N = 1530 (original ethics 
application, see  Appendix A) to N = 500 (N = 250 in each of the diabetic and ‘control’ populations). In 
order to reach test population sizes, supplemental sam ples had to be obtained from the laboratories 
of S iigo General Hospital. For the Diabetic Population: The remaining two hundred and twenty four 
sam ples were obtained by selecting them randomly from samples, which entered the lab for routine 
HbA1c testing. All sam pies (that were obtained through random selection) for genetic analysis were 
blinded to the researcher. ‘Control’ sam ples (N = 250) were obtained similarly, with the exception 
that they were sam ples that entered the lab for routine haematology testing.
To summarize, the first problem encountered within this study w as at the stage of research subject 
recruitment Only a very limited number of sam ples were obtained by the recruitment strategy initially 
decided upon during study design. The original sample number envisaged for the study (N -1 530 
individuals; 765 per diabetic and ‘control’ group, which w as statistically calculated) had to be revised 
down and sam pies obtained in the manner detailed above. For future reference, in order to meet the 
quota of sam ples set down during study design, it is essential to have a sufficient number of qualified 
staff that are committed and resourced to coiiecting the correct sample size. Following sample 
receipt, the first requisite w as to purify D N A  from all 500 whole blood samples.
4.2 DNA Purification from whole blood
Prior to genetic analysis, D N A  was extracted from all study sam ples by a W izard™  kit procedure. 
Results demonstrated that if the purification procedure w as successful, sufficient template D N A  
would be produced for use  in P C R  (see section 3.1). The W iza rd™  kit instructions state that the D N A  
pellet obtained from the procedure should be rehydrated in a 100 (il volume of D N A  Rehydration 
solution, however it w as decided to decrease this volume to 50 f.il in order to concentrate the 
available DNA. The rationale behind this decision w as that the sam ples were stored frozen, for a  
period of up to a four months before being extracted, a  factor that can cause a decrease in D N A
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concentration (W izard™ kit instructions). This w as an important finding a s  there is little evidence of 
this requirement in published literature.
D N A  obtained through the Wizard kit extraction procedure can be quantified (see Figure 3.0) but was 
not routinely done in this study due to mainly budgetary and time constraints. This meant that som e 
sam ples (approximately 1 0 % )  had to be re-extracted at a later date due to insufficient template for 
original P C R  analysis. D N A  purification from fresh whole blood sam ples would have produced more 
favourable results in terms of lowering the percentage of sam ples that required re-extraction. Repeat 
testing due to poor D N A  purification may cause  unacceptable delays in a  routine diagnostic service 
and therefore u se  of fresh specim ens is advised.
A  second type of D N A  purification w as also tried a s  part of this research, but w as not chosen a s  the 
final method of extraction for reproducibility problems. The aforementioned method involved 
extraction of D N A  from whole blood using a  resin called Chelex®  100 (Biorad) and a method used by 
W alsh etal., (1991). Both purification methods are more favorable than traditional procedures, which 
can involve phenol-chloroform extraction and/or ethanol precipitation (Budowle & Baechtel, 1990; 
Sambrook et al., 1989) a s  well a s  inorganic procedures that employ high salt concentration (Dykes, 
1988), excess proteinase K digestion (Grimberg e l al., 1989) and the use  of g la ss wool (Vogelstein & 
Gillespie, 1979). The Chelex extraction procedure is a favourable method of purification a s  it is 
simple, rapid, involves no organic solvents and does not require multiple tube transfers for most types 
of sam ples (Walsh et al., 1991). The W izard™  kit w as the chosen method for D N A  extraction in this 
research because of its pre-prepared, high quality reagents, ease  of use, high reproducibility of 
results and because only basic technologies were needed.
The D N A  purification methods attempted and utilized in this study compare favourably with methods 
used in published research on haemochromatosis mutation analysis. Other commercially available 
D N A  purification kits like Q IAam p®  Blood Mini kit (Qiagen GmbH, Germany) and Isolate 1 D N A  
extraction kit (Cruachem Ltd.), have been used in H F E  genotyping studies (Gomez-Llorente et al., 
2004; Datz et al., 1998), a s  well a s  variations on the Chelex extraction procedure (Bym es et al., 
2001; Ryan et al., 1998; Stott et al., 1999). Other D N A  purification methods such a s  methanol
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extraction (Bany et al., 2005) ana standard alkaline lysis (Elsea & Leykam, 2000) have a lso  been 
utilised in studies on haemochromatosis.
The use  of automated technology or genetic analysers for rapid D N A  quantification, had it been 
available, would ensure that unnecessary re-extractions or more lengthy quantification procedures 
could be avoided. The results for 15 sam ples were verified through re-testing by iwo external 
facilities. This formed part of the validation process for the ‘in-house’ assay. .Both external test 
facilities (Galway & Dublin) use  automated system s for genotyping and are accredited for genetic 
testing.
4.3 PCR Optimisation
Once sufficient D N A  template w as available for P C R  (following extraction), other factors, which can 
affect the su cce ss of PCR , were investigated. A s  initial attempts at P C R  were conducted using a 
ReadyM ix™  kit without magnesium chloride / M gC b  (Sigma-Aldrich), it w as necessary to optimise in 
terms of M gC b  concentration. From Figure 3.1 it is evident that P C R  w as unsuccessful at M g Cl? 
concentrations below 1.5 mM. Although P C R  w as successful at M g C b  concentrations between 2 mM 
and 4mM, it w as decided to utilise a concentration of 1.5mM per P C R  reaction to help minimise 
problems (like P C R  inhibition) that can occur a s  a  result of employing too high a  concentration of 
magnesium chloride. This is in agreement with current practices I literature (Bany et al., 2005; 
Gomez-Llorente et al., 2004; E lsea  & Leykam, 2000; Datzetal., 1998; Sambrook eta!., 1989).
To further refine a ssa y  conditions, primer annealing temperature w as evaluated and optimised. P C R  
reactions were set up and run at a series of different annealing temperatures between 5 0 ° C  and 
70°C. The range of temperatures used for annealing optimisation work w as decided on, following 
manual calculation of the melting temperatures (Tm) of all four primers. The optimum annealing 
temperature for a  primer is thought to be approximately 5°C  below its melting temperature. 
Calculation of Tm for each primer pair helped decide the temperature range used in optimisation of 
annealing temperature (see methods section 2.11.3). Figure 3.2 show s that the optimum annealing 
temperature for the C 282Y  primer pair w as 55°C. Similar work w as carried out on the H 63D  primer 
pair and it w as found that it had an identical optimum annealing temperature to that of the C 282Y
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primer pair (results are not shown). The annealing temperature used in this study w as within the 
temperature range used in other studies on H F E  mutation analysis, albeit with slightly different 
primers (Gomez-Llorente et al., 2004; Barry et al., 2005; Stott et al., 1999; Datz et ai., 1998). Primer 
concentration w as also investigated and the optimum concentration for P C R  w as found to be 5 
picomoles of each primer pair. Again, this concentration w as within the range used in other studies 
on haemochromatosis (Barry etal., 2005; Stott etal., 1999)
Template D M A  concentration w as also evaluated to ensure optimal P C R  conditions. Results indicate 
that a  20 ^l volume of product from the D N A  purification procedure produces sufficient D N A  to 
ensure further analysis of P C R  product is successful (see Figure 3.3). Other H F E  studies used 
similar volumes of D N A  from their respective extraction procedures (Gomez-Llorente et al., 2004). 
To optimise in terms of any other P C R  reaction components would have been superfluous, a s they 
came pre-optimised in the R eadyM ix™  kit
During the analytical period a  new P C R  Master mix (Promega) cam e onto the market and w as 
optimised in terms of all P C R  reaction components save  template concentration. Figure 3.4 
illustrates that both products produced comparable results. It w as decided that P C R  Master mix 
(Promega) should be employed instead of the R eadyM ix™  kit to help ensure minimal interference in 
P C R  efficiency which may occur a s  a  result of small variations in the concentration of magnesium 
chloride.
All of the findings of these optimisation trials yielded results that fall within the accepted limits a s  set 
out in the literature. However, it should be noted that every laboratory should take literature values 
as guidelines and optimise their own systems.
4.4 Restriction Endonuclease Digestion
Once the P C R  conditions had been optimised in terms of reaction component(s) and run conditions, 
it w as possible to u se  P C R  product for further analysis. In this study, P C R  product w as subjected to 
endonuclease digestion with various restriction enzym es in order to determine the presence /
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absence of C282Y, H63D and S65C, the three main mutations responsible for hereditary 
haemochromatosis. All digestions were earned out in accordance with manufacturers instructions.
To detect the C282Y mutation, PCR product (393 bp) was digested with the enzyme Rsa I, which 
produces a characteristic pattern of restriction fragments, all of which have definite sizes. Bands 
were visually evaluated, with those produced in samples being sized by comparison of their position 
to those of molecular weight markers. Two different molecular weight markers were employed in this 
research, they were a 50 bp DNA Step Ladder (Promega) and a Lambda Hind III marker (Sigma- 
Aldrich). The 50bp DNA Step Ladder has 16 DNA fragments ranging from 50 base pairs (bp) to 800 
bp, in exactly 50 bp increments. The Lambda Hind III digest has characteristic bands of size 125 bp, 
564 bp, 2027 bp, 2322 bp, 4361 bp, 6559 bp, 9416 bp and 23130 bp (only the smallest bands are 
evident on gel results presented). C282Y homozygotes produce bands of the following sizes; 29 bp, 
117 bp and 247 bp. Carriers of the C282Y mutation produce bands of 29 bp, 117 bp, 146 bp and 247 
bp. Samples that lack the C282Y mutation will produce restriction fragments of 146 bp and 247 bp 
(Feder et al., 1996; Jeffrey et al., 1999). See Figures 3.5 to 3.7 for typical restriction fragment 
patterns associated with the C282Y mutation.
The H63D mutation was detected by subjecting PCR product (294 bp) to enzyme digestion with Nde 
II. Digestion produced bands of characteristic size. H63D homozygotes had restriction fragments of 
57 bp and 237 bp and earners of the mutation had fragments of 57 bp, 99 bp, 138 bp and 237bp. 
Samples that lacked H63D had restriction fragment sizes of 57 bp, 99 bp and 138 bp (Merry weather- 
Clarke et ai., 1997a). Figures 3.8 to 3.10 show typical restriction patterns associated with the H63D 
mutation.
The final mutation assesed was the S65C mutation. Digests were performed with the restriction 
enzyme Hinfl to establish the presence / absence of the mutation. Samples that lacked the S65C 
mutation produced two restriction fragments (at 80 bp and 147 bp), whereas carriers of the mutation 
produced an extra restriction fragment (at 80 bp, 147 bp and 227 bp) (see Figures 3.11 and 3.12).
The rationale behind the usage of the four primers employed in the present study is detailed in 
section 1.7 and Figure 1.5 (Literature Review).
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Ail enzymes and primers employed in this research have been utilised in published literature on the 
mutational analysis of C282Y, H63D and S65C.
4.5 Quality Control (pre- and post- PCR)
A rigorous QC/QA program is essential for any laboratory procedure, but especially so in genetic 
analysis. Duplicate samples give insight to the reproducibility or precision of the analysis, ‘blanks’ or 
negative controls test each step of the analysis and help prevent false positive results and positive 
controls monitor the efficiency of the reaction to prevent false negative results.
Cross contamination should be minimised by strict separation of steps in separate rooms, minimal air 
flow between rooms and no movement of equipment and supplies between restricted areas. Working 
areas should be ciean with UV lights and disposable gloves being employed and separate lab coats 
worn in each defined area.
A typical recommendation for allocation of lab space for PCR states 1hat at least two separate areas 
be defined for pre- and post- PCR manipulations. The first defined area should be used for pre-PCR 
work such as weighing of chemicals, preparation of buffers and stocks for PCR, DNA extraction and 
preparation of PCR. The second defined area should be used for post-PCR work like 
electrophoresis, processing, sequencing and restriction analysis of PCR products and for loading of 
amplified products for second stage amplification. Segregation of lab space and equipment for each 
phase of work is heipfui in preventing undesirable contamination of stocks and samples by PCR 
products and vice versa (Innis et al., 1990). Because of limited space, adherence to these guidelines 
was difficult However, every attempt possible, was made to ensure the guidelines were observed at 
all times.
In this research, two defined areas were utilised to minimise cross-contamination during analysis and 
a different set of micropipettes and a different lab coat were used in each of the two areas. Quality in 
the extraction procedure and in PCR was assured by analysing random samples in duplicate. 
Negative controls for both procedures were also employed. The extraction procedure was conducted 
using 300 pi of molecular biology grade water instead of 300 pi of whole blood and therefore
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functioned as a ‘blank’ or negative control. A negative control for PCR was included in each run 
performed. This control contained all the components of a PCR reaction with the exception of 
template DNA (whose volume in the reaction was replaced with molecular biology grade water). On 
random occasions a tube was also prepared for PCR using commercially available human genomic 
DNA as a source of template DNA. The PCR product of this tube could then be visually compared 
(following electrophoresis), with products obtained from samples that were extracted or purified as 
part of this research by Wizard™ kit purification. Positive control samples for C282Y homozygosity, 
C282Y/H63D compound heterozygosity, S65C heterozygosity and S65C/H63D compound 
heterozygosity were sourced and mn alongside population samples, in both PCR and restriction 
endonuclease digestion procedures. Samples that were positive for C282Y homozygosity and 
C282Y/H63D compound heterozygosity were obtained through the laboratories of Sligo General 
Hospital following external genotyping by the Cytogenetics unit of NUI Galway. Dr. Sharon Barrett of 
the Centre tor Liver Disease in Dublin generously supplied S65C heterozygote and S65C/H63D 
compound heterozygous positive controls.
Another quality control procedure that was used in this research was validation of results through 
external testing of samples by two accredited genotyping institutions. Ten samples from the Diabetic 
population were sent to the Cytogenetics unit of NUI Galway for genotyping in terms of the C282Y 
and H63D haemochromatosis mutations. Five S65C carriers that were identified in this study were 
also sent to the Centre for Liver Disease in Dublin for confirmatory testing (four samples were from 
the ‘control’ population and 1 sample was from the diabetic population). These five samples were 
genotyped on a lightcycler for the three main haemochromatosis mutations C282Y, H63D & S65C. 
Results of all external analysis from both Galway and Dublin, were identical to those obtained in this 
study and therefore validate the methodologies employed in this study (Table 3.5). Figures 3.13 to 
3.17 inclusive, are examples of results graphs obtained for HFE mutation analysis by the Centre for 
Liver Disease in Dublin. Figure 3.13 shows results of a C282Y amplification run, Figure 3.14 shows 
results of a H63D amplification mn and Figure 3.15 shows results for a H63D negative sample. 
Figures 3.16 and 3.17 show results (C282Y and H63D) for one of our samples analysed (sample 
number C54). The fifteen samples that were sent to external institutions were all genotyped by highly 
automated technology such as lightcyclers in a real time PCR (RT-PCR) set-up. External validation 
of the method is very costly at approximately 120 euro per test, but it highlighted that the fundamental 
methodologies employed in this research are comparable in terms of reliability to the more automated
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technologies in use today. Sincere thanks is extended to Dr. Sharon Banett (Dublin), who analysed 
samples free of charge.
Two problems were encountered during the genetic analysis phase of the study. After 3 months of 
optimisation work, analysis was unavoidably delayed due to a breakdown of the Hybaid Omne E 
thermal cycler. The cycler was immediately returned to the suppliers for repair of the central heating 
element of the block, which took approximately two months. In the interim, a replacement cycler of a 
different type was eventually appropriated and work was resumed. However, following complete 
repair and return of the Hybaid thermal cycler, it was then necessary to repeat all work done on the 
replacement model to avoid any inter model variations. Prior to initiation of testing, (and at regular 
intervals thereafter), equipment calibration / maintenance should be and was conducted, to ensure 
both reproducibility in testing and quality of any results so generated.
The second problem encountered was one regarding Tris-borate EDTA (TBE) buffers (Sigma- 
Aldrich) which were used in the initial months of analysis for both gel preparation and as a running 
buffer for electrophoresis. It was found that the borate in the aforementioned buffers often 
precipitated out of solution irreversibly, even when prepared and stored in accordance with the 
manufacturers recommendations and this adverse event affected sample resolution. This finding 
was later confirmed by reports received by Sigma-Aldrich Technical services department. It was 
therefore decided by the author to discontinue the use of these products in analysis and to replace 
them with a TBE 10X concentrate buffer by Promega. In terms of reagents, it is advisable to try 
products from multiple manufacturers before making a final selection. This action aids the discovery 
of potential problems that may affect assay quality that could have been avoided.
4.6 Genetic Analysis
The results of this study report an incidence rate for C282Y homozygosity of 1 in 249 (0.4%) and 1 in 
83 (1.22%) for the tested diabetic and ‘control’ populations, respectively. C282Y heterozygosity 
occurred at a rate of 1 in 7 (14.86%) in diabetic individuals and 1 in 6 (18.22%), in individuals from 
the ‘control’ population. Homozygosity for the H63D mutation occurred in individuals from the 
diabetic and ‘control’ populations at rates of 1 in 20 (5.22%) and 1 in 28 (3.6%), respectively. H63D 
heterozygosity was reported at a rate of 1 in 4 (25.30%) in diabetic individuals and 1 in 5 (22.8%) in
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‘control’ individuals. Subsections from both the diabetic and ‘control’ populations were also 
genotyped for the S65C mutation, where it was found to occur with an incidence of 1 in 124 (0.81 %) 
in diabetics and 1 in 32 (3.2%) in ‘control’ individuals (see Table 4.2). Allele and genotype 
frequencies for both populations are shown in Table 3.4.
4.6.1 C282Y mutations
Table 3.0 shows the incidence of the C282Y mutation in the two populations tested. Genotypic 
results were available for 249 out of 250 people in the diabetic population and 247 out of 250 people 
in the ‘control’ population. Insufficient DNA concentrations in the remaining four samples meant that 
inconclusive genetic results were obtained. In a routine hospital setting a further sample would be 
obtained from the individual, however, as samples were anonymous in nature, it was impossible to 
acquire new blood samples from these four individuals. Time constraints in the analytical phase 
meant that the only other alternative -  i.e. acquisition and testing of four new samples, could not be 
pursued. Of the 249 diabetic individuals screened for C282Y, one was C282Y homozygous (0.4%), 
37 were heterozygotes (14.86%) and 211 had no C282Y mutation (84.74%). Screening of the 
‘contror population showed that 3 individuals were C282Y homozygotes (1.22%), 45 were 
heterozygotes (18.22%) and 199 lacked the C282Y mutation (80.56%).
Results from external genetic testing by Centre for Liver Disease, Dublin were available for sample 
numbers C8, C54, C78, C124 and C145. All five samples were found to lack the C282Y mutation 
(see Table 3.5). These external results were in complete agreement with resutts obtained in this 
study.
Results from this study report higher C282Y homozygote frequencies (in a control population) than 
those reported in the following studies. Beutler et al., (2002a) reported a 1/375 (0.27%) C282Y 
homozygote frequency in a population from California, while Olynyk et al., (1999) found a 1/200 
(0.5%) frequency in a population from Western Australia and Jackson et al., (2001) found a 1/147 
(0.68%) frequency in blood donors from South Wales, for the same genotype. A study in Canada 
(Arya et al., 1999) reported a C282Y homozygote frequency of 1/327 (0.31%). Jackson etal., (2001) 
found a C282Y homozygote incidence of 1/147 (0.68%). Studies in the U.S., Austria and France
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reported C282Y homozygote frequencies of 0.45%, 0.4% and 0.57% respectively (Barry etal., 2005; 
Datz et al., 1998; Deugnier et al., 2002). One reason to explain the high levels of this genotype in 
Ireland, may be the postulated Celtic / North West European origin of the mutation.
Data from studies in Ireland reports that up to 93% of hereditary haemochromatosis patients are 
C282Y homozygotes. Byrnes et al., (1999) conducted a retrospective analysis of Irish neonates and 
identified a C282Y allele frequency of 11%. These results correspond to a C282Y homozygote 
genotype frequency of 1/83 (1.2%), which is the highest reported C282Y allele frequency worldwide. 
A different study in Ireland reported a C282Y homozygote frequency of 1.24% (Murphy etal., 1998), 
which is almost identical to the same genotype frequency found in this research.
An article by Kelleher & Crowe (2001) reported an incidence of 1/5 (20%) for C282Y heterozygosity 
in the general Irish population.
The results of this study show agreement with this data by reporting C282Y homozygosity and 
C282Y heterozygosity incidences of 1.22% and 18.22% respectively, in the ‘control’ population (see 
Table 4.2). Other studies have reported tower frequencies (12.66%, 8.3%, 8.6%) for the C282Y 
heterozygous genotype in control populations (Jackson et al., 2001; Barry et al., 2005; ARUP 
Laboratories, 2002).
Results presented in this thesis, report a genotype frequency for C282Y homozygosity in diabetics of 
0.4%. This frequency is similar to that reported for a diabetic population in the U.K., where C282Y 
homozygosity was found to occur at a frequency of 0.49% (Singh et al., 1992). Other studies have 
reported higher frequencies for the same genotype in diabetic populations but have larger sample 
sizes than those of this study). In Italian and Danish studies frequencies of 1.34% and 1.26%, 
respectively, were reported (Conte et al., 1998; Ellervik etal., 2001). A study by Ellervik etal., (2001) 
reported a C282Y heterozygote frequency of 9.4% in diabetic individuals. Data from the present 
study found a C282Y heterozgote frequency of 14.86% in the diabetic population. Florkowski et al., 
(1999) reported higher C282Y homozgote and lower C282Y heterozygote frequencies (of 0.8% and 
7.4%, respectively), in a study they conducted with diabetic individuals, when compared to data from
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the present study. One reason suggested to account for the variations in C282Y homozygosity levels 
reported in diabetic individuals, is the different sample sizes used in each study.
The following allele frequencies for C282Y in control populations have been reported: 3.2% (Malecki 
et a!., 2005), 8.23% (Jackson et al., 2001) and 5.69% (Barry et al., 2005). The C282Y allele 
frequency for the control population found in this study was 10.3% (see Table 3.4). The C282Y allele 
frequency for the diabetic population in this study was reported as 7.8%. This allelic frequency is 
higher than that reported in diabetic population from Poland (Malecki et al., 2005). However, it 
should be noted that the study by Malecki et al., (2005) looked at type II diabetics specifically 
whereas no such distinction was made in this study (i.e. the diabetic population may have been made 
up of both type I and type II diabetics).
4.6.2 H63D mutations
Table 3.1 shows the incidence of the H63D mutation in both the diabetic and ‘control’ populations. 
Genotypic results were available for 249 out of 250 diabetic individuals and all 250 ‘control’ 
individuals. Again, the reason for the incompleteness of testing in the diabetic group, being 
inconclusive genetic results (due to insufficient DNA concentration in the sample), and time 
constraints in the analytical phase. Of the 249 diabetics screened for H63D, 13 were H63D 
homozygotes (5.22%), 63 were heterozygotes (25.30%) and 173 lacked the H63D mutation 
(69.48%). In the ‘control’ population, 9 homozygotes (3.6%) and 57 heterozygotes (22.8%) were 
identified. The remaining 184 ‘control’ individuals did not have the H63D mutation (73.6%). Table
4.2 details the frequencies for all genotypes.
Results from external genetic testing by Centre for Liver Disease, Dublin were available for sample 
numbers C8, C54, C78, C124 and C145. Only one sample (number C145) was found to carTy the 
H63D mutation, but in compound heterozygosity with the S65C mutation (see Table 3.5). The clinical 
significance of this genotype is still uncertain.
The frequency of H63D homozygosity (in a control population) reported in this research (3.6%) was 
similar to that of other studies. Studies in the U.K, Ireland and the U.S. found H63D homozygote
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frequencies of 2.38%, 3.67% and 3.09%, respectively (Jackson etal., 2001; Ryan etal., 1998; Bany 
et al., 2005). Frequencies for H63D heterozygosity in our ‘control’ population (22.8%) were 
comparable to levels reported in three of the aforementioned studies. That is, 23.8% (Jackson et al., 
2001), 24.77% (Ryan et al., 1998) and 19.34% (Barry et al., 2005). The H63D allele frequency in 
controls found in this research i.e. 15% (see Table 3.4) is comparable to that found in both a British 
population (15.3%) and a U.S. population (14.07%) (Jackson et al., 2001; Barry et al., 2005) and is 
higher than that (11.2%) found in a Polish population (Malecki etal., 2005).
Ellervik et al., (2001) reported H63D homozygote and heterozygote frequencies of 2.1% and 20%, 
respectively in a diabetic population. A different study by Florkowski et al., (1999) found a H63D 
homozygote frequency of 2.3% and a H63D heterozygote frequency of 26.7% in diabetics. Results 
from the present study report slightly higher frequencies of 5.22% and 25.30%, respectively for the 
same genotypes, in the diabetic population. H63D allele frequencies in our Diabetic population 
(17.9%) were slightly higher than those reported in a type II diabetic population by Malecki et al., 
(14.4%) in 2003.
Results from this study show that there was a higher frequency of H63D heterozygosity in the 
diabetic population than in the control population (Table 3.1). This difference was not statistically 
significant (see Appendix E).
4.6.3 S65C mutations
Table 3.2 shows the incidence of the S65C mutation in a subsection of both the diabetic and ‘control’ 
populations. The aim was to establish the S65C mutation incidence rate in 125 individuals from each 
of the two aforementioned test populations. As Table 3.2 indicates, only 124 results (out of 125), 
were obtained for the diabetic subsection tested. The reason being, that one sample was 
inadvertently analysed in duplicate (sample number 18), and a replacement sample could not be 
genotyped before the allowed analytical period elapsed. The incidence rate of S65C heterozygosity 
or S65C ‘earner’ rate was found to be 0.81% and 3.2% for the diabetic and ‘control’ populations, 
respectively (see Table 4.2).
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The five samples found to carry the S65C mutation were sent to the Centre for Liver Disease, Dublin 
for genotyping and therefore external validation. All five samples were confirmed to be S65C 
heterozygotes or carriers of the mutation (see Table 3.5). Analysis for the S65C mutation was not a 
service on offer I carried out by the genetic facility in Galway. Therefore the ten samples that were 
analysed in the Galway facility were only genotyped for C282Y and H63D.
Data from an unpublished research Masters study, reports a S65C carrier incidence of approximately 
1/56 (3 S65C carriers identified out of a population of 168) in an Irish population. However, the study 
population was biased in that it consisted of samples chosen from a population previously referred for 
haemochromatosis mutation testing (personal correspondence with Dr. S. Barrett, Centre for Liver 
Disease, Dublin).
Interestingly, results of this study have identified a higher carrier incidence of the S65C mutation than 
that reported in the aforementioned study. A S65C earner incidence of approximately 1/32 (3.2%) 
was found in the ‘controf population. However, only one individual in the diabetic population carried 
the same mutation (0.81%). These results suggest that the S65C mutation may be unrelated to 
diabetes mellitus.
The S65C variant has been reported to interfere with H63D analysis for some methods (lightcycler & 
Stott duplex method), such that H63D/S65C compound heterozygotes appear as H63D 
homozygotes. Therefore H63D homozygotes detected by the aforementioned methods must be 
further analysed to out rule interference by S65C, which can contribute to erroneous results (King & 
Barton, 2004). A study by Douabin et al., (1998) found the S65C mutation in 5 out of 160 control 
chromosomes, which represents an allele frequency of 3.2% for this mutation in the general 
population. The allelic frequency for S65C reported in the control population in this study was 1.6% 
(see Table 3.4). This frequency compares favourably to that reported by Barcy et al., in 2005 (1.8%). 
Different studies reported that the S65C mutation was present in up to 1.5% of the European 
population (Beutler et al., 2000; Jazwinska et al., 1996). S65C allele frequencies between 1.7 and 
2.2% (in control populations) have also been reported, but there has been no association of the S65C 
allele with a phenotype of high transferrin saturation (Arya et al., 1999).
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It is apparent from analysis of results in Tables 3.0 to 3.2, that there were three C282Y/H63D 
compound heterozygotes (0.8%) in the diabetic population (sample numbers 113, 122 and 196) 
whereas there were seven (1.41%) in the ‘control’ population (sample numbers C58, C73, C156, 
C229, C236, C238 and C242). Only one C282Y/S65C compound heterozygote (0.27%) was 
identified (‘control population' sample number C8). Two H63D/S65C compound heterozygotes 
(0.27%) were found, one in each of the diabetic and ‘control’ populations, sample numbers 54 & 
C145 (see Tables 3.3 and 4.2).
Kelleher & Crowe (2001) reported an incidence of 1/25 for C282Y/H63D compound heterozygosity in 
the general Irish population. The genotype frequency of C282Y/H63D compound heterozygosity in a 
control population has been reported at 2.38% (Jackson etal., 2001) and 1.98% (Bany etal., 2005), 
which is higher than the frequency reported for the same genotype in this study. Barry et al., also 
reported H63D/S65C compound heterozygote frequency of 0.65% in a control population. Although 
these frequencies for compound heterozygosity are higher than those reported in this study, it is 
important to note that this may have been due to larger sample sizes. Both Ellervik et al., (2001) and 
Florkowski et al., (1999) reported higher C282Y/H63D compound heterozygote frequencies of 1.1% 
and 2.1 %, respectively, than results obtained in the present study in a similar population.
The incidence of C282Y/H63D compound heterozygotes in this study was lower that that reported by 
Kelleher & Crowe (2001), occurring at approximately 1/36 in the ‘control’ population and 1/84 in the 
diabetic population. A reason suggested to account for this difference is the variance in sample size 
between the two studies. The present study has a relatively small sample size in comparison to 
some other ‘population’ studies on haemochromatosis.
Only four studies have looked at the three hereditary haemochromatosis mutations in the general 
population (Mura et al., 1999; Beutler et al., 2000, Bany et al., 2005 & Cimburovä et al., 2005). 
Another two studies evafuated all three mutations but were biased in their exclusion of certain 
genotypes (Remacha et al., 2000 & Holmstrom et al., 2002). None have been conducted on the Irish 
population to date.
4.6.4 Compound Heterozygotes
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Tabies 4.0 and 4.1 below, summarise the allele frequencies in diabetic and control populations, and 
indicate how data from the present study compares to published literature.
4.6.5 Haemochromatosis Allele Frequencies
Table 4.0: HFE allele frequencies in Diabetic Populations
Population Reference Ar eie Frequencies (%)
C282Y H63D S65C
Ireland 
(North West)
Present Study 7.8 17.9 0.81
Poland Malecki et al., 
2003
1.8 3.2 “
Canada Arya et al., 1999 24.8 & 14.7%
(high & low transfemn 
saturation groups)
1.7 & 2.2%
(high & low transferrin
saturation groups)
UK Jackson et al., 
2001
8.23 15.3
it is evident from an extensive review of literature that there are a very limited number of studies 
which investigate the allele frequencies of the haemochromatosis mutations in diabetic populations. 
From Table 4.0 it can be seen that the C282Y allele frequency found in the present study is 
comparable to that found in the U.K (Jackson et al., 2001), but much higher than that found in 
Canada (Arya et al., 1999). Similarly, the allele frequency found in the present study for H63D is 
comparable to the frequency reported by the same study in the U.K (Jackson et al., 2001) and higher 
than frequencies reported in both Poland and Canada, respectively (Malecki et al., 2003; Arya et al., 
1999). Allele frequencies for S65C were found to be lower than those reported in another study on a 
diabetic population (Arya et al., 1999).
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Table 4.1: HFE allele frequencies in Control Populations
Population Reference Allele Frequencies (°/<•)
C282Y H63D S65C
Ireland 
(North West)
Present Study 10.3 15 1.6
USA (Caucasian) Barry et al., 2005 5.69 14.07 1.8
Russia Potekhinaet al., 2005 3.5 15.2 0
Norway Milman et al., 2005 6.6 11.2 1.5
Denmark Milman et al., 2005 5.7 12.8 1.5
Finland Milman et al., 2005 3.6 9.8 1.6
Faroe Islands Milman et al., 2005 8.0 17.5 1.0
Czech Republic Cimburovä et al.,2005 3.4 14.9 1.25
Northern Spain Altes et al., 2004 3.0 20.0 1.0
Tunisia Sassietal., 2004 0.09 15.17 -
Croatia Risticet al., 2003 3.3 14.5 1.8
Slovenia Risticet al., 2003 4.0 14.5 0.5
Russia Mikhailova et al., 2003 3.7 13.3 1.7
Northern Italy Marianiet al., 2003 3.2 13.4 1.3
Italy Pietrapertosa et al., 2003 1.5 14.0 0.5
Poland Malecki et al., 2003 3.2 11.2 -
Sweden Holmstrom et al., 2002 6.2 11.4 1.6
Sweden Beckman et al., 2001 2.0 7.9 3.0
Mediterranean
Basin
Campo et al., 2001 0.15 18.6 0.15
France Aguilar-Martinezet al., 2001 3.0 16.9 -
UK Menyweather-Clarke et al., 
2000
8.1 15.2 -
Germany Merryweather-Clarke et al., 
2000
3.8 13.2 -
Austria Menyweather-Clarke et al., 
2000
3.7 12.9 -
Bulgaria Merryweather-Clarke et al., 
2000
0.0 23.0 -
Greece Merryweather-Clarke et al., 
2000
1.3 13.5 -
Spain Merryweather-Clarke et al., 
2000
3.6 30.4 -
USA (Caucasian) Beutler et al., 2000 6.3 15.2 1.6
USA (Hispanic) Beutler etal., 2000 2.7 12.4 0.6
USA (Asian) Beutler et al., 2000 0.2 3.3 0
USA (Black) Beutler et al., 2000 1.1 5.1 0.7
France Mura etal,, 1999 7.7 14.0 1.95
Scotland Miedzybrodzka et al., 1999 8 15.7 -
Ireland Ryan etal., 1998 14 17.9 -
Portugal Porto etal., 1998 2.8 23.0 -
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Results from studies on haemochromatosis allele frequencies in control populations are shown in 
Table 4.1. The C282Y allele frequency reported by the present study is comparable to other studies 
on general populations in Ireland and the U.K (Ryan eta!., 1998; Menyweather-Clarke eta!., 2000). 
It is important to note that the general Irish population (and that of the North West region also), 
remain the highest-ranking populations in terms of worldwide C282Y allele frequency. The allele 
frequency for H63D reported by the present study is comparable to published frequencies for the 
same mutation in ail 34 countries detailed in Table 4.1. Allele frequencies for S65C in studies in the 
US (Barry etal., 2005; Beutler et al., 2000), Finland (Milman etal., 2005), Sweden (Holmstrom etal., 
2002; Beckman et al., 2001), France (Mura et al., 1999), Croatia (Ristic et al., 2003) and Russia 
(Mikhailova et al., 2003) are comparable to the frequency reported in the present study.
4.6.6 Recommendations of Practice Guidelines for the Diagnosis of Haemochromatosis by 
Genetic Testing: Clinical Implications
Draft Best Practice Guidelines (King & Barton, 2004) for the molecular genetic diagnosis of hereditary 
haemochromatosis state the following:
In the case of diagnostic referral (i.e patient affected), if genetic analysis yields a:
(a) C282Y homozygote, then a diagnosis of hereditary haemochromatosis is made.
(b) C282Y/H63D compound heterozygote, then some individuals with this genotype will have 
iron overload but to a iesser extent than C282Y homozygotes (Lyon & Frank, 2001). Five 
per cent of patients with hereditary haemochromatosis have this genotype and so does 2% 
of the general population in the UK.
(c) C282Y heterozygote, then the individual is a earner of the C282Y mutation and a diagnosis 
of hereditary haemochromatosis is unlikely.
(d) H63D homozygote, the individual has a slight risk of developing ¡non overload (Mura et al., 
2000; Burke et al., 2000; Beutler et al., 2000). This genotype is present in approximately 2% 
of the population but its significance remains unclear.
(e) H63D heterozygote, the individual is a carrier of the H63D mutation and a diagnosis of 
hereditary haemochromatosis is unlikely.
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In the case of predictive referral (i.e. patient currently unaffected), if genetic analysis yields a:
(a) C282Y homozygote, then the person is at risk of developing haemochromatosis and indices 
of iron overload like femtin and transferrin saturation should be monitored on a yearly basis
(b) C282Y/H63D compound heterozygote & C282Y heterozygote, individuals are at risk of 
developing haemochromatosis and indices of iron overload should be monitored every three 
(compound heterozygotes) and five years (C282Y heterozygotes).
(c) H63D homozygote, the individual has a slight risk of hereditary haemochromatosis
(d) H63D heterozygote, there is no increased risk of developing iron overload.
To summarise, it is recognised that the methods employed in this work are slower and more time- 
consuming than currently available automated methods (e.g. multiplex multicolour analysis for 
simultaneous detection of the three main haemochromatosis mutations, Gomez-Llorente et al.,
2004), but they may be more cost-effective in situations where technical and scientific time can be 
factored as cost neutral. Highly specialised and expensive equipment such as light cyclers were 
unavailable at the testing institutes (I.T. Sligo & Sligo General Hospital) and although sample 
throughput was low, the basic principles of genotyping were well learned and successfully applied. 
These basic principles may now be applied to testing for other genetic mutations.
The main advantage of genotypic testing is that is provides a result, which remains the same, 
irrespective of the stage of iron accumulation, and is not influenced by dietary intake or tissue 
damage. It must be noted, however, that it is still uncertain whether the majority of people 
homozygous for C282Y will eventually develop clinical symptoms of the disorder (Dooley & 
Worwood, 2000). Genetic testing alone is only part of the picture and genetic counseling must go 
hand in glove with the analytical process.
4.7 Bhchemislry Analysis
Biochemical measures of iron status are used to screen for haemochromatosis, with tests for 
Iransfemn saturation (serum iron concentration divided by total Iron-binding capacity, multiplied by 
100) and serum femtin being recommended (Powell et al., 1998).
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In this study, various indices of iron overload such as serum iron, ferritin, Unbound Iron Binding 
Capacity (UIBC) and calculated TIBC (Total Iron Binding Capacity) were assessed. Parameters 
associated with diabetics such as glycated haemoglobin (HbA1c) were also analysed and AST and 
ALT levels were investigated on the basis that they can be reflective of liver function (caused by 
excessive iron deposition in the case of haemochromatosis). Many studies have been conducted 
which correlate biochemistry testing (for indices of body iron stores), with data from genetic analysis 
(Gleeson etal., 2004; O’Brien et al., 1990; Ellervik et al., 2001; Kankova et al., 2002; Barton etal.,
2005).
Data could only be presented for individuals who consented to study participation. Figure 3.6 
contains biochemistry results for twenty-six research subjects (18 male & 6 female), ranging in age 
from 20 to 82 years. At the time of testing, none of Ihe subjects had serum iron levels or TIBC (total 
iron binding capacity) levels outside the reference ranges of Sligo General Hospital. Four females 
(sample numbers 67, 72,56 and 51) and eight males (sample numbers 54,52,34,74,68,78,49 and 
50), had transfemn saturation levels outside the hospital reference range for their gender. Only one 
male (sample number 78) had ferritin levels elevated above the normal reference range. When 
aspartate aminotransferase (AST) and alanine aminotransferase levels were assessed, tour females 
(sample numbers 67, 39, 56 and 51) were out with the normal hospital reference levels for AST. 
None of the males had AST values outside the reference ranges. One male (sample number 46) and 
three females (sample numbers 39, 56 and 51) had elevated ALT levels. All twenty-six individuals 
had glycated haemoglobin (HbA1c) levels outside hospital non-diabetic reference ranges that are 
aligned with Diabetes Control and Complications Trial (DCCT). This simply meant that all 26 
individuals had not managed their diabetes effectively in the three months proceeding the test There 
is no specific value of HbA1c below which the risk of diabetic complications is elimated completely.
Serum iron is greatly increased in haemochromatosis. None of the population tested in this study 
had serum iron levels outside the normal hospital ranges.
Elevated fasting serum transfemn saturation and persistently raised seiurn ferritin concentration can 
be suggestive of haemochromatosis. Numerically, local biochemical testing methods will dictate what 
constitutes elevated transferrin saturation. A result of 45% or greater is a sentinel of
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haemochromatosis and is the value considered generally acceptable for genetic testing, especially to 
facilitate early detection of haemochromatosis (King & Barton, 2004). TIBC measures the total 
capacity of an individual’s blood to transport iron and correlates with the amount of the protein 
transfemn in the blood. It quantifies the amount of iron blood would carry, if the transferrin were fully 
saturated. Transfemn saturation is the most specific and sensitive test for iron accumulation. It is 
calculated from the serum iron concentration and the TIBC. The percentage saturation is calculated 
using the following formula: (100 x serum iron / TIBC). Values greater than 50% in women and 55% 
in men, is indicative of iron loading due to haemochromatosis (Dooley & Worwood, 2000). Two 
individuals tested in this study (one male and one female, sample numbers 34 and 72), had 
transferrin saturation values above this range and both were identified as C282Y heterozygotes. Ten 
other individuals had transferrin saturation levels higher than the reference range for Sligo General 
Hospital (sample numbers 67, 54, 52, 74, 68, 56, 51, 78, 49 and 50). Half of these ten samples were 
earners of HFE mutations. Raised transfemn saturation levels act as an early indicator of iron 
accumulation (Edwards & Kushner, 1993), but is not necessarily raised in young C282Y 
homozygotes.
While TIBC and transferrin essentially measure the same thing, they are typically used in conjunction 
with serum iron, to evaluate the iron status of individuals. In iron overload I haemochromatosis 
serum iron will be high and TIBC will be low or normal. The gold standard for the measurement of 
transferrin-iron saturation requires colorimetric measurement of iron and immunological 
measurement of transfemn. Transferrin-iron saturation may then be calculated using the molecular 
weight of transferrin (Crawford & Hickman, 2000; Gambino et al., 1997). Direct measurement of 
transfemn is less likely to suffer from interferences.
Genetic haemochromatosis characterized by transfemn saturation >45% is linked to C282Y 
homozygosity. Low ferritin is an excellent indicator of iron deficiency because ferritin is an acute 
phase protein, however, high ferritin levels are not necessarily synonymous with iron overload 
(Vantyghemetal., 2005).
Serum ferritin levels do not surpass the upper limit of normality until hepatic iron concentrations are 
elevated, after this they increase disproportionately with the degree of liver damage (Dooley &
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Worwood, 2000). A recent study states that 10% of type II diabetes mellitus patients with high fenitin 
levels had transferrin saturation levels greater than those considered normal i.e. 40%. Serum ferritin 
should be cautiously evaluated in individuals with type II diabetes as it may falsely indicate ‘normal 
iron stores’ (Fernandez-Real etal., 2002).
Because serum ferritin is an acute-phase reactant, elevated levels may be a result of chronic disease 
(hepatitis C), inflammation, alcohol abuse, malignancies (tumours) or iron overload. It is therefore 
necessary to interpret high serum ferritin carefully in the context of the presence or absence of the 
aforementioned conditions. Dietary iron supplements are known to increase fenitin levels and some 
diseases (like infections, late-stage cancers, lymphomas, and severe inflammation), whilst not 
directly affecting the body’s iron storage may cause artificially high ferritin levels. Such information 
highlights the limitations of serum ferritin as an indicator test for haemochromatosis. Serum femtin 
levels above 300 pg/L in men and post-menopausal women and > 200 pg/L in pre-menopausal 
women, is indicative of primary iron overload (Imperatore etal., 2004). The introduction of the serum 
femtin assay by Addison et al., in 1972 provided the drive awaited for, to allow for the study of 
haemochromatosis. The test has not proved as valuable as originally hoped in the detection of iron 
accumulation in the early stages (Dooley & Worwood, 2000).
Available evidence from screening studies strongly suggest that approximately 75% of C282Y 
homozygotes have biochemical expression of iron overload (O’Neil & Powell, 2005). In C282Y 
homozygote populations, 50% of women and 20% of men did not have increased femtin levels. 
Based on multivariate analysis, highly significant associations with increased ferritin levels in C282Y 
homozygotes, were male sex, increasing age and the absence of a non-expressor in the family 
(Lazarescu et al., 2005).
Liver function tests measure liver injury rather than liver function. Therefore, if a substance or 
molecule causes liver injury it will be reflected by changes in the normal levels of liver enzymes. 
Inflammation of hepatic cells results in elevated levels of Alanine Aminotransferase (ALT) and 
Aspartate Aminotransferase (AST). ALT is an enzyme produced in hepatic cells and is the most 
sensitive marker for liver cell damage. If hepatic cells are damaged, ALT leaks out of the cells and 
into the bloodstream thus causing an elevation in ALT levels. AST, a ubiquitous enzyme, also
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reflects hepatic cell damage and ratios between AST and ALT are useful to physicians in assessing 
the etiology of liver enzyme abnormalities, (http://www.qastromd.com/lft.htmn.
In Ireland (for a diagnosis of haemochromatosis), transferrin saturation is considered elevated when 
> 52%, serum ferritin when it is > 300 jog/L and ALT and AST when they are >40 IU/L (Ryan et al., 
2002).
The results of this study showed that one male had serum ferritin levels elevated above the 
aforementioned range (sample number 74), but was identified as not having any of the two 
haemochromatosis mutations of C282Y or H63D. Another male had relatively high serum ferritin 
levels of 260.8 fxg/L, but was also identified as lacking the C282Y and H63D mutations. This finding 
is not unusual as ferritin is an acute phase reactant and is raised in such conditions as moderate 
alcohol consumption.
Out of the twenty-six individuals that underwent biochemistry testing for this study, three were found 
to be C282Y heterozygotes (samples 67, 34 and 72), six were H63D heterozygotes (samples 54,74, 
76, 51, 222 and 46), and two were H63D homozygotes (samples 55 and 50).
The biochemical effect of the H63D mutation is unknown, as it does not affect assembly or 
expression of HFE gene (Lebron et al., 1998 and 1999). Biochemistry results from this study, 
although very limited, support this statement From Table 3.7 it can be seen that the majority of 
mean values for H63D homozygotes and heterozygotes (for the biochemistry parameters tested), 
were within the standard reference ranges for ‘normal’ individuals. The mean transferrin saturation 
levels were higher in C282Y heterozygotes and H63D heterozygotes than in wildtype individuals that 
underwent biochemistry testing. Mean AST and ALT levels were higher in H63D heterozygotes than 
in wildtype individuals. Mean serum iron levels were higher in C282Y heterozygotes than in 
individuals that had the wildtype genotype. It is important to note that the biochemistry results 
presented are based on a single blood sampling with no knowledge if it was taken in the fasting state. 
Repeat testing of a second fasting’ sample for all 26 individuals is required for confirmation of the 
results obtained.
140
Discussion
The diabetic parameter of glycated haemoglobin was also assessed in this study. Glycation is the 
post-translational, non-enzymic covalent chemical linkage of glucose onto proteins through amino 
groups. It occurs in tissues that are exposed to glucose and the extent of protein glycation is 
dependent on the level of exposure to glucose. At the time of measurement the percentage glycation 
of haemoglobin depends on the average age of the erythrocytes in the specimen, with the 
percentage of HbAic being higher in older cells. The mean life of erythrocytes is 117 days in non­
diabetics, with a gender difference of about 11 days less in females. Glycated haemoglobin level is 
an index of mean blood glucose over the proceeding 120 days and therefore functions as an indicator 
of how well diabetes has been controlled over this time period (Jeffcoate, 2003). Results for all 
twenty-six individuals in the present study were out with the normal reference range utilized in the 
hospital which has been aligned with those set down in the Diabetes Control and Complications Trial 
(DCCT).
Studies have shown that differences in the ferritin levels related to particular genotypes of C282Y and 
H63D in diabetic individuals were not detected (Kankova et al., 2002). A recent review by Halsall et 
al., (2003) suggests that there is little evidence for a strong association between serum femtin and 
the development of diabetes independent of HFE status (Eshed et al., 2001). This would explain the 
lack of success for screening for haemochromatosis in type II diabetes mellitus cohorts using 
biochemical markers as disease indicators (George et al., 1995; Turnbull et al., 1997). A study in 
Ireland stated that when screening diabetics for haemochromatosis, it is important to remember that 
persistently high femtin has a relatively low positive predictive value (16.6%) and that normal 
transferrin saturation levels do not exclude a diagnosis (O’Brien et al., 1990).
Biochemical results from this small study would show agreement with the statement that biochemical 
markers are not as reliable / successful as indicators of haemochromatosis as genotyping, for 
detecting haemochromatosis, especially in diabetic individuals.
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Four lines of scientific evidence favour the hypothesis that iron plays a role in diabetes (type II).
(1) The first piece of evidence is that an increased prevalence of haemochromatosis was found 
among unselected patients with type II diabetes mellitus. Phelps et 31,(1989) and Conte et al., 
(1998) reported that diabetes confers an increased risk for haemochromatosis, which was 2.4% and 
1.34% higher in Australian and Italian populations respectively. Different studies have described an 
increased frequency of the C282Y mutation in type II diabetics (Kwan et al., 1998; Moczulski et al., 
2001). However, the evidence for this is not always consistent with some studies reporting no 
significant difference in the prevalence of the C282Y mutation between individuals with type II 
diabetes and controls Fray ling et al., 1998; Braun et al., 1998; Dubois-Lafbngue et al., 1998; 
Femandez-Real etal., 1999). in a Spanish population the frequency of H63D was significantly higher 
in individuals with type II diabetes (Femangez-Real et al., 1999). This diversity of opinion may just 
reflect the diversity of populations tested. Results from the present study do not show an increased 
prevalence of haemochromatosis in diabetic individuals compared with control individuals.
(2) Frequent blood donations leading to decreased iron stores has been demonstrated to constitute a 
protective factor in the development of diabetes (Ascherio et al., 2001). This finding is important 
given the high prevalence of increased iron stores in countries of the Western world and the 
observation that increased iron stores appear to predict an increased incidence of type II diabetes 
Salonen etal., 1999).
(3) The next piece of evidence is that iron stores may influence insulin action in type II diabetes, in 
that it significantly increases insulin sensitivity and significantly decreases HbA1c blood levels in 
diabetics who undergo phlebotomy (Femandez-Real et al., 1999). Higher iron stores are associated 
with an increased risk of type II diabetes in women (Jiang etal., 2004).
(4) The final pieces of evidence are that patients with insulin-resistant hepatic iron overload (IR-HIO) 
who undergo phlebotomy can prevent significant tissue damage (Femandez-Real et al., 2002) and 
that insulin resistant features are often seen in patients with chronic hepatitis C virus. In these
4.8 Haemochromatosis & Diabetes
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individuals, iron stores and family history of diabetes (amongst other things), were found to predict 
the development of diabetes (Petit et a)., 2001).
Some studies have reported that C282Y and H63D allele frequencies do not differ significantly 
between control and diabetic populations (Singh et al., 1992; Kankova et al., 2002). Other studies 
have found more patients with diabetes were C282Y homozygotes than controls (Ellervik et al.,
2001), whilst others still have identified a higher prevalence of H63D homozygosity and 
heterozygosity in individuals with type II diabetes mellitus (Malecki et al., 2003). No difference in the 
frequency of C282Y/H63D compound heterozygosity between diabetics and controls was found by 
Ellervik et al., 2001. Halsall et al., (2003) suggests that C282Y gene frequency, number of C282Y 
homozygotes and C282Y/H63D compound heterozygotes are unlikely to be different in people with 
typical type II diabetes mellitus, than in age- and gender- matched controls. Table 4.2 below, 
compares the incidence of haemochromatosis genotypes in the Diabetic and ‘Control’ Populations 
tested in this study.
Table 4.2: Incidences of haemochromatosis genotypes in the tested Diabetic & ‘Control’ Populations
Diabetic Population Control Population
C282Y homozygotes 0.4% 1.22%
C282Y heterozygotes 14.86% 18.22%
No C282Y mutation 84.74% 80.56%
H63D homozygotes 5.22% 3.6%
H63D heterozygotes 25.30% 22.8%
No H63D mutation 69.48% 73.6%
S65C homozygotes 0% 0%
S65C heterozygotes 0.81% 3.2%
No S65C mutation 99.19% 96.8%
C282Y/H63D compound heterozygotes 0.8% 1.41%
C282Y/S65C compound heterozygotes 0% 0.27%
H63D/S65C compound heterozygotes 0.27% 0.27%
Allele and genotype distributions for both populations are shown in Table 3.4. Before comparisons 
between allele frequencies (for all 3 haemochromatosis mutations) of the two populations were
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made, it was determined whether both populations were in Hardy-Weinberg equilibrium /HWE. The 
‘Control’ population was in HWE for all three loci (C282Y, H63D and S65C). The Diabetic population 
was in HWE for the C282Y and S65C loci only. Calculations for allele and genotype frequencies, as 
well as those for chi square testing can be found in Appendix E. From statistical calculations it is 
evident that there was a significant difference between the observed and the expected H63D allele 
frequencies in the Diabetic population (the calculated chi square value was greater than the chi 
square value in statistical tables at a probability or p value of 0.05 with 1 degree freedom). This 
means that there is only a 5% probability that the calculated chi square value occurred by chance. A 
chi square test was also earned out to determine if there was a statistically significant difference 
between the five genotype frequencies, (C282Y homozygote, C282Y heterozygote, H63D 
homozygote, H63D heterozygote and S65C heterozygote) of the diabetic and control populations. 
No such difference was found.
There is still no conclusive evidence for a genetic association between the two haemochromatosis 
and diabetes, and as such screening for haemochromatosis in diabetic individuals remains 
controversial. In the U.S. there are an estimated 16 million individuals with diabetes. Iron overload 
may cause a significant amount of this diabetes. If this problem is based on iron, it can be treated, 
the diabetes arrested and in some cases reversed, then this population should be but is not being 
tested for iron overload (Iron Overload Diseases Association, 2006). A study by Conte etal., (1998) 
postulated that such a screening program would be beneficial to individuals with type II diabetes 
mellitus. Malecki et al., (2003) also stated that heterozygote earners of HFE mutations are at a 
higher risk of developing type II diabetes.
There is still much debate as to whether screening strategies should be based on genotyping or 
assessment of biochemical parameters indicative of iron overload, or a combination of both (Clark,
2002).
Genotyping identifies individuals who are at risk of developing haemochromatosis and distinguishes 
between C282Y homozygotes, heterozygotes and C282Y/H63D compound heterozygotes who each 
have varying risks of developing the disorder. Genotyping may also prevent the need for invasive 
procedures like liver biopsies in many asymptomatic individuals. One study states that genotype 
analysis was shown to be more cost-effective compared with phenotype analysis by serum iron
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studies in siblings and children of affected patients (El-Serag etal., 2000). Because the prevalence 
of haemochromatosis defined by biochemical studies and liver biopsy (among diabetics) has been 
reported to be as low as 0,1% and as high as 9.5% {George et ah, 1995; Phelps etal., 1989; Czink et 
al., 1991; Turnbull et al., 1997; O’Brien et al., 1990), genotyping should be identified and used as a 
more accurate method of determining disease prevalence.
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5.0 CONCLUSIONS
Conclusion
5.1 Conclusion
Three assays were developed for the HFE gene mutations C282Y, H63D and S65C, based on 
PCR, agarose gel electrophoresis and restriction enzyme digestion of amplicons. PCR assays 
were validated internally, by the use of multiple controls and externally, by confirmatory 
genotyping by independent genetic facilities.
The present study determined the incidence of the three haemochromatosis mutations C282Y, 
H63D and S65C in a population from the North West of Ireland. It is one of the first studies to 
investigate (a) the incidence of all three HFE mutations in a population from the North West 
region of Ireland and (b) the incidence of the same three mutations in a Diabetic population from 
the same region.
Incidences for C282Y homozygosity and C282Y heterozygosity in the control population were 
similar to those in the general Irish population as reported by Kelleher & Crowe, (2001). The 
incidence for C282Y/H63D compound heterozygosity was lower than those reported by the 
aforementioned authors. The H63D allele frequency in the diabetic population was found to be 
slightly higher than that reported by Malecki et al., (2005). Unexpectedly, the results of this study 
also determined that there was an S65C carrier frequency of one in thirty-two for the control 
population, which is thought to be the highest incidence discovered to date, in the general Irish 
population.
The present study investigated whether there was an increased incidence of the three 
haemochromatosis mutations in a diabetic population from the same region of Ireland. Results 
showed that there was a slight increase in the incidence of the H63D heterozygous genotype in 
diabetics when compared to controls, but this was not statistically significant Incidences for 
C282Y heterozygosity were comparable in both groups (Figure 4.2). However, statistical analysis 
of data from the present study showed that there was no evidence for significant differences 
between the frequencies of all five HFE genotypes in the ‘control’ and diabetic populations. 
Further research into the HFE mutational incidence in the North West population of Ireland is 
needed, to help inform policy on screening I diagnostic strategies and such studies should 
employ much larger sample sizes. In the majority of genetic testing facilities, highly automated 
analysers facilitate rapid mutational analysis of large numbers of samples. However, it should be
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noted that automated systems are not always ideal, with some methods incorrectly diagnosing 
individuals with the wrong genotype (H63D genotype versus S65C genotype).
Biochemical indices of iron overload were also examined in a subsection of twenty-six Diabetic 
individuals. Results showed that biochemical markers are not as reliable as indicators of 
haemochromatosis, as genotyping, for detecting haemochromatosis especially in diabetic 
individuals.
Emerging scientific evidence has shown a bi-directional relationship between iron metabolism 
and diabetes (type II), - iron affects glucose metabolism, and glucose metabolism impinges on 
several iron metabolic pathways (Fernandez-Real et al., 2002). Future studies into HFE 
mutations (existing and yet to be discovered), may contribute to the search for a link between the 
two conditions.
More research is needed to ascertain why such phenotypic variability exists amongst individuals 
with haemochromatosis, and as to why biochemical indicators of iron overload and genotype data 
are not always matched in their diagnosis of the disorder.
Genetic testing allows the early identification of individuals (whether diabetic or non-diabetic), 
who are at risk of developing clinical disease before pathologic iron storage occurs. This fact, in 
conjunction with the availability of a facile treatment for haemochromatosis, makes screening for 
the condition recommendable, especially in the Irish population, where the incidence of 
haemochromatosis alleles is at its highest worldwide. Diagnosing a genetic disorder not only 
allows for disease-specific management options, but also has implications for the affected 
individual’s entire family. Genotyping ensures ‘overdiagnosis’ rather than ‘underdiagnosis’, which 
in itself is less acceptable in terms of increasing the risk of mortality/morbidity and the 
development of complicating conditions.
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II. Scientific background of study
Hereditary Haemochromatosis (HH) is a common genetic disorder which causes 
abnormalities in iron metabolism within the body. The disorder is characterized 
by inappropriate absorption of iron and its subsequent deposition in the
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histidine in codon 63. These mutations are designated C282Y and H63D, 
respectively (Feder et al., 1996). Homozygosity for the C282Y mutation is closely 
linked to the disorder of FIH, as it accounts for 93% of HH chromosomes in 
Ireland, 90% in the U.K and 100% in Australia.6,7 Homozygous mutation at the 
845 locus has high penetrance (phenotypic expression of a gene) when untreated, 
due to the sufficient time iron has to be absorbed. Iron overload is unlikely in the 
845 heterozygous state-but is possible under certain circumstances like high 
intake of ascorbic acid or alcohol, or concurrent thalassemia minor (Felitti, 1999). 
Homozygosity at the 187 locus is also unlikely to cause iron overload, but is 
possible. The H63D mutation may contribute to hepatic iron overload, but rarely 
in the absence o f the C282Y mutation (Bacon et al., 1999s; Moirand et a1., 19999). 
This mutational status is described as compound heterozygosity for the 
C282Y/H63D mutations. Byrnes et al., (2001), investigated the prevalence of 
C282Y and H63D mutations within the Irish population, and an allele frequency 
of 11% for C282Y and 15% for H63D was found to exist.10 The highest 
frequency of C282Y alleles worldwide has been reported in the Irish population, 
with 1 in 20 people having the genetic susceptibility to develop significant iron 
overload.11
Studies by Adams et al., (1995)12’13, have concluded that early diagnosis o f HH 
through genetic analysis of the aforementioned gene mutations, and 
implementation of plans that monitor and treat hereditary haemochromatosis, i.e. 
measurement o f biochemical indices of iron overload and phlebotomy therapy, 
are cost-effective and support widespread population screening for the disorder. 
Early detection of HH in its presymptomatic phase (ideally in children with a 
familial history of haemochromatosis), may mean that the disorder never
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develops to the stage o f phenotypic expression, by which tune major therapeutic 
advantage has already been lost. HH can be fatal if  left undetected and without 
treatment (Bothwell et al., 1995), but if  therapy is initiated before tissue injury 
occurs, patients have a normal life expectancy.14 This proves that early diagnosis 
of in d iv id u a ls  is therefore crucial, and represents a major opportunity for chronic 
disease prevention.
Diabetes is a condition classically associated with hereditary haemochromatosis. 
In addition to the effect of iron on the pancreatic beta cells, there may also be a 
genetic link between the two conditions, which would explain the frequent 
occurrence of diabetes in siblings o f  patients with haemochromatosis and 
diabetes. Nelson et al., (1979), reported that the diabetes experienced in patients 
with haemochromatosis, was similar to that observed in patients with type II 
diabetes, with normal/exaggerated glucagons response but impaired response to 
glucose. Studies by O ’Brien et al., (1990), and Adams et al., (1991), showed that 
between 20 % and 80 % of cases with hereditary haemochromatosis also have 
diabetes mellitus, depending on the population studied. Results from studies in 
Denmark (EUervik et al., 2001), lend support to the theory that hereditary 
haemochromatosis is a disease often overlooked in patients with late-onset type I 
diabetes mellitus, a late manifestation o f iron overload. These results also suggest 
that there is an association between C282Y homozygosity and type I diabetes. To 
date there has been no comprehensive information on the prevalence of the two 
mutations in the BMW region and its association with Diabetes Mellitus type 1 
and type 2. There is a necessity to understand the allele frequency in the regional 
population, and the association between penetrance rates of the disease and 
homozygosity. There may be specific regional risk factors involved within the 
North West catchment including increased iron loading due to water quality 
characteristics, which may play a role in the prevalence o f hereditary 
haemochromatosis. Recently an association has been demonstrated between 
heterozygosity for the C282Y mutation and cardiovascular death in women 
(Roest et al, 1999).
Many techniques in molecular biology have been employed in the detection of 
C282Y and H63D mutations of the HFE gene. Merryweather-Clarke et al., (1997) 
used restriction fragment lengdi polymorphism (RFLP) analysis in conjunction 
with PCR, to determine the prevalence o f haemochromatosis mutations in 
European chromosomes.'5 Liang et al., (2000) detected the C282Y and H63D 
mutations through the analysis of single-nucleotide extension (SNE) products by 
capillary electrophoresis.16 Beutler et al., (2000) performed allele-specific 
oligonucleotide hybridization using peripheral-blood DNA amplified by PCR, to 
analyse samples for C282Y and H63D mutations.17 In this study, PCR 
methodology and other accepted techniques in molecular biology, will be used to 
detect the aforementioned gene mutations associated with HH, in both ‘normal’ 
and diabetic populations of the North West, through the genotyping of DNA 
obtained from buccal smears and blood samples.
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The objectives of the study are to determine and compare the incidence o f the 
two major mutations responsible for hereditary haemochromatosis, (i.e. C282Y 
and H63D of the HFE gene), in a diabetic population and a non-diabetic or 
‘normal’ population, from the North West region.
Recruitment of the study population (both diabetics and non-diabetics) will be on 
a voluntary basis, and will be conducted by study investigators, in the Outpatient 
Department and the Diabetic Clinic of Sligo General Hospital. As part o f the 
recruitment process, individuals will be given Information Sheets to help them 
decide on whether they would like to be involved in the study or not, and what 
will be required of them, should they decide to participate. Study participation 
will be confirmed by way of documented consent, following which, all study 
participants will be required to give both a blood and a buccal cell sample. 
Completion of a simple questionnaire will also be necessary.
The sample size for the study is 1530, comprised of n  = 765, for each of the 
diabetic and non-diabetic /  ’normal’ populations. The sample size for each o f the 
aforementioned populations was calculated using the sample size formula for a 
single proportion or percentage, which allows for 80% power and a 5% two- 
sided significance level, and an increase/decrease of 100% from the prevalence 
documented for the general Irish population (Kelleher and Crowe, Irish Medical 
Times, 2001).
Genetic analysis in the form of PCR (Polymerase Chain Reaction), will be carried 
out on DNA extracted from blood and or buccal cell samples, in order to 
determine the incidence of the C282Y and H63D mutations, responsible for 
hereditary haemochromatosis
Biochemical analyses will also be carried out on collected blood samples as part 
of the study, and the following tests will be conducted:
Serum Iron, Serum Ferritin, Transferrin Saturation, Total Iron Binding Capacity 
(TIBC), Full Blood Count, Liver Function Tests (LFT’s), fasting venous blood 
sugar level and glycosylated haemoglobin. In addition to these tests, blood 
samples from female participants will undergo pregnancy testing, in order to 
ensure the relevant individuals are excluded from the study, therefore avoiding 
any unnecessary risks.
Statistical analyses will be carried out on the data obtained from genetic and 
biochemical testing, and will be used to compare the incidence o f hereditary 
haemochromatosis in a diabetic population to that o f a non-diabetic or ‘normal’ 
population from the same region (i.e. the North West). Biochemical iron indices 
of individuals carrying the C282Y mutation will also be analysed in order to 
determine whether a link exists between C282Y homozygosity and iron levels in 
water, from varying water supply catchments within the region.
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12. Brief outline of project:
9
13. Study design (e.g. RCT, cohort, case control, epidemiological analysis)
The population sample size for the study, was calculated using the sample size 
formula for a single proportion or percentage, which allows for 80% power and a 
5% two-sided significance level, and an increase/decrease o f 100% from the 
prevalence documented for the general Irish population (Kelleher and Crowe, 
2001).
Randomisation o f study subject’s for both populations (diabetic and non­
diabetic), was achieved as a result o f the volunteer nature for study participation.
Study participants from the diabetic population will be case-matched by age (ten 
year age classes), and gender, to study participants in the non-diabetic or control 
population.
Research Ethics Committee Sligo General Hospital
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14. Size of the study (including controls) : 1530 individuals/subjects 
Will the study involve:
(a) Human Subjects Yes
i) How many patients will be recruited? -  765 individuals/subjects
ii) How many controls will be recruited? - 765 individuals/subjects
iii) What is the primary end point?
To determine and compare the incidence o f the major mutations for hereditary 
haemochromatosis, C282Y and H63D, in a diabetic population and a non-diabetic 
population from the North West region.
iv) How was the size of the study determined?
The population sample size for the study, was calculated using the sample size 
formula for a single proportion or percentage, which allows for 80% power and a 
5% two-sided significance level, and an increase/decrease of 100% from the 
prevalence documented for the general Irish population (Kelleher and Crowe, 2001). 
Randomisation o f study subject’s for both populations (diabetic and non-diabetic), 
was achieved as a result o f the volunteer nature for study participation. Study 
participants from the diabetic population will be case-matched by age (ten year age 
classes), and gender, to study participants in the non-diabetic or control population.
v) Was there formal statistical input into the overall design of the study?
Yes
vi) What method of analysis will be used?
Relevant Statistical analysis allowing comparison of populations.
Research Ethics Committee Sligo General Hospital
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(b) Patient Records Yes
i) How many records will be examined?
765
ii) How many control records will be examined?
765
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iii) What is the primaiy end point?
To determine and compare the incidence o f the major mutations for hereditary 
haemochromatosis, C282Y and H63D, in a diabetic population and a non­
diabetic population from the North West region.
iv) How was the size of the study determined?
The population sample size for the study, was calculated using the sample size 
formula for a single proportion or percentage, which allows for 80% power and 
a 5% two-sided significance level, and an increase/decrease of 100% from the 
prevalence documented for the general Irish population (Kelleher and Crowe, 
2001). Randomisation o f study subject’s for both populations (diabetic and non­
diabetic), was achieved as a result of the volunteer nature for study 
participation.Study participants from the diabetic population will be case- 
matched by age (ten year age classes), and gender, to study participants in the 
non-diabetic or control population.
v) Will information relevant to this study ONLY be extracted?
Yes
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SECTION 3 Recruitment of subjects
15. How will the subjects in the study be:
i) selected?
Positive for Diabetes Mellitus
ii) recruited?
Voluntary Recruitment at Dr. Donal Murrays Diabetic Clinic in SGH
i«) what inclusion criteria will be used?
Positive for diabetes mellitus
Aged greater than 20 years
Reside in the North West Region
Of a Celtic or North European Origin
iv) what exclusion criteria will be used?
Recent Excessive Blood Loss
Recent Blood Transfusion
Non- Celtic Or non North European
Origin
Pregnant
Under the age of 20 years
13
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16. How will the control subjects group (if used) be: (Type N/A i f  no controls)
i) selected?
Non-diabetic or “Normal” population (age & gender matched to the diabetic 
population).
ii) recruited?
Voluntary Recruitment in Outpatient Department in Sligo General 
Department
iii) what inclusion criteria will be used?
Aged greater than 20 years_____________
Reside in the North West Region________
Of a Celtic or North European Origin
iv) what exclusion criteria will be used?
Recent Excessive Blood Loss  _
Recent Blood Transfusion
Non- Celtic Or non North European
Origin___________________________
Pregnant
Under the age of 20 years
17. Will there be payment to research subjects of any soft? Yes
I f  yes, how much per subject and for what? N/A
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SECTION 4_________________________________      Consent
18. Is written consent to be obtained? Yes
I f  yes, please attach a copy o f the consent form to be used.
I f  no written consent is to be obtained, please justify.
See Consent Form Attached
19. Please attach a copy of the written information sheet or letter to be given to the 
subject
I f  no Information Sheet is to be given, please justify.
See research subject information sheet
20. Will any of the subjects or controls be from one of the following special 
populations?
Infants (<1 year):no 
Children (1-18 years): no 
Elderly (>59 years): yes 
Pregnant women: no 
Unconscious or severely ill: no 
Mentally disabled: no 
Mentally retarded: no 
Prisoners: no 
Students: yes
I f  yes, please specify and justify:
Study Participants must be 20 years of age or older. This would include elderly people & 
students who make up a large proportion of the Local Population
21. What special arrangements have been made to deal with the issues of consent for 
the subjects of special populations? Normal follow up procedures
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SECTION 5 Details of interventions
22. Will the study involve the use of Investigational New Drugs 
(IND) or new device?
No
No
If yes, complete the following:
i. Drug name: N/A
ii. IND#: N/A
iii. Company: N/A
iv. Phase: N/A
i n m IV
23. Will the study involve the use of an existing product outside 
the terms of its product licence?
No
If yes, specify (e.g. different populations, change of labelling): N/A
and also complete the following:
i. Drug name: N/A
ii. IND#: N/A
iii. Company: N/A
iv. Phase: N/A I IT III IV
24. Will the study involve the use of a drug inside its product licence?
No
If yes, complete the following:
v. Drug name: N/A
vi. IND#: N/A 
viL Company: N/A
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25. Will the study involve laboratory/clinical procedures NOT Yes
part of ordinary management?
If yes, please explain: PCR assay for mutations C282Y and H63D, routine serological 
testing
26. Will the study involve the withholding of treatment as a result of 
taking part in the research study? No
If yes, please explain: N/A
27. Will the study involve the clinical experimental use of
radiation or radioisotopes?
No
2S. Will the study involve the use of biohazardous or infectious agents?
No
If yes, please exjplain:
N/A
29. How will the health of the participants be monitored during and after the study?
Normal Clinical Procedures
30. What medical examinations will persons selected for inclusion in the study undergo 
before participating in the study?
Diabetes Testing & diabetes testing
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SECTION 6  Risks and ethical problems_____
31. Are there any potential hazards? Yes
I f  yes, please give details, and give the likelihood and details o f precautions taken to 
meet them, and arrangements to deal with adverse events.
Vaccination of workers of Hepatitis A and B
32. Is this study likely to cause any discomfort or distress? Yes
I f  yes, please give details and justify.
Diagnosis of C282Y homozygosity (emotional distress)
33. Are there any particular ethical problems or considerations that you consider to be
important or difficult with the proposed study? yes
Please give details 
Genetic councelling of C282Y homozygotes
34. Will treatments provided during the study be available if needed after termination
of the study?
N/A
35. Will information be given to the patient’s General Practitioner? Yes
Please note: permission should always be sought from research subjects before doing this.
I f  yes, please enclose an information sheet/letter for the GP.
I f  no, please justify:
See G.P. Letter attached
36. If the study is on hospital patients, will consent of all consultants
whose patients are involved in this research be sought? Yes
I f  no, please justify:
N/A
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Product liability and consumer protection legislation make the supplier and producer 
(manufacturer) or any person changing the nature o f a substance, e.g. by dilution, strictly 
liable for any harm resulting from a consumer’s (subject or patient) use o f a licensed product.
SECTION 7_____________________________ Compensation and confidentiality______
37. Have arrangements been made to provide indemnity and/or compensation in the 
event of a claim by, or on behalf of, a subject for non negligent harm?
(Please indicate N/A i f  not applicable)
No
I f  yes, please give details o f compensation arrangements with this application.
N/A
38. In cases of equipment or medical devices, have appropriate arrangements been 
made with the manufacturer to provide indemnity?
(Please indicate N/A if  not applicable)
N/A
I f  yes, please give details and enclose a copy o f the relevant correspondence with this 
application.
N/A
39. Will the study include the use of any of the following?
Audio/video recording No
Observation of patients No
I f  yes to either:
i) How are confidentiality and anonymity to be ensured ?N/A
ii) What arrangements have been made to obtain consent for these procedures?
N/A
40. What steps will be taken to safeguard confidentiality of personal records?
n A
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Personal records held in a secure environment in SGH. Access limited to predefined personnel 
involved in study / research
41. Will medical records be examined by research worker(s) not employed by the 
NWHB?
No
42. Will the study data be held on a computer?
Yes
If yes, will the data be held so that participants cannot be identified from 
computer files (i.e. no name, address, PCN or other potential identifier)?
Yes
Will records linking study participant ID numbers with identifying features be 
stored confidentially?
Yes
43. What steps will be taken to safeguard the information relating to specimens and the 
specimens themselves?
Normal steps for safe guarding
PLEASE ENSURE THAT YOU COMPLETE THE CHECKLIST ON THE FRONT 
COVER OF THE APPLICATION FORM AND ENCLOSE ALL RELEVANT 
ADDITIONAL DOCUMENTS.
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SECTION 8 Declaration
DECLARATION
The information in this form is accurate to the best of my knowledge and belief and I 
take full responsibility for it.
I agree to supply annual review and final reports on the pro forma provided, and to 
advise my sponsor, the REC and any local researchers taking part in the project of any
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1.0 PRECIS.
The objectives of the study are to determine and compare the incidence of the two major 
mutations responsible for hereditary haemochromatosis, (i.e. C282Y and H63D of the 
HFE gene), in a diabetic population and a non-diabetic or ‘normal’ population, from the 
North West region.
Recruitment of the study population (both diabetics and non-diabetics) will be on a 
voluntary basis, and will be conducted by study investigators, in the Outpatient 
Department and the Diabetic Clinic of Sligo General Hospital. As part of the recruitment 
process, individuals will be given Information Sheets to help them decide on whether 
they would like to be involved in the study or not, and what will be required of them, 
should they decide to participate. Study participation will be confirmed by way of 
documented consent, following which, all study participants will be required to give both 
a blood and a buccal cell sample. Completion of a simple questionnaire will also be 
necessary.
The sample size for the study is 1530, comprised of n = 765, for each of the diabetic and 
non-diabetic / ’normal’ populations. The sample size for each of the aforementioned 
populations was calculated using the sample size formula for a single proportion or 
percentage, which allows for 80% power and a 5% two-sided significance level, and an 
increase/decrease of 100% from the prevalence documented for the general Irish 
population (Kelleher and Crowe, Irish Medical Times, 2001).
Genetic analysis in the form of PCR (Polymerase Chain Reaction), will be carried out on 
DNA extracted from blood and or buccal cell samples, in order to determine the 
incidence of the C282Y and H63D mutations, responsible for hereditary 
haemochromatosis
Biochemical analyses will also be carried out on collected blood samples as part of the 
study, and the following tests will be conducted:
Serum Iron, Serum Ferritin, Transferrin Saturation, Total Iron Binding Capacity (TIBC), 
Full Blood Count, Liver Function Tests (LFT’s), fasting venous blood sugar level and 
glycosylated haemoglobin. In addition to these tests, blood samples from female 
participants will undergo pregnancy testing, in order to ensure the relevant individuals are 
excluded from the study, therefore avoiding any unnecessary risks.
Statistical analyses will be carried out on the data obtained from genetic and biochemical 
testing, and will be used to compare the incidence of hereditary haemochromatosis in a 
diabetic population to that of a non-diabetic or ‘normal’ population from the same region 
(i.e. the North West). Biochemical iron indices of individuals carrying the C282Y 
mutation will also be analysed in order to determine whether a link exists between C282Y 
homozygosity and iron levels in water, from varying water supply catchments within the 
region.
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2.0 INTRODUCTION.
Hereditary Haemochromatosis (HH) is a common genetic disorder which causes 
abnormalities in iron metabolism within the body. The disorder is characterized by 
inappropriate absorption of iron and its subsequent deposition in the parenchymal cells of 
major organs.1 The pathology of haemochromatosis is entirely a function of iron 
overload, i.e. when the body’s normal capacity for binding and storing iron is exceeded; 
the element exists in an unbound state, which makes it extremely reactive and therefore 
toxic.2 Excessive absorption and storage of dietary iron primarily affects the following 
organs; liver, heart, pancreas, endocrine organs, skin and joints,3 where it is deposited and 
accumulates, resulting in impairment of organ structure and function, that can lead to 
cirrhosis, diabetes mellitus, cardiac dysfunction, arthritis, hypogonadism and premature 
death (Edwards et al., 1980).
It is only in recent decades that the basic pathophysiology of haemochromatosis was 
discovered to lie in a defective gene, which controls the intestines mucosal barrier to iron 
absorption. In 1996, investigators at Mercator Genetics Corporation (Menlo Park, 
California), identified the gene responsible for hereditary haemochromatosis.4 The gene 
was described as the HLA-H gene, but has since been renamed by the Nomenclature 
Committee of the Genome Database, as the HFE gene. It can be found on the short arm of 
chromosome 6 of the human karyotype. HH is considered an autosomal recessive 
disorder because both copies o f the HFE gene, residing on the two homologs of the 
autosomal chromosome 6, need to have a particular mutation in order for the disorder to 
present itself. Two specific mutations of the HFE gene, when present in the appropriate 
arrangement can lead to the development of HH.5 Clinical genetic analysis has identified 
both of these mutations; one occurs at the 845 nucleotide locus causing substitution of 
tyrosine for cysteine in codon 282; and one occurs at the 187 nucleotide locus, causing 
substitution of aspartic acid for histidine in codon 63. These mutations are designated 
C282Y and H63D, respectively (Feder et al., 1996). Homozygosity for the C282Y 
mutation is closely linked to the disorder of HH, as it accounts for 93% of HH 
chromosomes in Ireland, 90% in the U.K and 100% in Australia.6,7 Homozygous 
mutation at the 845 locus has high penetrance (phenotypic expression of a gene) when 
untreated, due to the sufficient time iron has to be absorbed. Iron overload is unlikely in 
the 845 heterozygous state-but is possible under certain circumstances like high intake of 
ascorbic acid or alcohol, or concurrent thalassemia minor (Felitti, 1999). Homozygosity at 
the 187 locus is also unlikely to cause iron overload, but is possible. The H63D mutation 
may contribute to hepatic iron overload, but rarely in the absence of the C282Y mutation 
(Bacon et al., 1999s; Moirand et a i,  19999). This mutational status is described as 
compound heterozygosity for the C282Y/H63D mutations. Byrnes et al., (2001), 
investigated the prevalence of C282Y and H63D mutations within the Irish population, 
and an allele frequency of 11% for C282Y and 15% for H63D was found to exist.10 The 
highest frequency of C282Y alleles worldwide has been reported in the Irish population, 
with 1 in 20 people having the genetic susceptibility to develop significant iron 
overload.11
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Studies by Adams et al., (1995)12’13, have concluded that early diagnosis of HH through 
genetic analysis of the aforementioned gene mutations, and implementation of plans that 
monitor and treat hereditary haemochromatosis, i.e. measurement of biochemical indices 
of iron overload and phlebotomy therapy, are cost-effective and support widespread 
population screening for the disorder. Early detection of HH in its presymptomatic phase 
(ideally in children with a familial history of haemochromatosis), may mean that the 
disorder never develops to the stage of phenotypic expression, by which time major 
therapeutic advantage has already been lost. HH can be fatal if  left undetected and 
without treatment (Bothwell et al., 1995), but if  therapy is initiated before tissue injury 
occurs, patients have a normal life expectancy.14 This proves that early diagnosis of 
individuals is therefore crucial, and represents a major opportunity for chronic disease 
prevention.
Diabetes is a condition classically associated with hereditary haemochromatosis. In 
addition to the effect of iron on the pancreatic beta cells, there may also be a genetic link 
between the two conditions, which would explain the frequent occurrence of diabetes in 
siblings of patients with haemochromatosis and diabetes. Nelson et al., (1979), reported 
that the diabetes experienced in patients with haemochromatosis, was similar to that 
observed in patients with type II diabetes, with normal/exaggerated glucagons response 
but impaired response to glucose. Studies by O’Brien et al., (1990), and Adams et al., 
(1991), showed that between 20 % and 80 % of cases with hereditary haemochromatosis 
also have diabetes mellitus, depending on the population studied. Results from studies in 
Denmark (Ellervik et al., 2001), lend support to the theory that hereditary 
haemochromatosis is a disease often overlooked in patients with late-onset type I diabetes 
mellitus, a late manifestation of iron overload. These results also suggest that there is an 
association between C282Y homozygosity and type I diabetes. To date there has been no 
comprehensive information on the prevalence of the two mutations in the BMW region 
and its association with Diabetes Mellitus type 1 and type 2. There is a necessity to 
understand the allele frequency in the regional population, and the association between 
penetrance rates of the disease and homozygosity. There may be specific regional risk 
factors involved within the North West catchment including increased iron loading due to 
water quality characteristics, which may play a role in the prevalence of hereditary 
haemochromatosis. Recently an association has been demonstrated between 
heterozygosity for the C282Y mutation and cardiovascular death in women (Roest et al, 
1999).
Many techniques in molecular biology have been employed in the detection of C282Y 
and H63D mutations of the HFE gene. Menyweather-Clarke et a l, (1997) used 
restriction fragment length polymorphism (RFLP) analysis in conjunction with PCR, to 
determine the prevalence of haemochromatosis mutations in European chromosomes.15 
Liang et al., (2000) detected the C282Y and H63D mutations through the analysis of 
single-nucleotide extension (SNE) products by capillary electrophoresis.16 Beutler et al., 
(2000) performed allele-specific oligonucleotide hybridization using peripheral-blood 
DNA amplified by PCR, to analyse samples for C282Y and H63D mutations.17 In this 
study, PCR methodology and other accepted techniques in molecular biology, will be
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used to detect the aforementioned gene mutations associated with HH, in both ‘normal’ 
and diabetic populations of the North West, through the genotyping of DNA obtained 
from buccal smears and blood samples.
3.0 OBJECTIVE (S) OF STUDY
3.1 To analyse the incidence of the two major hereditary haemochromatosis mutations, 
C282Y and H63D (of the HFE gene), in a population from the North West region.
3.2 To compare the levels of the two aforementioned mutations in the ‘normal’ (non­
diabetic) population to those in a diabetic population, from the same region.
3.3 To compare biochemical iron indices of individuals carrying the C282Y mutation from
various water supply catchments within the North West region.
4.0 STUDY DESIGN & METHODOLOGY
4.1 LOCATION OF STUDY
Recruitment of individuals for participation in the study, biochemical analysis of 
biological samples (i.e. blood and buccal smear samples), and analysis of the mutational 
status of biological samples by PCR will be conducted at the following facility:
Sligo General Hospital,
The Mall,
Sligo,
Co. Sligo,
Ireland.
4.2 PERSONNEL RESPONSIBLE FOR THE STUDY.
Co-Principal Investigator (1): Dr. John Williams (External MSc. Research Supervisor)
Co-Principal Investigator (2): Dr. Jeremy Bird (Internal MSc. Research Supervisor)
Collaborators:
Consultant Physician: Dr. Donal Murray, MD, MRCP, MRCGP.
Medical Registrar: Dr. Shukri Ramadan.
MSc. Research Student: Ms. Lydia Kirk, BSc.
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4.3 STUDY SEQUENCE.
Recruitment of study participants
I
Consent for Participation —► Collection & Storage of Consent Forms 
& Questionnaire Completion 
I
Blood and Buccal cell sampling
4
& Questionnaires
4 4
Frozen storage Genetic Analysis
Of samples for by PCR
future analysis j
Results
4
Statistical Analysis
4
4
Results
I
Statistical Analysis
;
4
4
4
Compilation of Data/Results 
4
Report
4.4 PROCEDURES
4.4.1 SAMPLE COLLECTION PROCEDURES
Blood samples will be collected from study participants, by suitably qualified 
personnel utilising normal medical procedures already in place at SGH.
Buccal cell samples will be obtained using a mouth wash collection procedure.
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4.4.2 DNA EXTRACTION PROCEDURE
DNA will be extracted from blood and buccal cell samples using methods that 
incorporate Chelex 100 resin.
4.4.3 PROCEDURE FOR GENETIC ANALYSIS
DNA extracted from blood/buccal cell samples will be amplified by PCR. 
Subsequent restriction digestion and gel electrophoresis of DNA fragments will 
help identify the presence of C282Y and H63D mutations. Southern blotting 
techniques will confirm the presence of the individual mutations.
4.4.4 PROCEDURE FOR BIOCHEMISTRY ANALYSIS
The biochemical tests listed in section 1.0 of this protocol will be conducted in 
compliance with Standard Operating Methods (S.O.M.’s), currently in place in 
the laboratories ûf SGH.
4.4.5 STATISTICAL ANALYSIS
Suitable statistical analysis will be carried out on results obtained from genetic 
and biochemical analyses, to allow comparisons between the diabetic and the 
non-diabetic or ‘normal’ population.
4.4.6 STUDY DESIGN
The population sample size for the study, was calculated using the sample 
size formula for a single proportion or percentage* which allows for 80% 
power and a 5% two-sided significance level, and an increase/decrease of 
100% from the prevalence documented for the general Irish population 
(Kelleher and Crowe, 2001).
Randomisation of study subject’s for both populations (diabetic and non­
diabetic), was achieved as a result of the volunteer nature for study 
participation.
Study participants from the diabetic population will be case-matched by 
age (ten year age classes), and gender, to study participants in the non­
diabetic or control population.
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5.0 INCLUSION & EXCLUSION CRITERIA
Inclusion criteria for study participants in the:
Diabetic Population Non-Diabetic
Population
Positive for Diabetes 
Mellitus
Aged greater than 20
Aged greater than 20 Reside in the North 
West region
Reside in the North 
West region
Celtic / Northern 
European Origin
Celtic / Northern 
European Origin
-
Exclusion criteria for study participants in the:
Diabetic Population Non-Diabetic
Population
Recent Excessive Blood 
Loss
Recent Excessive Blood 
Loss
Recent Blood 
Transfusion
Recent Blood 
Transfusion
Pregnant Pregnant
Non-Celtic / Non-North 
European Origin
Non-Celtic / Non-North 
European origin
Under the age of 20 Under the age of 20
6.0 SUBJECT MONITORING & CRITERIA FOR THEIR WITHDRAWAL
The general health of study participants will be monitored in accordance with normal procedures 
in place in SGH, at times when blood and buccal cell sampling occur.
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Participation is on a voluntary basis. Study Participants are free to withdraw from the study at 
any time. Withdrawal will not affect the standard of care received. Individuals who choose to 
withdraw from the study are asked to notify any of the Study Investigator’s, as to their decision.
7.0 HUMAN SUBJECT PROTECTIONS
7.1 RATIONALE FOR SUBJECT SELECTION
Inclusion and Exclusion criteria (see Section 5.0) have been defined on the basis of 
published data. See Section 10.0 for References.
Individuals of non-Celtic origin are excluded from the study due to the feet that studies 
have shown that the incidence of hereditary haemochromatosis is at its highest in people 
of a Celtic origin.18,19,20’21'
8.0 ADVERSE EVENT REPORTING AND DATA MONITORING
Should adverse events occur during the course of the study period, they must be recorded in 
writing and brought to the attention of the Co-Principal Investigator (1), immediately.
9.0 CONSENT PROCESS & DOCUMENTS
On recruitment of study subjects, every individual will receive a Research Subject Information 
Sheet, which explains what the study is about and what will be expected of people who decide to 
participate. Patient Information sheets will be approved by SGH ethics committee prior to their 
distribution, and a copy of the approved document will be maintained in a clearly identifiable 
Study Folder for the entire duration of the study period.
Individuals who chose to participate in the study will be required to sign a consent form 
indicating their decision. Consent forms will be collected immediately prior to blood and buccal 
cell sampling. All completed consent forms will be maintained in a clearly identifiable Study 
Folder.
Participants will also be asked to complete a simple questionnaire of personal details relevant to 
the study. All completed questionnaires should be collected along with completed consent forms
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prior to sampling of blood and buccal cells, and will be maintained in a clearly identifiable Study
Folder.
Because the study is not being conducted by any study participant’s own G.P, a letter will be sent
to them informing them of their patient’s consent to participate in the study. A Research Subject
Information Sheet will also be sent.
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11.0 DOCUMENTATION
11.1 All raw data recorded on Taw data forms will be submitted to the Co-Principal (1) Study 
Investigator, who will maintain them for the duration of the study in a clearly identifiable 
Study Folder, and be responsible for their correct archival after completion of the study.
12.0 CONFIDENTIALITY
The highest standards of confidentiality will be applied to any personal information of study 
subject’s collected. Any information about study participants which leaves the hospital will have 
the names of subject’s removed, so that they are not recognisable.
13.0 FATE OF STUDY RESULTS/DATA
The results obtained from this study will form part of a publicly available MSc Research project 
submitted by Ms. Lydia Kirk, B.Sc. to the awarding body of HETAC. They may also be 
published in peer-reviewed journals.
14.0 PROTOCOL AMENDMENTS
14.1 No changes, revisions or modifications must be made to this study protocol unless 
approved by the Co-Principal Study Investigator’s: any such changes must be agreed by 
the Research Ethics Committee (SGH) and recorded in an addendum giving reasons for 
the alterations.
15.0  PROTOCOL DEVIATIONS
15.1 The details and procedures set out in the protocol must be followed at all times during 
the conduct of the study. Should any deviation from the authorised protocol occur it 
must be recorded and reported in writing to the Co-Principal (1) Study Investigator 
immediately.
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16.0 PROTOCOL APPROVAL
16.1 Approved by:    Date:
CO-PRINCIPAL INVESTIGATOR (1)
__________________  Date:
CO-PRINCIPAL INVESTIGATOR (2)
  ......................   Date:
Collaborating Consultant Physician
____________________  Date: .......
ON BEHALF OF Research Ethics Committee (SGH)
HaemochronrntDsis PTC,
»N orth W estern Health Board
Sligo General Hospital
The Mall, Sligo
Telephone (071) 71111. Fax (071) 74645
)col Number:
rnt Identification Number for this trial:
of Protocol: “Analysis of Haemochromatosis Mutations in the North West Population*
or(s) Directing Research:
1. I confiim that I have received a copy of the Research Subject Information Sheet for the above study. I have read it 
and I understand it. I have received an explanation of the nature, purpose, duration and foreseeable effects and 
risks of the study and what my involvement will be and the possible benefit of taking part.
2. I have had time to consider whether to take part in this study and I have had the opportunity to ask questions. I 
have also had time to consider what will be required of me, should I decide to participate in the study.
3. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being affected. I understand that my taking part in this study will be 
kept confidential, and my name or personal details will not be disclosed outside the hospital and GP surgery.
4. I have, to the best of my knowledge, informed the investigator of my medical history, previous participation in 
clinical trials, medication and any consultations that I have had with a doctor over the past 4 months.
5. I understand that my GP, Dr...................will be informed by Dr...................that I am taking part in this study.
6. I understand that sections of any of my medical notes may be looked at by responsible individuals from Sligo 
General Hospital or from regulatory authorities where it is relevant to my taking part in research. I give permission 
for these individuals to have access to my records for the purposes of this study.
7. I agree to take part in the above study.
le of patient Date Signature
le of person taking consent Date Signature
Principal Investigator (1) Date Signature
1 copy for patient, 1 copy for investigator, 1 copy for medical records
Date of Compilation: 12th November 2003
(1)
Version Number
Research Subject Information Sheet
1. Study title
“Analysis o f Haemochromatosis mutations in the North West Population”
2. Invitation paragraph
You are being invited to take part in the research study mentioned above. 
Before you decide, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear, or if you would like more information.
3. What is the purpose of the study?
Haemochromatosis is a condition characterised by the excessive absorption of 
dietary iron from the digestive tract. Over time, the excess iron accumulates in 
tissues throughout the body, leading to symptoms and signs of iron overload. 
These may include diabetes mellitus, liver disease (cirrhosis), heart failure, skin 
pigmentation, joint pains, and sexual dysfunction/ loss o f libido.
Haemochromatosis is usually an inherited disorder and is most common in 
Caucasian people. Recent studies have revealed that Ireland has the highest 
incidence of Hereditary Haemochromatosis in the world, where it is believed 
that 1 in 20 people have the genetic susceptibility to develop significant iron 
overload. Two mistakes in the gene called HFE cause the condition of 
Hereditary Haemochromatosis.
The primary goal of screening is to detect the presence of the gene mistakes 
responsible for the Hereditary Haemochromatosis before it produces any 
symptoms or causes complications. The aim of this study is to determine the 
number of non-diabetic people in the North Western region who possess the 
gene mistakes responsible for the disorder, and also to determine the type of 
mistake in the gene. The same determination will be carried out on people with 
Diabetes mellitus in the same region.
Specific attention is being given to diabetics, as Diabetes mellitus is reported in 
10-40% of patients with Haemochromatosis.
4. Why have I been chosen?
You have been chosen to take part in this study because you reside in the 
BMW region and are in good general health.
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5. Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part 
you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason. A decision to withdraw at any time or a decision not 
to take part will not affect the standard of care you receive.
6. What will happen to me if I take part?
Should you decide to participate in this research all that will be required of you 
is a quick visit to Sligo General Hospital for completion of a short 
questionnaire and to allow us to obtain blood sample and a cheek cell sample. 
The entire procedure will take no longer than 20 minutes to complete.
7. What are the alternatives for diagnosis or treatment?
Participation in this study is voluntary. In the event that it is discovered that 
you have Hereditary Haemochromatosis, the research doctor may suggest you 
speak to your GP about future phlebotomy therapy (regular donation o f blood 
to help decrease body stores of iron). This should prevent the development of 
many complications of the disorder.
8. What are the possible benefits of taking part?
The main benefit of participating in this study is that you will find out whether 
or not you have the disorder. Haemochromatosis could be asymptomatic for 
many years and its complications could be preventable if the disease is 
diagnosed early.
9. What are the possible risks of taking part?
Because your participation requires a blood sample to be taken, potential exists 
for slight bruising at the site of the vein puncture.
It is possible that insurance companies might “Load” your premium if you 
apply for insurance and you are known to have haemochromotosis, however, 
people who are diagnosed and treated for haemochromotosis before 
complications would have a normal life expectancy.
10. What if something goes wrong?
In the event that unforeseen circumstances arise, your doctors are covered by 
standard medical malpractice insurance. Nothing in this document restricts or 
curtails your rights.
11. Will my taking part in this study be kept confidential?
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Yes, all information which is collected during the course of the research will be 
kept strictly confidential. Any information about you, which leaves the 
hospital/surgery, will have your name and address removed so that you cannot 
be recognised from it.
12. What will happen to the results of the research study?
Results of the study will be collated within two years from study initiation and 
may be published after this time in a reputable medical forum.
13. Who is organising and funding the research?
A seed fund grant from the Institute of Technology, Sligo, will help fund this 
study.
14. Who has reviewed the study?
The Research Ethics Committee (REC) of Sligo General Hospital has reviewed 
the study prior to its commencement.
If you have any queries you can contact the REC at:
Research Ethics Committee 
Sligo General Hospital (SGH)
The Mall 
Sligo
15. Contact for Further Information
Dr. Donal Murray, Consultant Physician, SGH, Tel.:071-9171111, Extn. 4119 
Dr. John Williams, Head of Biochemistry, SGH, Tel.:071-9171111, Extn.4561 
Dr. Shukri Ramadan, Medical Registrar, SGH, Tel.: 071-9171111, Bleep 252 
Dr. Jeremy Bird, Lecturer, I.T. Sligo, Tel: 071-9155436 
Ms. Lydia Kirk, MSc. Researcher, I.T. Sligo, Tel: 071-9155414
Thank you for taking part in this study!
North W estern H ealth Board  
W) Sligo General Hospital
The Mall, Sligo 
---------------- Telephone (071) 71111. Fax (071) 74645
Dr. John Williams (Head of Biochemistry Dept.,) &
Co-Principal Investigator (1), 
Haemochromatosis Study, 
Sligo General Hospital, 
The Mall, 
Sligo.
Name of GP,
Address of GP.
DATE:
RE: Participation of Patient in Clinical Study
Study Title:
‘Analysis o f Haemochromatosis mutations in the North West Population’.
Dear GP,
This letter is to inform you o f your patient .............................................. consent to
participate in the aforementioned study. Please find enclosed a Research Subject 
Information Sheet (for your information), as given to said person to help them decide 
whether to participate in the study or not. Please feel free to contact me if you require 
any further information about the study.
Regards,
Dr. John Wilhams (SGH)
Date of Compilation: 12th November 2003 Version Number (1)
PATIENT QUESTIONNAIRE
Please complete all the following questions using block capital letters or by using a 
tick ‘V ’ to indicate the appropriate response (where applicable).
1. Surname: .................................................................................
2. Forename: ....................................................................................
3. Address: .....................................................................................
4. Age: 20-30yrs Q  31-4 lyrsl I 42-52yrs| I 53-63vrsl I
63+yrs □
5. Do you suffer from diabetes mellitus? Yes..................
N o.....................  □
Don’t Know... Q
6. Are you currently taking /  or have in the past week taken?:
Vitamin C supplements: Yes O  Nol I
Iron supplements: Yes Q  Nol I
7. Are you taking the above supplements:
Following your GP’s recommendation................I I
Through personal choice.....................................  O
Not Applicable...................................................... Q
8. Have you been diagnosed as having the condition of haemochromatosis?
Yes □  No □
9. To the best of your knowledge, has any member of your family been 
diagnosed as having haemochromatosis?
Yes O  No Q  Don’t know Q
If you answered ‘Yes’ to the above, please indicate in the space provided 
below, the number and type of relatives that have been diagnosed (e.g. I Aunt, 
2 Brothers etc). Please fill in ‘N/A’ in the space below if you answered either 
‘No’ or ‘Don’t know’.
Paae 1 o f 2
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10. Have you ever donated blood? Yesl 1 Nol I
11. Are you currently taking any medication? Yesl I Nol I
If  you answered ‘Yes’ to the above question, please list the medication you are 
taking in the space provided below.
12. Do you suffer from any of the following? (Tick ‘Yes’ or ‘No’ box as 
appropriate).
Yes No
Extreme Fatigue
Joint Pain
Arthritis
Impotence(loss of libido)
Skin
Bronzing/Discoloration
Heart Fluttering
Depression
Abdominal Pain
Liver disease
Gallbladder disease
Loss of body hair 
(including baldnes)
Weight loss
Weight gain
Elevated Cholesterol
Slow maturation (delayed 
physical development)
13. Name & Address of your G.P:
Note: Questionnaire’s should be returned to vour Research Doctor.
Thank you fo r taking the time to complete this 
questionnaire. Your assistance is greatly appreciated.
Page 2 o f  2
APPENDIX B
it; ; i
f  r: f * ' * '  j-T
G S c a u o i;  -/;-O P '‘r; a c r  { v » 4 »  0 °fr E T
:i j OZh Gaisshead V * J  I I *.-W'
C u s t o m e r :
D r  J e r e m y  B ir d ,  in s t itu te  o f  T e c h n o lo g y
,y&. a f " ” "’'5 ~ f  C u s t o m e r  N u m b e r :  1 9 0 2 5
I T  1 " N  O r d e r  N u m b e r :  0 0 0 0 3 7 3 3 8
^ ; . v  ,v O r d e r  I D :  3 1 1 2 1  - 0 0 5
• O r d e r  D a t e :  2 1 / 1 1 / 2 0 0 3
C o m m e n t s :
O i i g o N a m e :  C 2 8 2 Y F O l i g o  N u n n b e r :  3 1 1 2 1 A 1 C 0 6  1 / 4
T O G  C A A  G G G  T A A  A C A  G A T  C C - 3 '
i
d e l iv e r e d :
.one.
ra
1 1 .4  O D  
3 1 5 .6  p.g  
4 8 .6  nmol 
-  |iM
6 4 9 9
7^
N o .  B a s e s :
G C  % :
A  C  G
7  4  6
20 l
S y n th e s is  S c a le ;;  
I P u r i f i c a t i o n :
f* o r m :  
slitS? C o n t r o l :  
i l i s e d
0 .0 4  u m o i  s ta n c U ff0  
R P - C o lu n m  
L y o p h i l is e d  
D M T  M o n i t o r i n g
) N A
D l i g o M a m e :  C 2 8 2 Y R O H g o  N u m b e r :  3 1 1 2 1 A 1 D 0 6  2 / 4
" A C  C T C  C T C  A G G  C A C  T C C  T C - 3 ’
i l i  v e r e d : 1 0 .6 O D
3 4 8 .6 R g
5 5 .6 n m o l
in c .: - HM
W: 6 2 7 3
r. 6 3 .4
sses:
i f ' f T '  a/  . /O.
10
20
6 0 .0
T 
5
S y n th e s is  S e a le ;
! Delivery Form:I ;■.
; Q u a l i t y  C o n t r o l ;  
I L y o p h i l i s e d
0 . 0 4  u m o l  standard 
R P - C o lu i r m  
L y o p h i l is e d  
D M T  M o n i t o r i n g
' ¡ A
i i g o N a m e :  H 6 3 D F O i i g o  N u m b e r :  3 1 1 2 1 A 1 E 0 6  3 / 4
ZA T G G  T T A  A G G  C C T  G T T  G C - 3 ’
i v e r e d : 8 .7  O D N o .  B a s e s : 2 0
S y n t h e s is  S c a fle : 0 . 0 4  u m o l  s ta n d a rd
2 5 8 .0  |_ig G C  % : 5 0 .0
P u r i f i c a t i o n s R P - O o 1 u m n
3 9 .9  n m o l
D e l i v e r y  F o r m : L y o p h i l is e d
c .: -
A  C  G ■ T Q u a l i t y  C o u i r o k D M T  M o n i t o r i n g
6 4 / 2
5 7 . 3
4 4 6 Z .k:
-
L y o p h i l i s e d ]
••• . 
.F  G a is n f is a d
¿
• _ 13:t. l:KF; >
r t l í l G a i f e  U  J
; 3 <—•
< T “ ì  *  G " -  ! ■ i-1.4 -, >«,««.1 , . ^ , 1
■ G
j o N a m e :  H 6 3 D K O i i g o  M u m b e r :  3 1 1 2 1 A 1 H 0 4  4 / 4
r G O T  G T G  G Î T  G Î G  A T T  T T C  C - 3 '
■zh'zú: 9 .5  O D W .«, B a s e s ; 22 S y ïîiilê S Ü B  S>;\. ; : .0 4  a r r .o i ¿ -:snd ard
j Q y . ó  ;.ig  
4 3 . 7  n if io l
GC  % : 4 5 . 5 P n r í ñ a t e  
D e l i v e r y  F o r a :
R P -C o h J m V .
L v o ^ ju iU s e s l
•  ¡ í M
A  C G  ' I '
O  «  a  i t t y  C  o  si i r : >i ; V ÌVC f  Iv i orxf ro n  ng
* 7 0 S ?
5 8 . 4
i  4 6 r i
L v o ö h iH s ö d
: _________  ____ __  i
WILEY
Publishers Since 1807
LEGAL DEPARTMENT 
111 River Street, 3-05 
Hoboken, NJ 07030-5774
TEL 201.748.6011 
FAX 201.748.6008
May 9,2005
Lydia Kirk
Centre for Sustainability
New Business Innovation Centre
Institute of Technology Sligo
Ballinode, Ireland
Dear Ms. Kirk:
RE: Your recent request for permission to republish one figure on pages 1321-1328 from Hepatology
(2001) Vol. 33. This material will appear in your forthcoming dissertation, to be published by Institute of
Technology Sligo in 2005.
1. Permission is granted for this use. No rights are granted to use content that appears in the Material or 
the Work with credit to another source.
2. Permitted use is limited to your edition described above, and does not include the right to grant others 
permission to photocopy or otherwise reproduce this material except for versions made for use by 
visually or physically handicapped persons. Up to five copies o f the published thesis may be 
photocopied by a microfilm company.
3. Appropriate credit to our publication must appear on every copy o f your thesis, either on the first page 
of the quoted text, in a separate acknowledgment page, or figure legend. The following components 
must be included: Title, authors) and /or editor(s), journal title (if applicable), Copyright © 2001 
American Association for the Study o f Liver Diseases. Reprinted with permission of John Wiley & 
Sons, Inc.
4. This license is non-transferable. This license is for non-exclusive English language print rights and 
microfilm storage rights by Institute of Technology Sligo only, throughout the world For translation 
rights, please reapply for a license when you have plans to translate your work into a specific language.
Sincerely,
Paulette Goldweber 
Copyright & Permissions 
Legal Department
VISIT OUR WEBSITE @ h t t p ://WWW.WILEY.COM/GO/PERMISSIONS FOR PERMISSIONS INFORMATION AND REQUEST FORMS
APPENDIX D
Sligo General Hospital, Sligo, Ireland.
Tel: + 353 - 71 - 74678 . Fax: + 353 - 71 - 74679 . 
www.ref-sligo.ie
Research & Education Foundation
Ms. Lydia Kirk 
MSc Researcher 
School of Science 
IT Sligo 
Sligo
December 9th 2004
Re. Application for Research & Education Foundation Research Seed Grant 2004
Dear Lydia,
It gives me great pleasure to announce that you have been successful in your application 
for a research grant of €5,000. An independent committee has reviewed your application 
“Analysis o f  Haemochromatosis mutations in the North West population” and found your 
project eligible for a grant.
The Foundation wishes you every success with your study and hopes that you will 
present a poster o f your project for our Annual Multidisciplinary Research Conference.
A cheque with the above sum will be forwarded to you within the next few weeks.
Yours sincerely,
 ; ^  r  -
Mette Jensen Kavanagh 
Development Officer
APPENDIX E
Before comparing the allele frequencies of two populations, it is important to determine whether 
each population is in Hardy-Weinberg equilibrium.
The Hardy-Weinberg principle (HWP) (also Hardy-Weinberg equilibrium (HWE), or Hardy- 
Weinberg law) states that under certain conditions, after one generation of random mating, the 
genotype frequencies at a single gene locus will become fixed at a particular equilibrium value. It 
also specifies that those equilibrium frequencies can be represented as a simple function of the 
allele frequencies at that locus.
In the simplest case of a single locus with two alleles A and a with allele frequencies of p and q 
respectively, the HWP predicts that the genotypic frequencies for the AA homozygote to be p2, 
the Aa heterozygote to be 2pq and the other aa homozygote to be q2. The Hardy-Weinberg 
principle is an expression of the notion of a population in “genetic equilibrium” and is a basic 
principle of population genetics.
When a population is in Hardy-Weinberg equilibrium for a given genetic locus, it means that there 
is random mating (with respect to that locus), no selection, no mutation, no gene flow and the 
population is large enough to avoid the random effects of genetic drift 
(http://en.wikipedia.orq/wiki/Hardv-Weinberg principle. Accessed on 7th March 2006).
If populations are not in Hardy-Weinberg equilibrium then it is more likely that differences in allele 
frequencies of the Iwo populations is due to reproductive isolation.
For data analysis of the research presented in this thesis, the steps listed below were followed:
(1) Individual genotypes were scored
(2) Genotype frequencies were calculated
(3) Allele frequencies were calculated
(4) Using the observed allele frequencies, the expected genotype frequencies under Hardy- 
Weinberg equilibrium were calculated
____________________________________  Statistics_________________________________________
(5) A goodness-of-fit test (Chi-square) was used to compare the expected and observed 
frequencies (http://arows.uDs.edu/analvsis/data analvsistexthtm. Accessed on 7th 
March 2006).
(6) The null hypothesis (H0) is that the population is in Hardy-Weinberg equilibrium. The 
alternative hypothesis (Ha) is that the population is not in Hardy-Weinberg equilibrium.
Tables 3.0 to 3.2 & Table 4.0 were sources of data for statistical analysis (i.e. observed 
numbers).
Hardv-Weinbem equilibrium 
1) FortheC282Y locus
(a) in the Diabetic Population:
Genotype C282Y
homozygote
AA
C282Y
heterozygote
Aa
No C282Y 
mutation 
aa
Total
Observed
Number(s)
1 37 211 249
Allele frequency calculation:
p = 2 x observed number (AA) + observed number (Aa)
2 x (observed number (AA) + observed number (Aa) + observed number (aa) 
p -  2x1+37
2 x (1 +37 + 211)
p= 39 
498
p = 0.078 = C282Y allele frequency; as a % = 7.8%
and: q = 1 —p
q= 1-0.078
q = 0.922 = wildtype allele frequency; as a % = 92.2%
Aside:
Overall allele number is: 249 x 2 = 498 
7.8% of 498 = 39 - the number (N) and 
92.2% of 498 = 459 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = j^ n = (0.078)2 x 249 = 1.52 
Expected number (Aa) = 2pqn = 2 x 0.078 x 0.922 x 249 = 35.81 
Expected number (aa) = q2n = (0.922)2 x 249 = 211.67
Chi-square (x2) test states:
x2 - T (Observed -  Expected)2 
Expected
x2 = (1 -1 .52)2 + (37 - 35.81 )2 + (211 -  211.67)2 
1.52 35.81 211.67
x2 = 0.178+0.040+0.002
x2 = 0.58
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 0.58 and 0.58 is < 3.84, the null hypothesis (i.e. the population is in Hardy-Weinberg 
equilibrium) is accepted.
Therefore, the diabetic population is in HWE for the C282Y locus.
(b) in the ‘Control’ Population:
Genotype C282Y
homozygote
AA
C282Y
heterozygote
Aa
No C282Y 
mutation 
aa
Total
Observed
Number(s)
3 45 199 247
Allele frequency calculation:
p= 2 x observed number (AA) + observed number (Aa)
2 x (observed number (AA) + observed number (Aa) + observed number (aa)
p = 2x3+45
2 x (3+45+ 199)
p= 51 
494
p = 0.103 = C282Y allele frequency; as a % = 10.3%
and: g= 1 -p
q= 1-0.103
q = 0.897 = wildtype allele frequency; as a % = 89.7%
Aside:
Overall allele number is: 247 x 2 = 494
10.3% of 494 = 51 = the number (N) and
89.7% of 494 = 443 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = p2n = (0.103)2 x 247 = 2.62 
Expected number (Aa) = 2pqn = 2 x 0.103 x 0.897 x 247 = 45.64 
Expected number (aa) = g2n = (0.897)2 x 247 = 198.74
Chi-square (x2) test states:
x2 = y  (Observed -  Expected)2 
Expected
x2 = (3 -  2.62)2 + (45 -  45.64P + (199 -1 98.74)2 
2.62 45.64 198.74
x2 = 0.055+ 0.009+0.0003
x2 = 0.0643
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 0.0643 and 0.0643 is < 3.84, the null hypothesis (i.e. the population is in Hardy- 
Weinberg equilibrium) is accepted.
—► Therefore, the control population is in HWE for the C282Y locus.
(a) in the Diabetic Population:
2) For the H63D locus
Genotype H63D
homozygote
AA
H63D
heterozygote
Aa
No H63D 
mutation 
aa
Total
Observed
Number(s)
13 63 173 249
Allele frequency calculation:
p~ 2 x observed number (AA)+observed number (Aa)
2 x (observed number (AA) +observed number (Aa) + observed number (aa)
p = 2x13+63
2 x (13+63+ 173)
p = 89 
498
p = 0.179 = C282Y allele frequency; as a % = 17.9%
and: q = 1 - p
q= 1-0.179
q = 0.821 = wildtype allele frequency; as a % = 82.1 %
Aside:
Overall allele number is: 249 x 2 = 498
17.9% of 498 = 89 = the number (N) and
82.1% of 498 = 409 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = j^n = (0.179)2 x 249 = 7.98 
Expected number (Aa) = 2pqn = 2 x 0.179 x 0.821 x 249 = 73.19 
Expected number (aa) = g2n = (0.821 )2 x 249 = 167.84
Chi-square (x2) test states:
x2 = T (Observed -  Expected)2 
Expected
x2 = (13 -  7.98)2 + (63 -  73.19)2 + (173 - 167.84)2 
7.98 73.19 167.84
x2 = 3.16+ 1.42 + 0.16
x2 = 4.74
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 4.74 and 4.74 is > 3.84, the null hypothesis (i.e. the population is in Hardy-Weinberg 
equilibrium) is rejected.
—► Therefore, the diabetic population is not in HWE for the H63D locus.
(b) in the ‘Control’ Population:
Genotype C282Y
homozygote
AA
C282Y
heterozygote
Aa
No C282Y 
mutation 
aa
Total
Observed
Number(s)
9 57 184 250
Allele frequency calculation:
p = 2 x observed number (AA) + observed number (Aa)
2 x (observed number (AA) +observed number (Aa) +observed number (aa) 
p = 2x9+57
2x (9+57+ 184)
p= 75 
500
p = 0.15 = C282Y allele frequency; as a % = 15%
and: q = 1-p
q = 1-0.15
q = 0.85 = wildtype allele frequency; as a % = 85%
Aside:
Overall allele number is: 250 x 2 = 500 
15% of 500 = 75 = the number (N) and 
85% of 500 = 425 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = p2n = (0.15)2 x 250 = 5.625 
Expected number (Aa) = 2pqn = 2 x 0.15 x 0.85 x 250 = 63.75 
Expected number (aa) = q2n = (0.85)2 x 250 = 180.625
Chi-square (x2) test states:
x2 = y  (Observed -  Expected)2 
Expected
x2 = (9 -  5.625)2 + (57 -  63.75)2 + (184-180.625)2 
5.625 63.75 180.625
x2 = 2.025+0.72+0.06
x2= 2.805
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 2.805 and 2.805 is < 3.84, the null hypothesis (i.e. the population is in Hardy-Weinberg 
equilibrium) is accepted.
—► Therefore, the control population is in HWE for the H63D locus.
(a) in the Diabetic Population
3) For the S65C locus
Genotype C282Y
homozygote
AA
C282Y
heterozygote
Aa
No C282Y 
mutation 
aa
Total
Observed
Number(s)
0 1 123 124
Allele frequency calculation:
p = 2 x observed number (AA) + observed number (Aa)
2 x (observed number (AA) + observed number (Aa) + observed number (aa) 
p = 2x0+1
2x (0 + 1+123)
p = ! _
124
p = 0.0081 = C282Y allele frequency; as a % = 0.81 %
and: q = 1 - p
q = 1 -0.0081
q = 0.9919 = wildtype allele frequency; as a % = 99.19%
Aside:
Overall allele number is: 124 x 2 = 248
0.81% of 248 = 2 = the number (N) and
99.19% of 248 = 246 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = p2n = (0.0081)2 x 124 = 0.0081 
Expected number (Aa) = 2pqn = 2 x 0.0081 x 0.9919 x 124 = 1.99 
Expected number (aa) = q2n = (0.9919)2 x 124 = 122
Chi-square (x2) test states:
x2 = V (Observed - Expected)2 
Expected
x2 = (0 - 0.0081 )2+(1 -1 ,99)2 + (123 - 122)2 
0.0081 1.99 122
x2 = 0.0081 +0.493+0.008
x2 = 0.5091
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 0.5091 and 0.5091 is < 3.84, the null hypothesis (i.e. the population is in Hardy- 
Weinberg equilibrium) is accepted.
—► Therefore, the diabetic population is in HWE for the S65C focus.
(b) in the ‘Control’ Population:
Genotype C282Y
homozygote
AA
C282Y
heterozygote
Aa
No C282Y 
mutation 
aa
Total
Observed
Number(s)
0 4 121 125
Allele frequency calculation:
p = 2 x observed number (AA) + observed number (Aa)
2 x (observed number (AA) + observed number (Aa) + observed number (aa) 
p = 2x0+4
2x (0 +4 + 121)
P= 4 
250
p = 0.016 = C282Y allele frequency; as a % = 1.6%
and: g = 1 -p
q=1-0.016
q = 0.984 = wildtype allele frequency; as a % = 98.4%
Aside:
Overall allele number is: 125 x 2 = 250 
1.6% of 250 = 4 = the number (N) and 
98,4% of 250 = 246 = the number (N)
Therefore the Hardy-Weinberg expectation is:
Expected number (AA) = p2n = (0.016)2 x 125 = 0.032 
Expected number (Aa) = 2pqn = 2 x 0.016 x 0.984 x 125 = 3.936 
Expected number (aa) = q2n = (0.984)2 x 125 = 121.032
Chi-square (x2) test states:
x2 = 7  (Observed - Expected)2 
Expected
x2 = (0 -  0.032)2 + (4 -  3.936)2 + (121 -121.032)2 
0.032 3.936 121.032
x2 = 0.032 +0.001 +0.00000846
x2 = 0.033
The 5% significance level for 1 degree of freedom (1 df) = 3.84 (from statistics tables)
Since x2 = 0.033 and 0.033 is < 3.84, the null hypothesis (i.e. the population is in Hardy-Weinberg 
equilibrium) is accepted.
—> Therefore, the control population is in HWE for the S65C locus.
The preceeding data is presented in Table form in the Results section (see Table 3.6).
Additional Statistics:
A Chi square test was also performed to determine whether there was a difference between the 
genotype frequencies of the Diabetic & Control populations. Where genotype frequencies 
occurred at a rate of 1 per population, they were excluded from the main chi square calculation 
(see Table below) as they are considered not significant and a Fisher’s exact test must be 
performed (i.e. C282Y homozygous and S65C heterozygous genotypes). The calculation was
carried out on Minitab where raw data was used, different sample sizes were ignored and control 
results were converted to allow for minor differences in ‘n’. The control group was taken as giving 
the expected outcome.
Table: Chi square test data transcribed from Minitab analysis
Genotype Observed Expected Chi square Cumulative
Probability
P Value
C282Y heterozygote 37 45.00 3.83158 0.852774 0.147226
H63D homozygote 13 9.00
H63D heterozygote 63 57.00
Genotype Ex for Obs 
n
C282Y heterozygote 37 45.40 4.05255 0.868175 0.131825
H63D homozygote 13 8.96
H63D heterozygote 63 56.80
Results show that there is no difference between the genotype frequencies of Diabetics and 
Controls.
Each of the five genotypes was also taken separately and the two populations compared using 
two proportions. Confidence intervals (95%) were also calculated and transcribed from Minitab 
(see below).
Test and Confidence Interval for Two Proportions
(a) C282Y homozygotes:
Sample X N Sample p
1 1 249 0.004016
2 3 247 0.012146
Difference = p (1) -  p (2)
Estimate for difference: -0.00812968
95% Cl for difference: (-0.0238876,0.00762821)
Test for difference: = 0 (vs not = 0): z = -1.01 P value = 0.312
Note: The normal approximation may be inaccurate for small samples (i.e. when frequency 
per population, Minitab does Fisher’s exact test).
Fisher’s exact test P value = 0.371.
(b) C282Y heterozygotes:
Sample X N Sample p
1 37 249 0.148594
2 45 247 0.182186
Difference = p (1) -  p (2)
Estimate for difference: -0.0335919
95% Cl for difference: (-0.0989297,0.0317460)
Test for difference: = 0 (vs not = 0): z = -1.01 P value = 0.314
(c) H63D homozygotes:
Sample X N Sample p
1 13 249 0.052209
2 9 250 0.036000
Difference = p (1) — p (2)
Estimate for difference: 0.0162088
95% Cl for difference: (-0.0198003,0.0522180)
Test for difference: = 0 (vs not = 0): z = 0.88 P value = 0.378
(d) H63D heterozygotes:
Sample X N Sample p
1 63 249 0.253012
2 57 250 0.228000
Difference = p (1) — P (2)
Estimate for difference: 0.0250120
95% Cl for difference: (-0.0499572,0.0999813)
Test for difference: = 0 (vs not = 0): z = 0.65 P value = 0.513
(e) S65C heterozygotes:
Sample X N Sample p
1 1 124 0.008065
2 4 125 0.032000
Difference = p (1) — p (2)
Estimate for difference: -0.0239355
95% Cl for difference: (-0.0585731,0.0107021)
Testfer difference: = 0 (vs not=0): z = -1.35 P value = 0.178
Note: The normal approximation may be inaccurate for small samples (i.e. when frequency is 1 
per population, Minitab does Fisher’s exact test).
Fisher’s exact test: P value = 0.370.
All the P values in (a) to (e) show non-significance atlhe 95% confidence level.
Chi square test to determine whether there is a difference between the genotype frequencies of 
the Diabetic & Control populations.
Ho: there is a difference between the genotype frequencies of Diabetics and Controls 
Ha: there is no difference between the genotype frequencies of Diabetics and Controls
The Control population data will serve as the expected values in the Chi square test
Additional Statistics:
Data:
Genotype Diabetic PopulalLion Control Populat on
No. in 
population 
with 
genotype
Total
Population
Size
(Tested
Population)
%
Population
No. in 
population 
with 
genotype
Total
Population
size
(Tested
Population)
%
Population
C282Y
Homozyqote
1 249 0.4 3 247 0.0122
C282Y
Heterozygote
37 249 14.86 45 247 0.1822
H63D
Homozygote
13 249 5.22 9 250 0.036
H63D
Heterozygote
63 249 25.3 57 250 0.228
S65C
Heterozygote
1 124 0.81 4 125 0.032
Genotype %
Population
(Diabetic)
Total
Population
Size
(Control)
Expected
Number
(Control)
Observed
Number
(Control)
Difference 
(O - E)
(O -E F
E
C282Y
Homozygote
0.4 247 0.988 3 2.012 4.1
C282Y
Heterozygote
14.86 247 36.704 45 8.296 1.88
H63D
Homozygote
5.22 250 13.05 9 -4.05 1.26
H63D
Heterozygote
25.3 250 63.25 57 -6.25 0.62
S65C
Heterozygote
0.81 125 1.0125 4 2.9875 8.82
Chi square value/x2 = 16.68
Degrees of freedom (df) = (Number of genotypes -1 ) = 4
The critical value for x2 distribution with 4 df and and a level of 0.05 is : 9.49 (from Chi square 
tables).
The observed statistic of 16.68 is greater than the critical value, even at a = 0.01, therefore the 
null hypothesis (Ho) is rejected and the alternative hypothesis is accepted.
That is: There is no difference between the genotype frequencies of Diabetics and Controls.
